id	sid	tid	token	lemma	pos
ajlm-2065	1	1	abstract	abstract	ADJ
ajlm-2065	1	2	introduction	introduction	NOUN
ajlm-2065	1	3	methods	method	NOUN
ajlm-2065	1	4	results	result	VERB
ajlm-2065	1	5	discussion	discussion	NOUN
ajlm-2065	1	6	acknowledgements	acknowledgement	NOUN
ajlm-2065	1	7	references	reference	NOUN
ajlm-2065	1	8	about	about	ADP
ajlm-2065	1	9	the	the	DET
ajlm-2065	1	10	author(s	author(s	PROPN
ajlm-2065	1	11	)	)	PUNCT
ajlm-2065	1	12	kerri	kerri	PROPN
ajlm-2065	1	13	-	-	PUNCT
ajlm-2065	1	14	lee	lee	PROPN
ajlm-2065	1	15	a.	a.	PROPN
ajlm-2065	1	16	francois	francois	PROPN
ajlm-2065	1	17	discipline	discipline	NOUN
ajlm-2065	1	18	of	of	ADP
ajlm-2065	1	19	virology	virology	NOUN
ajlm-2065	1	20	,	,	PUNCT
ajlm-2065	1	21	faculty	faculty	NOUN
ajlm-2065	1	22	of	of	ADP
ajlm-2065	1	23	health	health	NOUN
ajlm-2065	1	24	sciences	sciences	PROPN
ajlm-2065	1	25	,	,	PUNCT
ajlm-2065	1	26	school	school	NOUN
ajlm-2065	1	27	of	of	ADP
ajlm-2065	1	28	laboratory	laboratory	NOUN
ajlm-2065	1	29	medicine	medicine	NOUN
ajlm-2065	1	30	and	and	CCONJ
ajlm-2065	1	31	medical	medical	ADJ
ajlm-2065	1	32	sciences	science	NOUN
ajlm-2065	1	33	,	,	PUNCT
ajlm-2065	1	34	college	college	NOUN
ajlm-2065	1	35	of	of	ADP
ajlm-2065	1	36	health	health	PROPN
ajlm-2065	1	37	sciences	sciences	PROPN
ajlm-2065	1	38	,	,	PUNCT
ajlm-2065	1	39	university	university	NOUN
ajlm-2065	1	40	of	of	ADP
ajlm-2065	1	41	kwazulu	kwazulu	PROPN
ajlm-2065	1	42	-	-	PUNCT
ajlm-2065	1	43	natal	natal	ADJ
ajlm-2065	1	44	,	,	PUNCT
ajlm-2065	1	45	durban	durban	PROPN
ajlm-2065	1	46	,	,	PUNCT
ajlm-2065	1	47	south	south	PROPN
ajlm-2065	1	48	africa	africa	PROPN
ajlm-2065	1	49	national	national	PROPN
ajlm-2065	1	50	health	health	PROPN
ajlm-2065	1	51	laboratory	laboratory	PROPN
ajlm-2065	1	52	services	service	NOUN
ajlm-2065	1	53	,	,	PUNCT
ajlm-2065	1	54	inkosi	inkosi	PROPN
ajlm-2065	1	55	albert	albert	PROPN
ajlm-2065	1	56	luthuli	luthuli	PROPN
ajlm-2065	1	57	central	central	PROPN
ajlm-2065	1	58	hospital	hospital	NOUN
ajlm-2065	1	59	,	,	PUNCT
ajlm-2065	1	60	durban	durban	PROPN
ajlm-2065	1	61	,	,	PUNCT
ajlm-2065	1	62	south	south	PROPN
ajlm-2065	1	63	africa	africa	PROPN
ajlm-2065	1	64	nokukhanya	nokukhanya	PROPN
ajlm-2065	1	65	msomi	msomi	PROPN
ajlm-2065	1	66	discipline	discipline	NOUN
ajlm-2065	1	67	of	of	ADP
ajlm-2065	1	68	virology	virology	NOUN
ajlm-2065	1	69	,	,	PUNCT
ajlm-2065	1	70	faculty	faculty	NOUN
ajlm-2065	1	71	of	of	ADP
ajlm-2065	1	72	health	health	NOUN
ajlm-2065	1	73	sciences	sciences	PROPN
ajlm-2065	1	74	,	,	PUNCT
ajlm-2065	1	75	school	school	NOUN
ajlm-2065	1	76	of	of	ADP
ajlm-2065	1	77	laboratory	laboratory	NOUN
ajlm-2065	1	78	medicine	medicine	NOUN
ajlm-2065	1	79	and	and	CCONJ
ajlm-2065	1	80	medical	medical	ADJ
ajlm-2065	1	81	sciences	science	NOUN
ajlm-2065	1	82	,	,	PUNCT
ajlm-2065	1	83	college	college	NOUN
ajlm-2065	1	84	of	of	ADP
ajlm-2065	1	85	health	health	PROPN
ajlm-2065	1	86	sciences	sciences	PROPN
ajlm-2065	1	87	,	,	PUNCT
ajlm-2065	1	88	university	university	NOUN
ajlm-2065	1	89	of	of	ADP
ajlm-2065	1	90	kwazulu	kwazulu	PROPN
ajlm-2065	1	91	-	-	PUNCT
ajlm-2065	1	92	natal	natal	ADJ
ajlm-2065	1	93	,	,	PUNCT
ajlm-2065	1	94	durban	durban	PROPN
ajlm-2065	1	95	,	,	PUNCT
ajlm-2065	1	96	south	south	PROPN
ajlm-2065	1	97	africa	africa	PROPN
ajlm-2065	1	98	national	national	PROPN
ajlm-2065	1	99	health	health	PROPN
ajlm-2065	1	100	laboratory	laboratory	PROPN
ajlm-2065	1	101	services	service	NOUN
ajlm-2065	1	102	,	,	PUNCT
ajlm-2065	1	103	inkosi	inkosi	PROPN
ajlm-2065	1	104	albert	albert	PROPN
ajlm-2065	1	105	luthuli	luthuli	PROPN
ajlm-2065	1	106	central	central	PROPN
ajlm-2065	1	107	hospital	hospital	NOUN
ajlm-2065	1	108	,	,	PUNCT
ajlm-2065	1	109	durban	durban	PROPN
ajlm-2065	1	110	,	,	PUNCT
ajlm-2065	1	111	south	south	PROPN
ajlm-2065	1	112	africa	africa	PROPN
ajlm-2065	1	113	kerusha	kerusha	PROPN
ajlm-2065	1	114	govender	govender	PROPN
ajlm-2065	1	115	discipline	discipline	NOUN
ajlm-2065	1	116	of	of	ADP
ajlm-2065	1	117	virology	virology	NOUN
ajlm-2065	1	118	,	,	PUNCT
ajlm-2065	1	119	faculty	faculty	NOUN
ajlm-2065	1	120	of	of	ADP
ajlm-2065	1	121	health	health	NOUN
ajlm-2065	1	122	sciences	sciences	PROPN
ajlm-2065	1	123	,	,	PUNCT
ajlm-2065	1	124	school	school	NOUN
ajlm-2065	1	125	of	of	ADP
ajlm-2065	1	126	laboratory	laboratory	NOUN
ajlm-2065	1	127	medicine	medicine	NOUN
ajlm-2065	1	128	and	and	CCONJ
ajlm-2065	1	129	medical	medical	ADJ
ajlm-2065	1	130	sciences	science	NOUN
ajlm-2065	1	131	,	,	PUNCT
ajlm-2065	1	132	college	college	NOUN
ajlm-2065	1	133	of	of	ADP
ajlm-2065	1	134	health	health	PROPN
ajlm-2065	1	135	sciences	sciences	PROPN
ajlm-2065	1	136	,	,	PUNCT
ajlm-2065	1	137	university	university	NOUN
ajlm-2065	1	138	of	of	ADP
ajlm-2065	1	139	kwazulu	kwazulu	PROPN
ajlm-2065	1	140	-	-	PUNCT
ajlm-2065	1	141	natal	natal	ADJ
ajlm-2065	1	142	,	,	PUNCT
ajlm-2065	1	143	durban	durban	PROPN
ajlm-2065	1	144	,	,	PUNCT
ajlm-2065	1	145	south	south	PROPN
ajlm-2065	1	146	africa	africa	PROPN
ajlm-2065	1	147	national	national	PROPN
ajlm-2065	1	148	health	health	PROPN
ajlm-2065	1	149	laboratory	laboratory	PROPN
ajlm-2065	1	150	services	service	NOUN
ajlm-2065	1	151	,	,	PUNCT
ajlm-2065	1	152	inkosi	inkosi	PROPN
ajlm-2065	1	153	albert	albert	PROPN
ajlm-2065	1	154	luthuli	luthuli	PROPN
ajlm-2065	1	155	central	central	PROPN
ajlm-2065	1	156	hospital	hospital	NOUN
ajlm-2065	1	157	,	,	PUNCT
ajlm-2065	1	158	durban	durban	PROPN
ajlm-2065	1	159	,	,	PUNCT
ajlm-2065	1	160	south	south	PROPN
ajlm-2065	1	161	africa	africa	PROPN
ajlm-2065	1	162	lilishia	lilishia	PROPN
ajlm-2065	1	163	gounder	gounder	PROPN
ajlm-2065	1	164	discipline	discipline	NOUN
ajlm-2065	1	165	of	of	ADP
ajlm-2065	1	166	virology	virology	NOUN
ajlm-2065	1	167	,	,	PUNCT
ajlm-2065	1	168	faculty	faculty	NOUN
ajlm-2065	1	169	of	of	ADP
ajlm-2065	1	170	health	health	NOUN
ajlm-2065	1	171	sciences	sciences	PROPN
ajlm-2065	1	172	,	,	PUNCT
ajlm-2065	1	173	school	school	NOUN
ajlm-2065	1	174	of	of	ADP
ajlm-2065	1	175	laboratory	laboratory	NOUN
ajlm-2065	1	176	medicine	medicine	NOUN
ajlm-2065	1	177	and	and	CCONJ
ajlm-2065	1	178	medical	medical	ADJ
ajlm-2065	1	179	sciences	science	NOUN
ajlm-2065	1	180	,	,	PUNCT
ajlm-2065	1	181	college	college	NOUN
ajlm-2065	1	182	of	of	ADP
ajlm-2065	1	183	health	health	PROPN
ajlm-2065	1	184	sciences	sciences	PROPN
ajlm-2065	1	185	,	,	PUNCT
ajlm-2065	1	186	university	university	NOUN
ajlm-2065	1	187	of	of	ADP
ajlm-2065	1	188	kwazulu	kwazulu	PROPN
ajlm-2065	1	189	-	-	PUNCT
ajlm-2065	1	190	natal	natal	ADJ
ajlm-2065	1	191	,	,	PUNCT
ajlm-2065	1	192	durban	durban	PROPN
ajlm-2065	1	193	,	,	PUNCT
ajlm-2065	1	194	south	south	PROPN
ajlm-2065	1	195	africa	africa	PROPN
ajlm-2065	1	196	national	national	PROPN
ajlm-2065	1	197	health	health	PROPN
ajlm-2065	1	198	laboratory	laboratory	PROPN
ajlm-2065	1	199	services	service	NOUN
ajlm-2065	1	200	,	,	PUNCT
ajlm-2065	1	201	inkosi	inkosi	PROPN
ajlm-2065	1	202	albert	albert	PROPN
ajlm-2065	1	203	luthuli	luthuli	PROPN
ajlm-2065	1	204	central	central	PROPN
ajlm-2065	1	205	hospital	hospital	NOUN
ajlm-2065	1	206	,	,	PUNCT
ajlm-2065	1	207	durban	durban	PROPN
ajlm-2065	1	208	,	,	PUNCT
ajlm-2065	1	209	south	south	PROPN
ajlm-2065	1	210	africa	africa	PROPN
ajlm-2065	1	211	pravi	pravi	PROPN
ajlm-2065	1	212	moodley	moodley	PROPN
ajlm-2065	1	213	discipline	discipline	NOUN
ajlm-2065	1	214	of	of	ADP
ajlm-2065	1	215	virology	virology	NOUN
ajlm-2065	1	216	,	,	PUNCT
ajlm-2065	1	217	faculty	faculty	NOUN
ajlm-2065	1	218	of	of	ADP
ajlm-2065	1	219	health	health	NOUN
ajlm-2065	1	220	sciences	sciences	PROPN
ajlm-2065	1	221	,	,	PUNCT
ajlm-2065	1	222	school	school	NOUN
ajlm-2065	1	223	of	of	ADP
ajlm-2065	1	224	laboratory	laboratory	NOUN
ajlm-2065	1	225	medicine	medicine	NOUN
ajlm-2065	1	226	and	and	CCONJ
ajlm-2065	1	227	medical	medical	ADJ
ajlm-2065	1	228	sciences	science	NOUN
ajlm-2065	1	229	,	,	PUNCT
ajlm-2065	1	230	college	college	NOUN
ajlm-2065	1	231	of	of	ADP
ajlm-2065	1	232	health	health	PROPN
ajlm-2065	1	233	sciences	sciences	PROPN
ajlm-2065	1	234	,	,	PUNCT
ajlm-2065	1	235	university	university	NOUN
ajlm-2065	1	236	of	of	ADP
ajlm-2065	1	237	kwazulu	kwazulu	PROPN
ajlm-2065	1	238	-	-	PUNCT
ajlm-2065	1	239	natal	natal	ADJ
ajlm-2065	1	240	,	,	PUNCT
ajlm-2065	1	241	durban	durban	PROPN
ajlm-2065	1	242	,	,	PUNCT
ajlm-2065	1	243	south	south	PROPN
ajlm-2065	1	244	africa	africa	PROPN
ajlm-2065	1	245	national	national	PROPN
ajlm-2065	1	246	health	health	PROPN
ajlm-2065	1	247	laboratory	laboratory	PROPN
ajlm-2065	1	248	services	service	NOUN
ajlm-2065	1	249	,	,	PUNCT
ajlm-2065	1	250	inkosi	inkosi	PROPN
ajlm-2065	1	251	albert	albert	PROPN
ajlm-2065	1	252	luthuli	luthuli	PROPN
ajlm-2065	1	253	central	central	PROPN
ajlm-2065	1	254	hospital	hospital	NOUN
ajlm-2065	1	255	,	,	PUNCT
ajlm-2065	1	256	durban	durban	PROPN
ajlm-2065	1	257	,	,	PUNCT
ajlm-2065	1	258	south	south	PROPN
ajlm-2065	1	259	africa	africa	PROPN
ajlm-2065	1	260	raveen	raveen	ADJ
ajlm-2065	1	261	parboosing	parboose	VERB
ajlm-2065	1	262	discipline	discipline	NOUN
ajlm-2065	1	263	of	of	ADP
ajlm-2065	1	264	virology	virology	NOUN
ajlm-2065	1	265	,	,	PUNCT
ajlm-2065	1	266	faculty	faculty	NOUN
ajlm-2065	1	267	of	of	ADP
ajlm-2065	1	268	health	health	NOUN
ajlm-2065	1	269	sciences	sciences	PROPN
ajlm-2065	1	270	,	,	PUNCT
ajlm-2065	1	271	school	school	NOUN
ajlm-2065	1	272	of	of	ADP
ajlm-2065	1	273	laboratory	laboratory	NOUN
ajlm-2065	1	274	medicine	medicine	NOUN
ajlm-2065	1	275	and	and	CCONJ
ajlm-2065	1	276	medical	medical	ADJ
ajlm-2065	1	277	sciences	science	NOUN
ajlm-2065	1	278	,	,	PUNCT
ajlm-2065	1	279	college	college	NOUN
ajlm-2065	1	280	of	of	ADP
ajlm-2065	1	281	health	health	PROPN
ajlm-2065	1	282	sciences	sciences	PROPN
ajlm-2065	1	283	,	,	PUNCT
ajlm-2065	1	284	university	university	NOUN
ajlm-2065	1	285	of	of	ADP
ajlm-2065	1	286	kwazulu	kwazulu	PROPN
ajlm-2065	1	287	-	-	PUNCT
ajlm-2065	1	288	natal	natal	ADJ
ajlm-2065	1	289	,	,	PUNCT
ajlm-2065	1	290	durban	durban	PROPN
ajlm-2065	1	291	,	,	PUNCT
ajlm-2065	1	292	south	south	PROPN
ajlm-2065	1	293	africa	africa	PROPN
ajlm-2065	1	294	national	national	PROPN
ajlm-2065	1	295	health	health	PROPN
ajlm-2065	1	296	laboratory	laboratory	PROPN
ajlm-2065	1	297	services	service	NOUN
ajlm-2065	1	298	,	,	PUNCT
ajlm-2065	1	299	inkosi	inkosi	PROPN
ajlm-2065	1	300	albert	albert	PROPN
ajlm-2065	1	301	luthuli	luthuli	PROPN
ajlm-2065	1	302	central	central	PROPN
ajlm-2065	1	303	hospital	hospital	NOUN
ajlm-2065	1	304	,	,	PUNCT
ajlm-2065	1	305	durban	durban	PROPN
ajlm-2065	1	306	,	,	PUNCT
ajlm-2065	1	307	south	south	PROPN
ajlm-2065	1	308	africa	africa	PROPN
ajlm-2065	1	309	department	department	PROPN
ajlm-2065	1	310	of	of	ADP
ajlm-2065	1	311	medical	medical	ADJ
ajlm-2065	1	312	virology	virology	NOUN
ajlm-2065	1	313	,	,	PUNCT
ajlm-2065	1	314	faculty	faculty	NOUN
ajlm-2065	1	315	of	of	ADP
ajlm-2065	1	316	health	health	NOUN
ajlm-2065	1	317	sciences	sciences	PROPN
ajlm-2065	1	318	,	,	PUNCT
ajlm-2065	1	319	university	university	NOUN
ajlm-2065	1	320	of	of	ADP
ajlm-2065	1	321	the	the	DET
ajlm-2065	1	322	witwatersrand	witwatersrand	NOUN
ajlm-2065	1	323	,	,	PUNCT
ajlm-2065	1	324	johannesburg	johannesburg	PROPN
ajlm-2065	1	325	,	,	PUNCT
ajlm-2065	1	326	south	south	PROPN
ajlm-2065	1	327	africa	africa	PROPN
ajlm-2065	1	328	indrani	indrani	PROPN
ajlm-2065	1	329	chetty	chetty	PROPN
ajlm-2065	1	330	discipline	discipline	NOUN
ajlm-2065	1	331	of	of	ADP
ajlm-2065	1	332	virology	virology	NOUN
ajlm-2065	1	333	and	and	CCONJ
ajlm-2065	1	334	national	national	PROPN
ajlm-2065	1	335	health	health	PROPN
ajlm-2065	1	336	laboratory	laboratory	PROPN
ajlm-2065	1	337	service	service	NOUN
ajlm-2065	1	338	,	,	PUNCT
ajlm-2065	1	339	inkosi	inkosi	PROPN
ajlm-2065	1	340	albert	albert	PROPN
ajlm-2065	1	341	luthuli	luthuli	PROPN
ajlm-2065	1	342	central	central	PROPN
ajlm-2065	1	343	hospital	hospital	NOUN
ajlm-2065	1	344	,	,	PUNCT
ajlm-2065	1	345	durban	durban	PROPN
ajlm-2065	1	346	,	,	PUNCT
ajlm-2065	1	347	south	south	PROPN
ajlm-2065	1	348	africa	africa	PROPN
ajlm-2065	1	349	lunga	lunga	PROPN
ajlm-2065	1	350	xaba	xaba	PROPN
ajlm-2065	1	351	discipline	discipline	NOUN
ajlm-2065	1	352	of	of	ADP
ajlm-2065	1	353	virology	virology	NOUN
ajlm-2065	1	354	and	and	CCONJ
ajlm-2065	1	355	national	national	PROPN
ajlm-2065	1	356	health	health	PROPN
ajlm-2065	1	357	laboratory	laboratory	PROPN
ajlm-2065	1	358	service	service	NOUN
ajlm-2065	1	359	,	,	PUNCT
ajlm-2065	1	360	inkosi	inkosi	PROPN
ajlm-2065	1	361	albert	albert	PROPN
ajlm-2065	1	362	luthuli	luthuli	PROPN
ajlm-2065	1	363	central	central	PROPN
ajlm-2065	1	364	hospital	hospital	NOUN
ajlm-2065	1	365	,	,	PUNCT
ajlm-2065	1	366	durban	durban	PROPN
ajlm-2065	1	367	,	,	PUNCT
ajlm-2065	1	368	south	south	PROPN
ajlm-2065	1	369	africa	africa	PROPN
ajlm-2065	1	370	aabida	aabida	PROPN
ajlm-2065	1	371	khan	khan	PROPN
ajlm-2065	1	372	discipline	discipline	NOUN
ajlm-2065	1	373	of	of	ADP
ajlm-2065	1	374	virology	virology	NOUN
ajlm-2065	1	375	,	,	PUNCT
ajlm-2065	1	376	faculty	faculty	NOUN
ajlm-2065	1	377	of	of	ADP
ajlm-2065	1	378	health	health	NOUN
ajlm-2065	1	379	sciences	sciences	PROPN
ajlm-2065	1	380	,	,	PUNCT
ajlm-2065	1	381	school	school	NOUN
ajlm-2065	1	382	of	of	ADP
ajlm-2065	1	383	laboratory	laboratory	NOUN
ajlm-2065	1	384	medicine	medicine	NOUN
ajlm-2065	1	385	and	and	CCONJ
ajlm-2065	1	386	medical	medical	ADJ
ajlm-2065	1	387	sciences	science	NOUN
ajlm-2065	1	388	,	,	PUNCT
ajlm-2065	1	389	college	college	NOUN
ajlm-2065	1	390	of	of	ADP
ajlm-2065	1	391	health	health	PROPN
ajlm-2065	1	392	sciences	sciences	PROPN
ajlm-2065	1	393	,	,	PUNCT
ajlm-2065	1	394	university	university	NOUN
ajlm-2065	1	395	of	of	ADP
ajlm-2065	1	396	kwazulu	kwazulu	PROPN
ajlm-2065	1	397	-	-	PUNCT
ajlm-2065	1	398	natal	natal	ADJ
ajlm-2065	1	399	,	,	PUNCT
ajlm-2065	1	400	durban	durban	PROPN
ajlm-2065	1	401	,	,	PUNCT
ajlm-2065	1	402	south	south	PROPN
ajlm-2065	1	403	africa	africa	PROPN
ajlm-2065	1	404	national	national	PROPN
ajlm-2065	1	405	health	health	PROPN
ajlm-2065	1	406	laboratory	laboratory	PROPN
ajlm-2065	1	407	services	service	NOUN
ajlm-2065	1	408	,	,	PUNCT
ajlm-2065	1	409	inkosi	inkosi	PROPN
ajlm-2065	1	410	albert	albert	PROPN
ajlm-2065	1	411	luthuli	luthuli	PROPN
ajlm-2065	1	412	central	central	PROPN
ajlm-2065	1	413	hospital	hospital	NOUN
ajlm-2065	1	414	,	,	PUNCT
ajlm-2065	1	415	durban	durban	PROPN
ajlm-2065	1	416	,	,	PUNCT
ajlm-2065	1	417	south	south	PROPN
ajlm-2065	1	418	africa	africa	PROPN
ajlm-2065	1	419	citation	citation	PROPN
ajlm-2065	1	420	francois	francois	PROPN
ajlm-2065	2	1	k	k	X
ajlm-2065	2	2	-	-	PUNCT
ajlm-2065	2	3	la	la	ADJ
ajlm-2065	2	4	,	,	PUNCT
ajlm-2065	2	5	msomi	msomi	NOUN
ajlm-2065	2	6	n	n	CCONJ
ajlm-2065	2	7	,	,	PUNCT
ajlm-2065	2	8	govender	govender	PROPN
ajlm-2065	2	9	k	k	NOUN
ajlm-2065	2	10	,	,	PUNCT
ajlm-2065	2	11	et	et	PROPN
ajlm-2065	2	12	al	al	PROPN
ajlm-2065	2	13	.	.	PROPN
ajlm-2065	2	14	seroprevalence	seroprevalence	NOUN
ajlm-2065	2	15	of	of	ADP
ajlm-2065	2	16	sars	sar	NOUN
ajlm-2065	2	17	-	-	PUNCT
ajlm-2065	2	18	cov-2	cov-2	NOUN
ajlm-2065	2	19	immunoglobulin	immunoglobulin	NOUN
ajlm-2065	2	20	g	g	NOUN
ajlm-2065	2	21	in	in	ADP
ajlm-2065	2	22	hiv	hiv	PROPN
ajlm-2065	2	23	-	-	PUNCT
ajlm-2065	2	24	positive	positive	ADJ
ajlm-2065	2	25	and	and	CCONJ
ajlm-2065	2	26	hiv	hiv	NOUN
ajlm-2065	2	27	-	-	PUNCT
ajlm-2065	2	28	negative	negative	ADJ
ajlm-2065	2	29	individuals	individual	NOUN
ajlm-2065	2	30	in	in	ADP
ajlm-2065	2	31	kwazulu	kwazulu	NOUN
ajlm-2065	2	32	-	-	PUNCT
ajlm-2065	2	33	natal	natal	ADJ
ajlm-2065	2	34	,	,	PUNCT
ajlm-2065	2	35	south	south	PROPN
ajlm-2065	2	36	africa	africa	PROPN
ajlm-2065	2	37	.	.	PUNCT
ajlm-2065	3	1	afr	afr	PROPN
ajlm-2065	3	2	j	j	PROPN
ajlm-2065	3	3	lab	lab	PROPN
ajlm-2065	3	4	med	med	PROPN
ajlm-2065	3	5	.	.	PUNCT
ajlm-2065	4	1	2023;12(1	2023;12(1	NUM
ajlm-2065	4	2	)	)	PUNCT
ajlm-2065	4	3	,	,	PUNCT
ajlm-2065	5	1	a2065	a2065	PROPN
ajlm-2065	5	2	.	.	PUNCT
ajlm-2065	6	1	https://doi.org/10.4102/ajlm.v12i1.2065	https://doi.org/10.4102/ajlm.v12i1.2065	X
ajlm-2065	6	2	original	original	ADJ
ajlm-2065	6	3	research	research	NOUN
ajlm-2065	6	4	seroprevalence	seroprevalence	NOUN
ajlm-2065	6	5	of	of	ADP
ajlm-2065	6	6	sars	sar	NOUN
ajlm-2065	6	7	-	-	PUNCT
ajlm-2065	6	8	cov-2	cov-2	NOUN
ajlm-2065	6	9	immunoglobulin	immunoglobulin	NOUN
ajlm-2065	6	10	g	g	NOUN
ajlm-2065	6	11	in	in	ADP
ajlm-2065	6	12	hiv	hiv	PROPN
ajlm-2065	6	13	-	-	PUNCT
ajlm-2065	6	14	positive	positive	ADJ
ajlm-2065	6	15	and	and	CCONJ
ajlm-2065	6	16	hiv	hiv	NOUN
ajlm-2065	6	17	-	-	PUNCT
ajlm-2065	6	18	negative	negative	ADJ
ajlm-2065	6	19	individuals	individual	NOUN
ajlm-2065	6	20	in	in	ADP
ajlm-2065	6	21	kwazulu	kwazulu	NOUN
ajlm-2065	6	22	-	-	PUNCT
ajlm-2065	6	23	natal	natal	ADJ
ajlm-2065	6	24	,	,	PUNCT
ajlm-2065	6	25	south	south	PROPN
ajlm-2065	6	26	africa	africa	PROPN
ajlm-2065	6	27	kerri	kerri	PROPN
ajlm-2065	6	28	-	-	PUNCT
ajlm-2065	6	29	lee	lee	PROPN
ajlm-2065	6	30	a.	a.	PROPN
ajlm-2065	6	31	francois	francois	PROPN
ajlm-2065	6	32	,	,	PUNCT
ajlm-2065	6	33	nokukhanya	nokukhanya	ADJ
ajlm-2065	6	34	msomi	msomi	NOUN
ajlm-2065	6	35	,	,	PUNCT
ajlm-2065	6	36	kerusha	kerusha	PROPN
ajlm-2065	6	37	govender	govender	NOUN
ajlm-2065	6	38	,	,	PUNCT
ajlm-2065	6	39	lilishia	lilishia	ADJ
ajlm-2065	6	40	gounder	gounder	NOUN
ajlm-2065	6	41	,	,	PUNCT
ajlm-2065	6	42	pravi	pravi	PROPN
ajlm-2065	6	43	moodley	moodley	NOUN
ajlm-2065	6	44	,	,	PUNCT
ajlm-2065	6	45	raveen	raveen	ADJ
ajlm-2065	6	46	parboosing	parboose	VERB
ajlm-2065	6	47	,	,	PUNCT
ajlm-2065	6	48	indrani	indrani	PROPN
ajlm-2065	6	49	chetty	chetty	PROPN
ajlm-2065	6	50	,	,	PUNCT
ajlm-2065	6	51	lunga	lunga	PROPN
ajlm-2065	6	52	xaba	xaba	PROPN
ajlm-2065	6	53	,	,	PUNCT
ajlm-2065	6	54	aabida	aabida	PROPN
ajlm-2065	6	55	khan	khan	PROPN
ajlm-2065	6	56	received	receive	VERB
ajlm-2065	6	57	:	:	PUNCT
ajlm-2065	6	58	26	26	NUM
ajlm-2065	6	59	aug	aug	PROPN
ajlm-2065	6	60	.	.	PROPN
ajlm-2065	6	61	2022	2022	NUM
ajlm-2065	6	62	;	;	PUNCT
ajlm-2065	6	63	accepted	accept	VERB
ajlm-2065	6	64	:	:	PUNCT
ajlm-2065	6	65	29	29	NUM
ajlm-2065	6	66	mar	mar	PROPN
ajlm-2065	6	67	.	.	PROPN
ajlm-2065	6	68	2023	2023	NUM
ajlm-2065	6	69	;	;	PUNCT
ajlm-2065	6	70	published	publish	VERB
ajlm-2065	6	71	:	:	PUNCT
ajlm-2065	6	72	29	29	NUM
ajlm-2065	6	73	june	june	PROPN
ajlm-2065	6	74	2023	2023	NUM
ajlm-2065	6	75	copyright	copyright	NOUN
ajlm-2065	6	76	:	:	PUNCT
ajlm-2065	6	77	©	©	PROPN
ajlm-2065	6	78	2023	2023	NUM
ajlm-2065	6	79	.	.	PUNCT
ajlm-2065	7	1	the	the	DET
ajlm-2065	7	2	author(s	author(s	NOUN
ajlm-2065	7	3	)	)	PUNCT
ajlm-2065	7	4	.	.	PUNCT
ajlm-2065	8	1	licensee	licensee	NOUN
ajlm-2065	8	2	:	:	PUNCT
ajlm-2065	8	3	aosis	aosis	NOUN
ajlm-2065	8	4	.	.	PUNCT
ajlm-2065	9	1	this	this	PRON
ajlm-2065	9	2	is	be	AUX
ajlm-2065	9	3	an	an	DET
ajlm-2065	9	4	open	open	ADJ
ajlm-2065	9	5	access	access	NOUN
ajlm-2065	9	6	article	article	NOUN
ajlm-2065	9	7	distributed	distribute	VERB
ajlm-2065	9	8	under	under	ADP
ajlm-2065	9	9	the	the	DET
ajlm-2065	9	10	terms	term	NOUN
ajlm-2065	9	11	of	of	ADP
ajlm-2065	9	12	the	the	DET
ajlm-2065	9	13	creative	creative	ADJ
ajlm-2065	9	14	commons	common	NOUN
ajlm-2065	9	15	attribution	attribution	NOUN
ajlm-2065	9	16	license	license	NOUN
ajlm-2065	9	17	,	,	PUNCT
ajlm-2065	9	18	which	which	PRON
ajlm-2065	9	19	permits	permit	VERB
ajlm-2065	9	20	unrestricted	unrestricted	ADJ
ajlm-2065	9	21	use	use	NOUN
ajlm-2065	9	22	,	,	PUNCT
ajlm-2065	9	23	distribution	distribution	NOUN
ajlm-2065	9	24	,	,	PUNCT
ajlm-2065	9	25	and	and	CCONJ
ajlm-2065	9	26	reproduction	reproduction	NOUN
ajlm-2065	9	27	in	in	ADP
ajlm-2065	9	28	any	any	DET
ajlm-2065	9	29	medium	medium	NOUN
ajlm-2065	9	30	,	,	PUNCT
ajlm-2065	9	31	provided	provide	VERB
ajlm-2065	9	32	the	the	DET
ajlm-2065	9	33	original	original	ADJ
ajlm-2065	9	34	work	work	NOUN
ajlm-2065	9	35	is	be	AUX
ajlm-2065	9	36	properly	properly	ADV
ajlm-2065	9	37	cited	cite	VERB
ajlm-2065	9	38	.	.	PUNCT
ajlm-2065	10	1	abstract	abstract	ADJ
ajlm-2065	10	2	background	background	NOUN
ajlm-2065	10	3	:	:	PUNCT
ajlm-2065	10	4	kwazulu	kwazulu	VERB
ajlm-2065	10	5	-	-	PUNCT
ajlm-2065	10	6	natal	natal	NOUN
ajlm-2065	10	7	ranked	rank	VERB
ajlm-2065	10	8	second	second	ADV
ajlm-2065	10	9	highest	high	ADJ
ajlm-2065	10	10	among	among	ADP
ajlm-2065	10	11	south	south	ADJ
ajlm-2065	10	12	african	african	ADJ
ajlm-2065	10	13	provinces	province	NOUN
ajlm-2065	10	14	for	for	ADP
ajlm-2065	10	15	the	the	DET
ajlm-2065	10	16	number	number	NOUN
ajlm-2065	10	17	of	of	ADP
ajlm-2065	10	18	laboratory	laboratory	NOUN
ajlm-2065	10	19	-	-	PUNCT
ajlm-2065	10	20	confirmed	confirm	VERB
ajlm-2065	10	21	cases	case	NOUN
ajlm-2065	10	22	during	during	ADP
ajlm-2065	10	23	the	the	DET
ajlm-2065	10	24	second	second	ADJ
ajlm-2065	10	25	wave	wave	NOUN
ajlm-2065	10	26	of	of	ADP
ajlm-2065	10	27	the	the	DET
ajlm-2065	10	28	severe	severe	ADJ
ajlm-2065	10	29	acute	acute	ADJ
ajlm-2065	10	30	respiratory	respiratory	ADJ
ajlm-2065	10	31	syndrome	syndrome	NOUN
ajlm-2065	10	32	coronavirus	coronavirus	NOUN
ajlm-2065	10	33	2	2	NUM
ajlm-2065	10	34	(	(	PUNCT
ajlm-2065	10	35	sars	sar	NOUN
ajlm-2065	10	36	-	-	PUNCT
ajlm-2065	10	37	cov-2	cov-2	NOUN
ajlm-2065	10	38	)	)	PUNCT
ajlm-2065	10	39	pandemic	pandemic	NOUN
ajlm-2065	10	40	.	.	PUNCT
ajlm-2065	11	1	the	the	DET
ajlm-2065	11	2	seroprevalence	seroprevalence	NOUN
ajlm-2065	11	3	of	of	ADP
ajlm-2065	11	4	sars	sar	NOUN
ajlm-2065	11	5	-	-	PUNCT
ajlm-2065	11	6	cov-2	cov-2	NOUN
ajlm-2065	11	7	among	among	ADP
ajlm-2065	11	8	certain	certain	ADJ
ajlm-2065	11	9	vulnerable	vulnerable	ADJ
ajlm-2065	11	10	groups	group	NOUN
ajlm-2065	11	11	,	,	PUNCT
ajlm-2065	11	12	such	such	ADJ
ajlm-2065	11	13	as	as	ADP
ajlm-2065	11	14	people	people	NOUN
ajlm-2065	11	15	living	live	VERB
ajlm-2065	11	16	with	with	ADP
ajlm-2065	11	17	hiv	hiv	PROPN
ajlm-2065	11	18	in	in	ADP
ajlm-2065	11	19	kwazulu	kwazulu	PROPN
ajlm-2065	11	20	-	-	PUNCT
ajlm-2065	11	21	natal	natal	NOUN
ajlm-2065	11	22	,	,	PUNCT
ajlm-2065	11	23	is	be	AUX
ajlm-2065	11	24	unknown	unknown	ADJ
ajlm-2065	11	25	.	.	PUNCT
ajlm-2065	12	1	objective	objective	NOUN
ajlm-2065	12	2	:	:	PUNCT
ajlm-2065	12	3	the	the	DET
ajlm-2065	12	4	study	study	NOUN
ajlm-2065	12	5	aimed	aim	VERB
ajlm-2065	12	6	to	to	PART
ajlm-2065	12	7	determine	determine	VERB
ajlm-2065	12	8	the	the	DET
ajlm-2065	12	9	prevalence	prevalence	NOUN
ajlm-2065	12	10	of	of	ADP
ajlm-2065	12	11	sars	sar	NOUN
ajlm-2065	12	12	-	-	PUNCT
ajlm-2065	12	13	cov-2	cov-2	NOUN
ajlm-2065	12	14	immunoglobulin	immunoglobulin	NOUN
ajlm-2065	12	15	g	g	PROPN
ajlm-2065	12	16	(	(	PUNCT
ajlm-2065	12	17	igg	igg	PROPN
ajlm-2065	12	18	)	)	PUNCT
ajlm-2065	12	19	in	in	ADP
ajlm-2065	12	20	hiv	hiv	PROPN
ajlm-2065	12	21	-	-	PUNCT
ajlm-2065	12	22	positive	positive	ADJ
ajlm-2065	12	23	versus	versus	ADP
ajlm-2065	12	24	hiv	hiv	NOUN
ajlm-2065	12	25	-	-	PUNCT
ajlm-2065	12	26	negative	negative	ADJ
ajlm-2065	12	27	patients	patient	NOUN
ajlm-2065	12	28	.	.	PUNCT
ajlm-2065	13	1	methods	method	NOUN
ajlm-2065	13	2	:	:	PUNCT
ajlm-2065	13	3	this	this	PRON
ajlm-2065	13	4	was	be	AUX
ajlm-2065	13	5	a	a	DET
ajlm-2065	13	6	retrospective	retrospective	ADJ
ajlm-2065	13	7	analysis	analysis	NOUN
ajlm-2065	13	8	of	of	ADP
ajlm-2065	13	9	residual	residual	ADJ
ajlm-2065	13	10	clinical	clinical	ADJ
ajlm-2065	13	11	blood	blood	NOUN
ajlm-2065	13	12	specimens	specimen	NOUN
ajlm-2065	13	13	unrelated	unrelated	ADJ
ajlm-2065	13	14	to	to	ADP
ajlm-2065	13	15	coronavirus	coronavirus	NOUN
ajlm-2065	13	16	disease	disease	NOUN
ajlm-2065	13	17	2019	2019	NUM
ajlm-2065	13	18	(	(	PUNCT
ajlm-2065	13	19	covid-19	covid-19	PROPN
ajlm-2065	13	20	)	)	PUNCT
ajlm-2065	13	21	submitted	submit	VERB
ajlm-2065	13	22	for	for	ADP
ajlm-2065	13	23	diagnostic	diagnostic	ADJ
ajlm-2065	13	24	testing	testing	NOUN
ajlm-2065	13	25	at	at	ADP
ajlm-2065	13	26	inkosi	inkosi	PROPN
ajlm-2065	13	27	albert	albert	PROPN
ajlm-2065	13	28	luthuli	luthuli	PROPN
ajlm-2065	13	29	central	central	PROPN
ajlm-2065	13	30	hospital	hospital	NOUN
ajlm-2065	13	31	,	,	PUNCT
ajlm-2065	13	32	durban	durban	NOUN
ajlm-2065	13	33	,	,	PUNCT
ajlm-2065	13	34	from	from	ADP
ajlm-2065	13	35	10	10	NUM
ajlm-2065	13	36	november	november	PROPN
ajlm-2065	13	37	2020	2020	NUM
ajlm-2065	13	38	to	to	ADP
ajlm-2065	13	39	09	09	NUM
ajlm-2065	13	40	february	february	NOUN
ajlm-2065	13	41	2021	2021	NUM
ajlm-2065	13	42	.	.	PUNCT
ajlm-2065	14	1	specimens	specimen	NOUN
ajlm-2065	14	2	were	be	AUX
ajlm-2065	14	3	tested	test	VERB
ajlm-2065	14	4	for	for	ADP
ajlm-2065	14	5	sars	sar	NOUN
ajlm-2065	14	6	-	-	PUNCT
ajlm-2065	14	7	cov-2	cov-2	NOUN
ajlm-2065	14	8	immunoglobulin	immunoglobulin	NOUN
ajlm-2065	14	9	g	g	NOUN
ajlm-2065	14	10	on	on	ADP
ajlm-2065	14	11	the	the	DET
ajlm-2065	14	12	abbott	abbott	PROPN
ajlm-2065	14	13	architect	architect	NOUN
ajlm-2065	14	14	analyser	analyser	NOUN
ajlm-2065	14	15	.	.	PUNCT
ajlm-2065	15	1	results	result	NOUN
ajlm-2065	15	2	:	:	PUNCT
ajlm-2065	15	3	a	a	DET
ajlm-2065	15	4	total	total	NOUN
ajlm-2065	15	5	of	of	ADP
ajlm-2065	15	6	1977/8829	1977/8829	NUM
ajlm-2065	15	7	(	(	PUNCT
ajlm-2065	15	8	22.4	22.4	NUM
ajlm-2065	15	9	%	%	NOUN
ajlm-2065	15	10	)	)	PUNCT
ajlm-2065	15	11	specimens	specimen	NOUN
ajlm-2065	15	12	were	be	AUX
ajlm-2065	15	13	positive	positive	ADJ
ajlm-2065	15	14	for	for	ADP
ajlm-2065	15	15	sars	sar	NOUN
ajlm-2065	15	16	-	-	PUNCT
ajlm-2065	15	17	cov-2	cov-2	NOUN
ajlm-2065	15	18	antibodies	antibodie	VERB
ajlm-2065	15	19	.	.	PUNCT
ajlm-2065	16	1	seroprevalence	seroprevalence	NOUN
ajlm-2065	16	2	varied	varied	ADJ
ajlm-2065	16	3	between	between	ADP
ajlm-2065	16	4	health	health	NOUN
ajlm-2065	16	5	districts	district	NOUN
ajlm-2065	16	6	from	from	ADP
ajlm-2065	16	7	16.4	16.4	NUM
ajlm-2065	16	8	%	%	NOUN
ajlm-2065	16	9	to	to	ADP
ajlm-2065	16	10	37.3	37.3	NUM
ajlm-2065	16	11	%	%	NOUN
ajlm-2065	16	12	,	,	PUNCT
ajlm-2065	16	13	and	and	CCONJ
ajlm-2065	16	14	was	be	AUX
ajlm-2065	16	15	19	19	NUM
ajlm-2065	16	16	%	%	NOUN
ajlm-2065	16	17	in	in	ADP
ajlm-2065	16	18	hiv	hiv	PROPN
ajlm-2065	16	19	-	-	PUNCT
ajlm-2065	16	20	positive	positive	ADJ
ajlm-2065	16	21	and	and	CCONJ
ajlm-2065	16	22	35.3	35.3	NUM
ajlm-2065	16	23	%	%	NOUN
ajlm-2065	16	24	in	in	ADP
ajlm-2065	16	25	hiv	hiv	PROPN
ajlm-2065	16	26	-	-	PUNCT
ajlm-2065	16	27	negative	negative	ADJ
ajlm-2065	16	28	specimens	specimen	NOUN
ajlm-2065	16	29	.	.	PUNCT
ajlm-2065	17	1	seroprevalence	seroprevalence	NOUN
ajlm-2065	17	2	was	be	AUX
ajlm-2065	17	3	higher	high	ADJ
ajlm-2065	17	4	among	among	ADP
ajlm-2065	17	5	female	female	ADJ
ajlm-2065	17	6	patients	patient	NOUN
ajlm-2065	17	7	(	(	PUNCT
ajlm-2065	17	8	23.6	23.6	NUM
ajlm-2065	17	9	%	%	NOUN
ajlm-2065	17	10	vs	vs	ADP
ajlm-2065	17	11	19.8	19.8	NUM
ajlm-2065	17	12	%	%	NOUN
ajlm-2065	17	13	;	;	PUNCT
ajlm-2065	17	14	p	p	X
ajlm-2065	17	15	<	<	X
ajlm-2065	17	16	0.0001	0.0001	NUM
ajlm-2065	17	17	)	)	PUNCT
ajlm-2065	17	18	and	and	CCONJ
ajlm-2065	17	19	increased	increase	VERB
ajlm-2065	17	20	with	with	ADP
ajlm-2065	17	21	increasing	increase	VERB
ajlm-2065	17	22	age	age	NOUN
ajlm-2065	17	23	,	,	PUNCT
ajlm-2065	17	24	with	with	ADP
ajlm-2065	17	25	a	a	DET
ajlm-2065	17	26	statistically	statistically	ADV
ajlm-2065	17	27	significant	significant	ADJ
ajlm-2065	17	28	difference	difference	NOUN
ajlm-2065	17	29	between	between	ADP
ajlm-2065	17	30	the	the	DET
ajlm-2065	17	31	farthest	farth	ADJ
ajlm-2065	17	32	age	age	NOUN
ajlm-2065	17	33	groups	group	NOUN
ajlm-2065	17	34	(	(	PUNCT
ajlm-2065	17	35	<	<	X
ajlm-2065	17	36	10	10	NUM
ajlm-2065	17	37	years	year	NOUN
ajlm-2065	17	38	and	and	CCONJ
ajlm-2065	17	39	>	>	X
ajlm-2065	17	40	79	79	NUM
ajlm-2065	17	41	years	year	NOUN
ajlm-2065	17	42	;	;	PUNCT
ajlm-2065	17	43	p	p	X
ajlm-2065	17	44	<	<	X
ajlm-2065	17	45	0.0001	0.0001	NUM
ajlm-2065	17	46	)	)	PUNCT
ajlm-2065	17	47	.	.	PUNCT
ajlm-2065	18	1	the	the	DET
ajlm-2065	18	2	seroprevalence	seroprevalence	NOUN
ajlm-2065	18	3	increased	increase	VERB
ajlm-2065	18	4	from	from	ADP
ajlm-2065	18	5	17	17	NUM
ajlm-2065	18	6	%	%	NOUN
ajlm-2065	18	7	on	on	ADP
ajlm-2065	18	8	10	10	NUM
ajlm-2065	18	9	november	november	PROPN
ajlm-2065	18	10	2020	2020	NUM
ajlm-2065	18	11	to	to	ADP
ajlm-2065	18	12	43	43	NUM
ajlm-2065	18	13	%	%	NOUN
ajlm-2065	18	14	on	on	ADP
ajlm-2065	18	15	09	09	NUM
ajlm-2065	18	16	february	february	NOUN
ajlm-2065	18	17	2021	2021	NUM
ajlm-2065	18	18	during	during	ADP
ajlm-2065	18	19	the	the	DET
ajlm-2065	18	20	second	second	ADJ
ajlm-2065	18	21	wave	wave	NOUN
ajlm-2065	18	22	.	.	PUNCT
ajlm-2065	19	1	conclusion	conclusion	NOUN
ajlm-2065	19	2	:	:	PUNCT
ajlm-2065	19	3	our	our	PRON
ajlm-2065	19	4	results	result	NOUN
ajlm-2065	19	5	highlight	highlight	VERB
ajlm-2065	19	6	that	that	SCONJ
ajlm-2065	19	7	during	during	ADP
ajlm-2065	19	8	the	the	DET
ajlm-2065	19	9	second	second	ADJ
ajlm-2065	19	10	covid-19	covid-19	PROPN
ajlm-2065	19	11	wave	wave	NOUN
ajlm-2065	19	12	in	in	ADP
ajlm-2065	19	13	kwazulu	kwazulu	PROPN
ajlm-2065	19	14	-	-	PUNCT
ajlm-2065	19	15	natal	natal	NOUN
ajlm-2065	19	16	a	a	DET
ajlm-2065	19	17	large	large	ADJ
ajlm-2065	19	18	proportion	proportion	NOUN
ajlm-2065	19	19	of	of	ADP
ajlm-2065	19	20	people	people	NOUN
ajlm-2065	19	21	living	live	VERB
ajlm-2065	19	22	with	with	ADP
ajlm-2065	19	23	hiv	hiv	PROPN
ajlm-2065	19	24	were	be	AUX
ajlm-2065	19	25	still	still	ADV
ajlm-2065	19	26	immunologically	immunologically	ADV
ajlm-2065	19	27	susceptible	susceptible	ADJ
ajlm-2065	19	28	.	.	PUNCT
ajlm-2065	20	1	the	the	DET
ajlm-2065	20	2	reduced	reduce	VERB
ajlm-2065	20	3	seropositivity	seropositivity	NOUN
ajlm-2065	20	4	in	in	ADP
ajlm-2065	20	5	people	people	NOUN
ajlm-2065	20	6	with	with	ADP
ajlm-2065	20	7	virological	virological	ADJ
ajlm-2065	20	8	failure	failure	NOUN
ajlm-2065	20	9	further	far	ADV
ajlm-2065	20	10	emphasises	emphasise	VERB
ajlm-2065	20	11	the	the	DET
ajlm-2065	20	12	importance	importance	NOUN
ajlm-2065	20	13	of	of	ADP
ajlm-2065	20	14	targeted	target	VERB
ajlm-2065	20	15	vaccination	vaccination	NOUN
ajlm-2065	20	16	and	and	CCONJ
ajlm-2065	20	17	vaccine	vaccine	NOUN
ajlm-2065	20	18	response	response	NOUN
ajlm-2065	20	19	monitoring	monitoring	NOUN
ajlm-2065	20	20	in	in	ADP
ajlm-2065	20	21	these	these	DET
ajlm-2065	20	22	individuals	individual	NOUN
ajlm-2065	20	23	.	.	PUNCT
ajlm-2065	21	1	what	what	PRON
ajlm-2065	21	2	the	the	DET
ajlm-2065	21	3	study	study	NOUN
ajlm-2065	21	4	adds	add	VERB
ajlm-2065	21	5	:	:	PUNCT
ajlm-2065	21	6	this	this	DET
ajlm-2065	21	7	study	study	NOUN
ajlm-2065	21	8	contributes	contribute	VERB
ajlm-2065	21	9	to	to	ADP
ajlm-2065	21	10	data	datum	NOUN
ajlm-2065	21	11	on	on	ADP
ajlm-2065	21	12	sars	sar	NOUN
ajlm-2065	21	13	-	-	PUNCT
ajlm-2065	21	14	cov-2	cov-2	NOUN
ajlm-2065	21	15	seroprevalence	seroprevalence	NOUN
ajlm-2065	21	16	before	before	ADV
ajlm-2065	21	17	and	and	CCONJ
ajlm-2065	21	18	during	during	ADP
ajlm-2065	21	19	the	the	DET
ajlm-2065	21	20	second	second	ADJ
ajlm-2065	21	21	wave	wave	NOUN
ajlm-2065	21	22	in	in	ADP
ajlm-2065	21	23	kwazulu	kwazulu	NOUN
ajlm-2065	21	24	-	-	PUNCT
ajlm-2065	21	25	natal	natal	ADJ
ajlm-2065	21	26	,	,	PUNCT
ajlm-2065	21	27	south	south	PROPN
ajlm-2065	21	28	africa	africa	PROPN
ajlm-2065	21	29	,	,	PUNCT
ajlm-2065	21	30	which	which	PRON
ajlm-2065	21	31	has	have	VERB
ajlm-2065	21	32	the	the	DET
ajlm-2065	21	33	highest	high	ADJ
ajlm-2065	21	34	hiv	hiv	NOUN
ajlm-2065	21	35	prevalence	prevalence	NOUN
ajlm-2065	21	36	globally	globally	ADV
ajlm-2065	21	37	.	.	PUNCT
ajlm-2065	22	1	reduced	reduce	VERB
ajlm-2065	22	2	seropositivity	seropositivity	NOUN
ajlm-2065	22	3	was	be	AUX
ajlm-2065	22	4	found	find	VERB
ajlm-2065	22	5	among	among	ADP
ajlm-2065	22	6	people	people	NOUN
ajlm-2065	22	7	living	live	VERB
ajlm-2065	22	8	with	with	ADP
ajlm-2065	22	9	hiv	hiv	PROPN
ajlm-2065	22	10	with	with	ADP
ajlm-2065	22	11	virological	virological	ADJ
ajlm-2065	22	12	failure	failure	NOUN
ajlm-2065	22	13	,	,	PUNCT
ajlm-2065	22	14	highlighting	highlight	VERB
ajlm-2065	22	15	the	the	DET
ajlm-2065	22	16	importance	importance	NOUN
ajlm-2065	22	17	of	of	ADP
ajlm-2065	22	18	targeted	target	VERB
ajlm-2065	22	19	booster	booster	NOUN
ajlm-2065	22	20	vaccination	vaccination	NOUN
ajlm-2065	22	21	and	and	CCONJ
ajlm-2065	22	22	vaccine	vaccine	NOUN
ajlm-2065	22	23	response	response	NOUN
ajlm-2065	22	24	monitoring	monitoring	NOUN
ajlm-2065	22	25	.	.	PUNCT
ajlm-2065	23	1	keywords	keyword	NOUN
ajlm-2065	23	2	:	:	PUNCT
ajlm-2065	23	3	sars	sar	NOUN
ajlm-2065	23	4	-	-	PUNCT
ajlm-2065	23	5	cov-2	cov-2	NOUN
ajlm-2065	23	6	igg	igg	NOUN
ajlm-2065	23	7	prevalence	prevalence	NOUN
ajlm-2065	23	8	;	;	PUNCT
ajlm-2065	23	9	seroprevalence	seroprevalence	NOUN
ajlm-2065	23	10	hiv	hiv	NOUN
ajlm-2065	23	11	-	-	PUNCT
ajlm-2065	23	12	positive	positive	ADJ
ajlm-2065	23	13	and	and	CCONJ
ajlm-2065	23	14	hiv	hiv	NOUN
ajlm-2065	23	15	-	-	PUNCT
ajlm-2065	23	16	negative	negative	ADJ
ajlm-2065	23	17	;	;	PUNCT
ajlm-2065	23	18	anti	anti	ADJ
ajlm-2065	23	19	-	-	ADJ
ajlm-2065	23	20	sars	sar	NOUN
ajlm-2065	23	21	-	-	PUNCT
ajlm-2065	23	22	cov-2	cov-2	NOUN
ajlm-2065	23	23	igg	igg	PROPN
ajlm-2065	23	24	hiv	hiv	PROPN
ajlm-2065	23	25	-	-	PUNCT
ajlm-2065	23	26	positive	positive	ADJ
ajlm-2065	23	27	and	and	CCONJ
ajlm-2065	23	28	negative	negative	ADJ
ajlm-2065	23	29	;	;	PUNCT
ajlm-2065	23	30	seroprevalence	seroprevalence	NOUN
ajlm-2065	23	31	sars	sar	NOUN
ajlm-2065	23	32	-	-	PUNCT
ajlm-2065	23	33	cov-2	cov-2	NOUN
ajlm-2065	23	34	igg	igg	PROPN
ajlm-2065	23	35	;	;	PUNCT
ajlm-2065	23	36	kwazulu	kwazulu	VERB
ajlm-2065	23	37	-	-	PUNCT
ajlm-2065	23	38	natal	natal	NOUN
ajlm-2065	23	39	.	.	PUNCT
ajlm-2065	24	1	introduction	introduction	NOUN
ajlm-2065	24	2	coronavirus	coronavirus	NOUN
ajlm-2065	24	3	disease	disease	NOUN
ajlm-2065	24	4	2019	2019	NUM
ajlm-2065	24	5	(	(	PUNCT
ajlm-2065	24	6	covid-19	covid-19	PROPN
ajlm-2065	24	7	)	)	PUNCT
ajlm-2065	24	8	,	,	PUNCT
ajlm-2065	24	9	caused	cause	VERB
ajlm-2065	24	10	by	by	ADP
ajlm-2065	24	11	severe	severe	ADJ
ajlm-2065	24	12	acute	acute	ADJ
ajlm-2065	24	13	respiratory	respiratory	ADJ
ajlm-2065	24	14	syndrome	syndrome	NOUN
ajlm-2065	24	15	coronavirus	coronavirus	NOUN
ajlm-2065	24	16	2	2	NUM
ajlm-2065	24	17	(	(	PUNCT
ajlm-2065	24	18	sars	sar	NOUN
ajlm-2065	24	19	-	-	PUNCT
ajlm-2065	24	20	cov-2	cov-2	NOUN
ajlm-2065	24	21	)	)	PUNCT
ajlm-2065	24	22	,	,	PUNCT
ajlm-2065	24	23	is	be	AUX
ajlm-2065	24	24	one	one	NUM
ajlm-2065	24	25	of	of	ADP
ajlm-2065	24	26	the	the	DET
ajlm-2065	24	27	most	most	ADV
ajlm-2065	24	28	significant	significant	ADJ
ajlm-2065	24	29	pandemics	pandemic	NOUN
ajlm-2065	24	30	in	in	ADP
ajlm-2065	24	31	history	history	NOUN
ajlm-2065	24	32	.	.	PUNCT
ajlm-2065	25	1	in	in	ADP
ajlm-2065	25	2	africa	africa	PROPN
ajlm-2065	25	3	,	,	PUNCT
ajlm-2065	25	4	south	south	PROPN
ajlm-2065	25	5	africa	africa	PROPN
ajlm-2065	25	6	has	have	VERB
ajlm-2065	25	7	the	the	DET
ajlm-2065	25	8	highest	high	ADJ
ajlm-2065	25	9	number	number	NOUN
ajlm-2065	25	10	of	of	ADP
ajlm-2065	25	11	confirmed	confirm	VERB
ajlm-2065	25	12	cases	case	NOUN
ajlm-2065	25	13	(	(	PUNCT
ajlm-2065	25	14	africa	africa	PROPN
ajlm-2065	25	15	cdc	cdc	PROPN
ajlm-2065	25	16	covid-19	covid-19	PROPN
ajlm-2065	25	17	dashboard	dashboard	NOUN
ajlm-2065	25	18	,	,	PUNCT
ajlm-2065	25	19	2021	2021	NUM
ajlm-2065	25	20	–	–	PUNCT
ajlm-2065	25	21	https://africacdc.org/covid-19/	https://africacdc.org/covid-19/	NOUN
ajlm-2065	25	22	)	)	PUNCT
ajlm-2065	25	23	.	.	PUNCT
ajlm-2065	26	1	kwazulu	kwazulu	PROPN
ajlm-2065	26	2	-	-	PUNCT
ajlm-2065	26	3	natal	natal	PROPN
ajlm-2065	26	4	province	province	NOUN
ajlm-2065	26	5	ranked	rank	VERB
ajlm-2065	26	6	second	second	ADV
ajlm-2065	26	7	-	-	PUNCT
ajlm-2065	26	8	highest	high	ADJ
ajlm-2065	26	9	nationally	nationally	ADV
ajlm-2065	26	10	for	for	ADP
ajlm-2065	26	11	the	the	DET
ajlm-2065	26	12	number	number	NOUN
ajlm-2065	26	13	of	of	ADP
ajlm-2065	26	14	laboratory	laboratory	NOUN
ajlm-2065	26	15	-	-	PUNCT
ajlm-2065	26	16	confirmed	confirm	VERB
ajlm-2065	26	17	cases	case	NOUN
ajlm-2065	26	18	during	during	ADP
ajlm-2065	26	19	the	the	DET
ajlm-2065	26	20	second	second	ADJ
ajlm-2065	26	21	wave	wave	NOUN
ajlm-2065	26	22	of	of	ADP
ajlm-2065	26	23	the	the	DET
ajlm-2065	26	24	sars	sar	NOUN
ajlm-2065	26	25	-	-	PUNCT
ajlm-2065	26	26	cov-2	cov-2	NOUN
ajlm-2065	26	27	epidemic	epidemic	NOUN
ajlm-2065	26	28	in	in	ADP
ajlm-2065	26	29	south	south	PROPN
ajlm-2065	26	30	africa.1	africa.1	PROPN
ajlm-2065	26	31	the	the	DET
ajlm-2065	26	32	first	first	ADJ
ajlm-2065	26	33	wave	wave	NOUN
ajlm-2065	26	34	in	in	ADP
ajlm-2065	26	35	kwazulu	kwazulu	PROPN
ajlm-2065	26	36	-	-	PUNCT
ajlm-2065	26	37	natal	natal	NOUN
ajlm-2065	26	38	was	be	AUX
ajlm-2065	26	39	around	around	ADP
ajlm-2065	26	40	june	june	PROPN
ajlm-2065	26	41	2020	2020	NUM
ajlm-2065	26	42	–	–	PUNCT
ajlm-2065	26	43	july	july	PROPN
ajlm-2065	26	44	2020	2020	NUM
ajlm-2065	26	45	.	.	PUNCT
ajlm-2065	27	1	the	the	DET
ajlm-2065	27	2	wave	wave	NOUN
ajlm-2065	27	3	was	be	AUX
ajlm-2065	27	4	followed	follow	VERB
ajlm-2065	27	5	by	by	ADP
ajlm-2065	27	6	lower	low	ADJ
ajlm-2065	27	7	but	but	CCONJ
ajlm-2065	27	8	sustained	sustained	ADJ
ajlm-2065	27	9	viral	viral	ADJ
ajlm-2065	27	10	circulation	circulation	NOUN
ajlm-2065	27	11	between	between	ADP
ajlm-2065	27	12	august	august	PROPN
ajlm-2065	27	13	2020	2020	NUM
ajlm-2065	27	14	and	and	CCONJ
ajlm-2065	27	15	october	october	PROPN
ajlm-2065	27	16	2020	2020	NUM
ajlm-2065	27	17	and	and	CCONJ
ajlm-2065	27	18	a	a	DET
ajlm-2065	27	19	more	more	ADV
ajlm-2065	27	20	explosive	explosive	ADJ
ajlm-2065	27	21	second	second	ADJ
ajlm-2065	27	22	wave	wave	NOUN
ajlm-2065	27	23	from	from	ADP
ajlm-2065	27	24	november	november	PROPN
ajlm-2065	27	25	2020	2020	NUM
ajlm-2065	27	26	to	to	ADP
ajlm-2065	27	27	february	february	PROPN
ajlm-2065	27	28	2021	2021	NUM
ajlm-2065	27	29	.	.	PUNCT
ajlm-2065	28	1	the	the	DET
ajlm-2065	28	2	second	second	ADJ
ajlm-2065	28	3	wave	wave	NOUN
ajlm-2065	28	4	was	be	AUX
ajlm-2065	28	5	of	of	ADP
ajlm-2065	28	6	greater	great	ADJ
ajlm-2065	28	7	magnitude	magnitude	NOUN
ajlm-2065	28	8	than	than	ADP
ajlm-2065	28	9	the	the	DET
ajlm-2065	28	10	first	first	ADJ
ajlm-2065	28	11	,	,	PUNCT
ajlm-2065	28	12	with	with	SCONJ
ajlm-2065	28	13	the	the	DET
ajlm-2065	28	14	emergence	emergence	NOUN
ajlm-2065	28	15	of	of	ADP
ajlm-2065	28	16	the	the	DET
ajlm-2065	28	17	more	more	ADV
ajlm-2065	28	18	transmissible	transmissible	ADJ
ajlm-2065	28	19	beta	beta	NOUN
ajlm-2065	28	20	variant.2,3	variant.2,3	PROPN
ajlm-2065	28	21	the	the	DET
ajlm-2065	28	22	third	third	ADJ
ajlm-2065	28	23	wave	wave	NOUN
ajlm-2065	28	24	of	of	ADP
ajlm-2065	28	25	the	the	DET
ajlm-2065	28	26	epidemic	epidemic	NOUN
ajlm-2065	28	27	in	in	ADP
ajlm-2065	28	28	south	south	PROPN
ajlm-2065	28	29	africa	africa	PROPN
ajlm-2065	28	30	started	start	VERB
ajlm-2065	28	31	in	in	ADP
ajlm-2065	28	32	may	may	PROPN
ajlm-2065	28	33	2021	2021	NUM
ajlm-2065	28	34	,	,	PUNCT
ajlm-2065	28	35	with	with	ADP
ajlm-2065	28	36	a	a	DET
ajlm-2065	28	37	resurgence	resurgence	NOUN
ajlm-2065	28	38	in	in	ADP
ajlm-2065	28	39	kwazulu	kwazulu	NOUN
ajlm-2065	28	40	-	-	PUNCT
ajlm-2065	28	41	natal	natal	NOUN
ajlm-2065	28	42	in	in	ADP
ajlm-2065	28	43	june	june	PROPN
ajlm-2065	28	44	2021	2021	NUM
ajlm-2065	28	45	.	.	PUNCT
ajlm-2065	29	1	the	the	DET
ajlm-2065	29	2	more	more	ADV
ajlm-2065	29	3	transmissible	transmissible	ADJ
ajlm-2065	29	4	delta	delta	NOUN
ajlm-2065	29	5	variant	variant	NOUN
ajlm-2065	29	6	rapidly	rapidly	ADV
ajlm-2065	29	7	displaced	displace	VERB
ajlm-2065	29	8	the	the	DET
ajlm-2065	29	9	beta	beta	ADJ
ajlm-2065	29	10	variant	variant	NOUN
ajlm-2065	29	11	between	between	ADP
ajlm-2065	29	12	may	may	PROPN
ajlm-2065	29	13	2021	2021	NUM
ajlm-2065	29	14	and	and	CCONJ
ajlm-2065	29	15	august	august	PROPN
ajlm-2065	29	16	2021	2021	NUM
ajlm-2065	29	17	,	,	PUNCT
ajlm-2065	29	18	while	while	SCONJ
ajlm-2065	29	19	the	the	DET
ajlm-2065	29	20	even	even	ADV
ajlm-2065	29	21	more	more	ADV
ajlm-2065	29	22	highly	highly	ADV
ajlm-2065	29	23	transmissible	transmissible	ADJ
ajlm-2065	29	24	omicron	omicron	NOUN
ajlm-2065	29	25	variant	variant	NOUN
ajlm-2065	29	26	overtook	overtake	VERB
ajlm-2065	29	27	the	the	DET
ajlm-2065	29	28	delta	delta	NOUN
ajlm-2065	29	29	variant	variant	NOUN
ajlm-2065	29	30	between	between	ADP
ajlm-2065	29	31	november	november	PROPN
ajlm-2065	29	32	2021	2021	NUM
ajlm-2065	29	33	and	and	CCONJ
ajlm-2065	29	34	january	january	PROPN
ajlm-2065	29	35	2022.2,4	2022.2,4	NUM
ajlm-2065	29	36	polymerase	polymerase	NOUN
ajlm-2065	29	37	chain	chain	NOUN
ajlm-2065	29	38	reaction	reaction	NOUN
ajlm-2065	29	39	(	(	PUNCT
ajlm-2065	29	40	pcr	pcr	PROPN
ajlm-2065	29	41	)	)	PUNCT
ajlm-2065	29	42	is	be	AUX
ajlm-2065	29	43	most	most	ADV
ajlm-2065	29	44	accurate	accurate	ADJ
ajlm-2065	29	45	for	for	ADP
ajlm-2065	29	46	the	the	DET
ajlm-2065	29	47	diagnosis	diagnosis	NOUN
ajlm-2065	29	48	of	of	ADP
ajlm-2065	29	49	acute	acute	ADJ
ajlm-2065	29	50	sars	sar	NOUN
ajlm-2065	29	51	-	-	PUNCT
ajlm-2065	29	52	cov-2	cov-2	NOUN
ajlm-2065	29	53	infection.5	infection.5	PROPN
ajlm-2065	29	54	however	however	ADV
ajlm-2065	29	55	,	,	PUNCT
ajlm-2065	29	56	the	the	DET
ajlm-2065	29	57	use	use	NOUN
ajlm-2065	29	58	of	of	ADP
ajlm-2065	29	59	pcr	pcr	NOUN
ajlm-2065	29	60	-	-	PUNCT
ajlm-2065	29	61	confirmed	confirm	VERB
ajlm-2065	29	62	cases	case	NOUN
ajlm-2065	29	63	for	for	ADP
ajlm-2065	29	64	reporting	reporting	NOUN
ajlm-2065	29	65	may	may	AUX
ajlm-2065	29	66	underestimate	underestimate	VERB
ajlm-2065	29	67	the	the	DET
ajlm-2065	29	68	true	true	ADJ
ajlm-2065	29	69	extent	extent	NOUN
ajlm-2065	29	70	of	of	ADP
ajlm-2065	29	71	the	the	DET
ajlm-2065	29	72	sars	sar	NOUN
ajlm-2065	29	73	-	-	PUNCT
ajlm-2065	29	74	cov-2	cov-2	NOUN
ajlm-2065	29	75	pandemic	pandemic	NOUN
ajlm-2065	29	76	.	.	PUNCT
ajlm-2065	30	1	although	although	SCONJ
ajlm-2065	30	2	not	not	PART
ajlm-2065	30	3	indicated	indicate	VERB
ajlm-2065	30	4	for	for	ADP
ajlm-2065	30	5	the	the	DET
ajlm-2065	30	6	diagnosis	diagnosis	NOUN
ajlm-2065	30	7	of	of	ADP
ajlm-2065	30	8	acute	acute	ADJ
ajlm-2065	30	9	infection	infection	NOUN
ajlm-2065	30	10	,	,	PUNCT
ajlm-2065	30	11	serology	serology	NOUN
ajlm-2065	30	12	may	may	AUX
ajlm-2065	30	13	give	give	VERB
ajlm-2065	30	14	a	a	DET
ajlm-2065	30	15	more	more	ADV
ajlm-2065	30	16	accurate	accurate	ADJ
ajlm-2065	30	17	reflection	reflection	NOUN
ajlm-2065	30	18	of	of	ADP
ajlm-2065	30	19	the	the	DET
ajlm-2065	30	20	true	true	ADJ
ajlm-2065	30	21	prevalence	prevalence	NOUN
ajlm-2065	30	22	of	of	ADP
ajlm-2065	30	23	infection	infection	NOUN
ajlm-2065	30	24	in	in	ADP
ajlm-2065	30	25	people	people	NOUN
ajlm-2065	30	26	who	who	PRON
ajlm-2065	30	27	may	may	AUX
ajlm-2065	30	28	not	not	PART
ajlm-2065	30	29	have	have	AUX
ajlm-2065	30	30	had	have	VERB
ajlm-2065	30	31	a	a	DET
ajlm-2065	30	32	pcr	pcr	ADJ
ajlm-2065	30	33	test	test	NOUN
ajlm-2065	30	34	during	during	ADP
ajlm-2065	30	35	acute	acute	ADJ
ajlm-2065	30	36	infection	infection	NOUN
ajlm-2065	30	37	or	or	CCONJ
ajlm-2065	30	38	who	who	PRON
ajlm-2065	30	39	were	be	AUX
ajlm-2065	30	40	asymptomatic.6	asymptomatic.6	NOUN
ajlm-2065	30	41	even	even	ADV
ajlm-2065	30	42	though	though	SCONJ
ajlm-2065	30	43	south	south	PROPN
ajlm-2065	30	44	africa	africa	PROPN
ajlm-2065	30	45	has	have	AUX
ajlm-2065	30	46	passed	pass	VERB
ajlm-2065	30	47	the	the	DET
ajlm-2065	30	48	third	third	ADJ
ajlm-2065	30	49	,	,	PUNCT
ajlm-2065	30	50	fourth	fourth	ADJ
ajlm-2065	30	51	and	and	CCONJ
ajlm-2065	30	52	fifth	fifth	ADJ
ajlm-2065	30	53	waves	wave	NOUN
ajlm-2065	30	54	of	of	ADP
ajlm-2065	30	55	the	the	DET
ajlm-2065	30	56	sars	sar	NOUN
ajlm-2065	30	57	-	-	PUNCT
ajlm-2065	30	58	cov-2	cov-2	NOUN
ajlm-2065	30	59	epidemic	epidemic	NOUN
ajlm-2065	30	60	and	and	CCONJ
ajlm-2065	30	61	is	be	AUX
ajlm-2065	30	62	currently	currently	ADV
ajlm-2065	30	63	experiencing	experience	VERB
ajlm-2065	30	64	a	a	DET
ajlm-2065	30	65	transition	transition	NOUN
ajlm-2065	30	66	phase	phase	NOUN
ajlm-2065	30	67	,	,	PUNCT
ajlm-2065	30	68	serological	serological	ADJ
ajlm-2065	30	69	surveillance	surveillance	NOUN
ajlm-2065	30	70	remains	remain	VERB
ajlm-2065	30	71	a	a	DET
ajlm-2065	30	72	vital	vital	ADJ
ajlm-2065	30	73	tool	tool	NOUN
ajlm-2065	30	74	to	to	PART
ajlm-2065	30	75	understand	understand	VERB
ajlm-2065	30	76	the	the	DET
ajlm-2065	30	77	true	true	ADJ
ajlm-2065	30	78	extent	extent	NOUN
ajlm-2065	30	79	of	of	ADP
ajlm-2065	30	80	sars	sar	NOUN
ajlm-2065	30	81	-	-	PUNCT
ajlm-2065	30	82	cov-2	cov-2	NOUN
ajlm-2065	30	83	exposure	exposure	NOUN
ajlm-2065	30	84	and	and	CCONJ
ajlm-2065	30	85	inform	inform	VERB
ajlm-2065	30	86	public	public	ADJ
ajlm-2065	30	87	health	health	NOUN
ajlm-2065	30	88	responses.7	responses.7	PROPN
ajlm-2065	30	89	seroprevalence	seroprevalence	NOUN
ajlm-2065	30	90	in	in	ADP
ajlm-2065	30	91	2020	2020	NUM
ajlm-2065	30	92	was	be	AUX
ajlm-2065	30	93	estimated	estimate	VERB
ajlm-2065	30	94	to	to	PART
ajlm-2065	30	95	be	be	AUX
ajlm-2065	30	96	5–10	5–10	ADJ
ajlm-2065	30	97	times	time	NOUN
ajlm-2065	30	98	higher	high	ADJ
ajlm-2065	30	99	than	than	ADP
ajlm-2065	30	100	reported	report	VERB
ajlm-2065	30	101	cases	case	NOUN
ajlm-2065	30	102	identified	identify	VERB
ajlm-2065	30	103	by	by	ADP
ajlm-2065	30	104	pcr.8,9,10	pcr.8,9,10	PROPN
ajlm-2065	30	105	a	a	DET
ajlm-2065	30	106	population	population	NOUN
ajlm-2065	30	107	-	-	PUNCT
ajlm-2065	30	108	based	base	VERB
ajlm-2065	30	109	seroepidemiological	seroepidemiological	ADJ
ajlm-2065	30	110	survey	survey	NOUN
ajlm-2065	30	111	in	in	ADP
ajlm-2065	30	112	gauteng	gauteng	PROPN
ajlm-2065	30	113	province	province	PROPN
ajlm-2065	30	114	in	in	ADP
ajlm-2065	30	115	south	south	PROPN
ajlm-2065	30	116	africa	africa	PROPN
ajlm-2065	30	117	,	,	PUNCT
ajlm-2065	30	118	that	that	PRON
ajlm-2065	30	119	started	start	VERB
ajlm-2065	30	120	8	8	NUM
ajlm-2065	30	121	weeks	week	NOUN
ajlm-2065	30	122	into	into	ADP
ajlm-2065	30	123	the	the	DET
ajlm-2065	30	124	first	first	ADJ
ajlm-2065	30	125	wave	wave	NOUN
ajlm-2065	30	126	and	and	CCONJ
ajlm-2065	30	127	ended	end	VERB
ajlm-2065	30	128	at	at	ADP
ajlm-2065	30	129	the	the	DET
ajlm-2065	30	130	peak	peak	NOUN
ajlm-2065	30	131	of	of	ADP
ajlm-2065	30	132	the	the	DET
ajlm-2065	30	133	second	second	ADJ
ajlm-2065	30	134	wave	wave	NOUN
ajlm-2065	30	135	,	,	PUNCT
ajlm-2065	30	136	estimated	estimate	VERB
ajlm-2065	30	137	that	that	SCONJ
ajlm-2065	30	138	there	there	PRON
ajlm-2065	30	139	were	be	VERB
ajlm-2065	30	140	2.89	2.89	NUM
ajlm-2065	30	141	million	million	NUM
ajlm-2065	30	142	sars	sar	NOUN
ajlm-2065	30	143	-	-	PUNCT
ajlm-2065	30	144	cov-2	cov-2	NOUN
ajlm-2065	30	145	infections	infection	NOUN
ajlm-2065	30	146	,	,	PUNCT
ajlm-2065	30	147	which	which	PRON
ajlm-2065	30	148	is	be	AUX
ajlm-2065	30	149	7–8	7–8	NUM
ajlm-2065	30	150	times	time	NOUN
ajlm-2065	30	151	higher	high	ADJ
ajlm-2065	30	152	than	than	ADP
ajlm-2065	30	153	the	the	DET
ajlm-2065	30	154	reported	report	VERB
ajlm-2065	30	155	332	332	NUM
ajlm-2065	30	156	000	000	NUM
ajlm-2065	30	157	pcr	pcr	ADJ
ajlm-2065	30	158	cases.10	cases.10	NOUN
ajlm-2065	30	159	local	local	ADJ
ajlm-2065	30	160	sars	sar	NOUN
ajlm-2065	30	161	-	-	PUNCT
ajlm-2065	30	162	cov-2	cov-2	PART
ajlm-2065	30	163	seroprevalence	seroprevalence	NOUN
ajlm-2065	30	164	rates	rate	NOUN
ajlm-2065	30	165	were	be	AUX
ajlm-2065	30	166	over	over	ADP
ajlm-2065	30	167	60	60	NUM
ajlm-2065	30	168	%	%	NOUN
ajlm-2065	30	169	in	in	ADP
ajlm-2065	30	170	black	black	ADJ
ajlm-2065	30	171	south	south	ADJ
ajlm-2065	30	172	african	african	ADJ
ajlm-2065	30	173	blood	blood	NOUN
ajlm-2065	30	174	donors11	donors11	NOUN
ajlm-2065	30	175	and	and	CCONJ
ajlm-2065	30	176	30	30	NUM
ajlm-2065	30	177	%	%	NOUN
ajlm-2065	30	178	–	–	PUNCT
ajlm-2065	30	179	40	40	NUM
ajlm-2065	30	180	%	%	NOUN
ajlm-2065	30	181	among	among	ADP
ajlm-2065	30	182	patients	patient	NOUN
ajlm-2065	30	183	accessing	access	VERB
ajlm-2065	30	184	care	care	NOUN
ajlm-2065	30	185	during	during	ADP
ajlm-2065	30	186	the	the	DET
ajlm-2065	30	187	first	first	ADJ
ajlm-2065	30	188	wave	wave	NOUN
ajlm-2065	30	189	in	in	ADP
ajlm-2065	30	190	the	the	DET
ajlm-2065	30	191	cape	cape	NOUN
ajlm-2065	30	192	town	town	NOUN
ajlm-2065	30	193	metropolitan	metropolitan	PROPN
ajlm-2065	30	194	sub	sub	NOUN
ajlm-2065	30	195	-	-	ADJ
ajlm-2065	30	196	districts.12	districts.12	ADJ
ajlm-2065	30	197	similarly	similarly	ADV
ajlm-2065	30	198	,	,	PUNCT
ajlm-2065	30	199	seroprevalence	seroprevalence	NOUN
ajlm-2065	30	200	studies	study	NOUN
ajlm-2065	30	201	in	in	ADP
ajlm-2065	30	202	spain	spain	PROPN
ajlm-2065	30	203	,	,	PUNCT
ajlm-2065	30	204	geneva	geneva	PROPN
ajlm-2065	30	205	and	and	CCONJ
ajlm-2065	30	206	new	new	PROPN
ajlm-2065	30	207	york	york	PROPN
ajlm-2065	30	208	reported	report	VERB
ajlm-2065	30	209	seroprevalence	seroprevalence	NOUN
ajlm-2065	30	210	higher	high	ADJ
ajlm-2065	30	211	than	than	ADP
ajlm-2065	30	212	the	the	DET
ajlm-2065	30	213	number	number	NOUN
ajlm-2065	30	214	of	of	ADP
ajlm-2065	30	215	reported	report	VERB
ajlm-2065	30	216	cases.13,14,15	cases.13,14,15	NOUN
ajlm-2065	30	217	ideally	ideally	ADV
ajlm-2065	30	218	,	,	PUNCT
ajlm-2065	30	219	population	population	NOUN
ajlm-2065	30	220	-	-	PUNCT
ajlm-2065	30	221	based	base	VERB
ajlm-2065	30	222	serosurveys	serosurvey	NOUN
ajlm-2065	30	223	should	should	AUX
ajlm-2065	30	224	be	be	AUX
ajlm-2065	30	225	used	use	VERB
ajlm-2065	30	226	to	to	PART
ajlm-2065	30	227	estimate	estimate	VERB
ajlm-2065	30	228	seroprevalence	seroprevalence	NOUN
ajlm-2065	30	229	nationally.16	nationally.16	PROPN
ajlm-2065	30	230	however	however	ADV
ajlm-2065	30	231	,	,	PUNCT
ajlm-2065	30	232	serosurveys	serosurvey	NOUN
ajlm-2065	30	233	require	require	VERB
ajlm-2065	30	234	extensive	extensive	ADJ
ajlm-2065	30	235	resources	resource	NOUN
ajlm-2065	30	236	,	,	PUNCT
ajlm-2065	30	237	and	and	CCONJ
ajlm-2065	30	238	involve	involve	VERB
ajlm-2065	30	239	active	active	ADJ
ajlm-2065	30	240	recruitment	recruitment	NOUN
ajlm-2065	30	241	and	and	CCONJ
ajlm-2065	30	242	prospective	prospective	ADJ
ajlm-2065	30	243	follow	follow	NOUN
ajlm-2065	30	244	-	-	PUNCT
ajlm-2065	30	245	up	up	NOUN
ajlm-2065	30	246	of	of	ADP
ajlm-2065	30	247	individuals	individual	NOUN
ajlm-2065	30	248	.	.	PUNCT
ajlm-2065	31	1	using	use	VERB
ajlm-2065	31	2	residual	residual	ADJ
ajlm-2065	31	3	clinical	clinical	ADJ
ajlm-2065	31	4	specimens	specimen	NOUN
ajlm-2065	31	5	submitted	submit	VERB
ajlm-2065	31	6	for	for	ADP
ajlm-2065	31	7	either	either	CCONJ
ajlm-2065	31	8	routine	routine	ADJ
ajlm-2065	31	9	screening	screening	NOUN
ajlm-2065	31	10	or	or	CCONJ
ajlm-2065	31	11	diagnostic	diagnostic	ADJ
ajlm-2065	31	12	testing	testing	NOUN
ajlm-2065	31	13	could	could	AUX
ajlm-2065	31	14	provide	provide	VERB
ajlm-2065	31	15	a	a	DET
ajlm-2065	31	16	snapshot16,17	snapshot16,17	NOUN
ajlm-2065	31	17	and	and	CCONJ
ajlm-2065	31	18	is	be	AUX
ajlm-2065	31	19	a	a	DET
ajlm-2065	31	20	convenient	convenient	ADJ
ajlm-2065	31	21	way	way	NOUN
ajlm-2065	31	22	to	to	PART
ajlm-2065	31	23	conduct	conduct	VERB
ajlm-2065	31	24	passive	passive	ADJ
ajlm-2065	31	25	surveillance	surveillance	NOUN
ajlm-2065	31	26	.	.	PUNCT
ajlm-2065	32	1	in	in	ADP
ajlm-2065	32	2	south	south	PROPN
ajlm-2065	32	3	africa	africa	PROPN
ajlm-2065	32	4	,	,	PUNCT
ajlm-2065	32	5	seroprevalence	seroprevalence	NOUN
ajlm-2065	32	6	studies	study	NOUN
ajlm-2065	32	7	using	use	VERB
ajlm-2065	32	8	convenience	convenience	NOUN
ajlm-2065	32	9	specimens	specimen	NOUN
ajlm-2065	32	10	have	have	AUX
ajlm-2065	32	11	been	be	AUX
ajlm-2065	32	12	conducted	conduct	VERB
ajlm-2065	32	13	by	by	ADP
ajlm-2065	32	14	the	the	DET
ajlm-2065	32	15	south	south	ADJ
ajlm-2065	32	16	african	african	ADJ
ajlm-2065	32	17	blood	blood	NOUN
ajlm-2065	32	18	bank	bank	PROPN
ajlm-2065	32	19	services	service	NOUN
ajlm-2065	32	20	(	(	PUNCT
ajlm-2065	32	21	sanbs	sanbs	PROPN
ajlm-2065	32	22	)	)	PUNCT
ajlm-2065	32	23	in	in	ADP
ajlm-2065	32	24	the	the	DET
ajlm-2065	32	25	western	western	ADJ
ajlm-2065	32	26	cape	cape	NOUN
ajlm-2065	32	27	and	and	CCONJ
ajlm-2065	32	28	gauteng.11,12,18	gauteng.11,12,18	NOUN
ajlm-2065	32	29	kwazulu	kwazulu	PROPN
ajlm-2065	32	30	-	-	PUNCT
ajlm-2065	32	31	natal	natal	NOUN
ajlm-2065	32	32	has	have	VERB
ajlm-2065	32	33	the	the	DET
ajlm-2065	32	34	world	world	NOUN
ajlm-2065	32	35	’s	’s	PART
ajlm-2065	32	36	highest	high	ADJ
ajlm-2065	32	37	hiv	hiv	PROPN
ajlm-2065	32	38	prevalence19	prevalence19	NOUN
ajlm-2065	32	39	and	and	CCONJ
ajlm-2065	32	40	has	have	VERB
ajlm-2065	32	41	the	the	DET
ajlm-2065	32	42	second	second	ADJ
ajlm-2065	32	43	highest	high	ADJ
ajlm-2065	32	44	number	number	NOUN
ajlm-2065	32	45	of	of	ADP
ajlm-2065	32	46	reported	report	VERB
ajlm-2065	32	47	sars	sar	NOUN
ajlm-2065	32	48	-	-	PUNCT
ajlm-2065	32	49	cov-2	cov-2	PART
ajlm-2065	32	50	infections	infection	NOUN
ajlm-2065	32	51	nationally	nationally	ADV
ajlm-2065	32	52	.	.	PUNCT
ajlm-2065	33	1	second	second	ADJ
ajlm-2065	33	2	-	-	PUNCT
ajlm-2065	33	3	wave	wave	NOUN
ajlm-2065	33	4	infections	infection	NOUN
ajlm-2065	33	5	in	in	ADP
ajlm-2065	33	6	south	south	PROPN
ajlm-2065	33	7	africa	africa	PROPN
ajlm-2065	33	8	caused	cause	VERB
ajlm-2065	33	9	by	by	ADP
ajlm-2065	33	10	the	the	DET
ajlm-2065	33	11	beta	beta	ADJ
ajlm-2065	33	12	variant	variant	NOUN
ajlm-2065	33	13	were	be	AUX
ajlm-2065	33	14	associated	associate	VERB
ajlm-2065	33	15	with	with	ADP
ajlm-2065	33	16	increased	increase	VERB
ajlm-2065	33	17	disease	disease	NOUN
ajlm-2065	33	18	severity	severity	NOUN
ajlm-2065	33	19	,	,	PUNCT
ajlm-2065	33	20	especially	especially	ADV
ajlm-2065	33	21	in	in	ADP
ajlm-2065	33	22	people	people	NOUN
ajlm-2065	33	23	living	live	VERB
ajlm-2065	33	24	with	with	ADP
ajlm-2065	33	25	hiv20	hiv20	PROPN
ajlm-2065	33	26	when	when	SCONJ
ajlm-2065	33	27	no	no	DET
ajlm-2065	33	28	vaccines	vaccine	NOUN
ajlm-2065	33	29	were	be	AUX
ajlm-2065	33	30	available	available	ADJ
ajlm-2065	33	31	.	.	PUNCT
ajlm-2065	34	1	thus	thus	ADV
ajlm-2065	34	2	,	,	PUNCT
ajlm-2065	34	3	an	an	DET
ajlm-2065	34	4	accurate	accurate	ADJ
ajlm-2065	34	5	estimate	estimate	NOUN
ajlm-2065	34	6	of	of	ADP
ajlm-2065	34	7	sars	sar	NOUN
ajlm-2065	34	8	-	-	PUNCT
ajlm-2065	34	9	cov-2	cov-2	PART
ajlm-2065	34	10	seroprevalence	seroprevalence	NOUN
ajlm-2065	34	11	among	among	ADP
ajlm-2065	34	12	people	people	NOUN
ajlm-2065	34	13	living	live	VERB
ajlm-2065	34	14	with	with	ADP
ajlm-2065	34	15	hiv	hiv	PROPN
ajlm-2065	34	16	was	be	AUX
ajlm-2065	34	17	important	important	ADJ
ajlm-2065	34	18	in	in	ADP
ajlm-2065	34	19	the	the	DET
ajlm-2065	34	20	early	early	ADJ
ajlm-2065	34	21	phase	phase	NOUN
ajlm-2065	34	22	of	of	ADP
ajlm-2065	34	23	the	the	DET
ajlm-2065	34	24	sars	sar	NOUN
ajlm-2065	34	25	-	-	PUNCT
ajlm-2065	34	26	cov-2	cov-2	NOUN
ajlm-2065	34	27	epidemic	epidemic	NOUN
ajlm-2065	34	28	for	for	ADP
ajlm-2065	34	29	outbreak	outbreak	NOUN
ajlm-2065	34	30	surveillance	surveillance	NOUN
ajlm-2065	34	31	,	,	PUNCT
ajlm-2065	34	32	implementation	implementation	NOUN
ajlm-2065	34	33	of	of	ADP
ajlm-2065	34	34	vaccination	vaccination	NOUN
ajlm-2065	34	35	strategies	strategy	NOUN
ajlm-2065	34	36	,	,	PUNCT
ajlm-2065	34	37	and	and	CCONJ
ajlm-2065	34	38	to	to	PART
ajlm-2065	34	39	assess	assess	VERB
ajlm-2065	34	40	the	the	DET
ajlm-2065	34	41	effectiveness	effectiveness	NOUN
ajlm-2065	34	42	of	of	ADP
ajlm-2065	34	43	non	non	ADJ
ajlm-2065	34	44	-	-	ADJ
ajlm-2065	34	45	pharmaceutical	pharmaceutical	ADJ
ajlm-2065	34	46	interventions	intervention	NOUN
ajlm-2065	34	47	in	in	ADP
ajlm-2065	34	48	kwazulu	kwazulu	NOUN
ajlm-2065	34	49	-	-	PUNCT
ajlm-2065	34	50	natal	natal	NOUN
ajlm-2065	34	51	.	.	PUNCT
ajlm-2065	35	1	we	we	PRON
ajlm-2065	35	2	therefore	therefore	ADV
ajlm-2065	35	3	determined	determine	VERB
ajlm-2065	35	4	the	the	DET
ajlm-2065	35	5	sars	sar	NOUN
ajlm-2065	35	6	-	-	PUNCT
ajlm-2065	35	7	cov-2	cov-2	NOUN
ajlm-2065	35	8	immunoglobulin	immunoglobulin	NOUN
ajlm-2065	35	9	g	g	PROPN
ajlm-2065	35	10	(	(	PUNCT
ajlm-2065	35	11	igg	igg	PROPN
ajlm-2065	35	12	)	)	PUNCT
ajlm-2065	35	13	seroprevalence	seroprevalence	NOUN
ajlm-2065	35	14	among	among	ADP
ajlm-2065	35	15	people	people	NOUN
ajlm-2065	35	16	with	with	ADP
ajlm-2065	35	17	hiv	hiv	PROPN
ajlm-2065	35	18	infection	infection	NOUN
ajlm-2065	35	19	in	in	ADP
ajlm-2065	35	20	kwazulu	kwazulu	PROPN
ajlm-2065	35	21	-	-	PUNCT
ajlm-2065	35	22	natal	natal	NOUN
ajlm-2065	35	23	.	.	PUNCT
ajlm-2065	36	1	methods	method	NOUN
ajlm-2065	36	2	ethical	ethical	ADJ
ajlm-2065	36	3	considerations	consideration	NOUN
ajlm-2065	36	4	this	this	DET
ajlm-2065	36	5	study	study	NOUN
ajlm-2065	36	6	was	be	AUX
ajlm-2065	36	7	approved	approve	VERB
ajlm-2065	36	8	by	by	ADP
ajlm-2065	36	9	university	university	PROPN
ajlm-2065	36	10	of	of	ADP
ajlm-2065	36	11	kwazulu	kwazulu	PROPN
ajlm-2065	36	12	-	-	PUNCT
ajlm-2065	36	13	natal	natal	ADJ
ajlm-2065	36	14	biomedical	biomedical	ADJ
ajlm-2065	36	15	research	research	NOUN
ajlm-2065	36	16	ethics	ethic	NOUN
ajlm-2065	36	17	committee	committee	PROPN
ajlm-2065	36	18	(	(	PUNCT
ajlm-2065	36	19	ref	ref	NOUN
ajlm-2065	36	20	.	.	PUNCT
ajlm-2065	37	1	bca256/010	bca256/010	NOUN
ajlm-2065	37	2	)	)	PUNCT
ajlm-2065	37	3	.	.	PUNCT
ajlm-2065	38	1	informed	inform	VERB
ajlm-2065	38	2	patient	patient	ADJ
ajlm-2065	38	3	consent	consent	NOUN
ajlm-2065	38	4	was	be	AUX
ajlm-2065	38	5	not	not	PART
ajlm-2065	38	6	required	require	VERB
ajlm-2065	38	7	as	as	SCONJ
ajlm-2065	38	8	this	this	PRON
ajlm-2065	38	9	was	be	AUX
ajlm-2065	38	10	a	a	DET
ajlm-2065	38	11	retrospective	retrospective	ADJ
ajlm-2065	38	12	study	study	NOUN
ajlm-2065	38	13	using	use	VERB
ajlm-2065	38	14	residual	residual	ADJ
ajlm-2065	38	15	diagnostic	diagnostic	ADJ
ajlm-2065	38	16	specimens	specimen	NOUN
ajlm-2065	38	17	.	.	PUNCT
ajlm-2065	39	1	no	no	DET
ajlm-2065	39	2	additional	additional	ADJ
ajlm-2065	39	3	specimens	specimen	NOUN
ajlm-2065	39	4	were	be	AUX
ajlm-2065	39	5	collected	collect	VERB
ajlm-2065	39	6	.	.	PUNCT
ajlm-2065	40	1	all	all	DET
ajlm-2065	40	2	residual	residual	ADJ
ajlm-2065	40	3	clinical	clinical	ADJ
ajlm-2065	40	4	specimens	specimen	NOUN
ajlm-2065	40	5	were	be	AUX
ajlm-2065	40	6	de	de	ADJ
ajlm-2065	40	7	-	-	VERB
ajlm-2065	40	8	identified	identify	VERB
ajlm-2065	40	9	and	and	CCONJ
ajlm-2065	40	10	labelled	label	VERB
ajlm-2065	40	11	with	with	ADP
ajlm-2065	40	12	a	a	DET
ajlm-2065	40	13	unique	unique	ADJ
ajlm-2065	40	14	study	study	NOUN
ajlm-2065	40	15	number	number	NOUN
ajlm-2065	40	16	;	;	PUNCT
ajlm-2065	40	17	patient	patient	ADJ
ajlm-2065	40	18	privacy	privacy	NOUN
ajlm-2065	40	19	and	and	CCONJ
ajlm-2065	40	20	confidentiality	confidentiality	NOUN
ajlm-2065	40	21	data	datum	NOUN
ajlm-2065	40	22	were	be	AUX
ajlm-2065	40	23	protected	protect	VERB
ajlm-2065	40	24	in	in	ADP
ajlm-2065	40	25	accordance	accordance	NOUN
ajlm-2065	40	26	with	with	ADP
ajlm-2065	40	27	the	the	DET
ajlm-2065	40	28	declaration	declaration	NOUN
ajlm-2065	40	29	of	of	ADP
ajlm-2065	40	30	helsinki	helsinki	PROPN
ajlm-2065	40	31	.	.	PUNCT
ajlm-2065	41	1	data	datum	NOUN
ajlm-2065	41	2	were	be	AUX
ajlm-2065	41	3	collected	collect	VERB
ajlm-2065	41	4	in	in	ADP
ajlm-2065	41	5	a	a	DET
ajlm-2065	41	6	password	password	NOUN
ajlm-2065	41	7	-	-	PUNCT
ajlm-2065	41	8	protected	protect	VERB
ajlm-2065	41	9	excel	excel	NOUN
ajlm-2065	41	10	spreadsheet	spreadsheet	NOUN
ajlm-2065	41	11	(	(	PUNCT
ajlm-2065	41	12	microsoft	microsoft	PROPN
ajlm-2065	41	13	corp	corp	PROPN
ajlm-2065	41	14	.	.	PROPN
ajlm-2065	41	15	,	,	PUNCT
ajlm-2065	41	16	redmond	redmond	PROPN
ajlm-2065	41	17	,	,	PUNCT
ajlm-2065	41	18	washington	washington	PROPN
ajlm-2065	41	19	,	,	PUNCT
ajlm-2065	41	20	united	united	PROPN
ajlm-2065	41	21	states	states	PROPN
ajlm-2065	41	22	)	)	PUNCT
ajlm-2065	41	23	on	on	ADP
ajlm-2065	41	24	a	a	DET
ajlm-2065	41	25	dedicated	dedicated	ADJ
ajlm-2065	41	26	computer	computer	NOUN
ajlm-2065	41	27	behind	behind	ADP
ajlm-2065	41	28	firewall	firewall	NOUN
ajlm-2065	41	29	-	-	PUNCT
ajlm-2065	41	30	protected	protect	VERB
ajlm-2065	41	31	servers	server	NOUN
ajlm-2065	41	32	,	,	PUNCT
ajlm-2065	41	33	which	which	PRON
ajlm-2065	41	34	was	be	AUX
ajlm-2065	41	35	only	only	ADV
ajlm-2065	41	36	accessible	accessible	ADJ
ajlm-2065	41	37	to	to	ADP
ajlm-2065	41	38	the	the	DET
ajlm-2065	41	39	primary	primary	ADJ
ajlm-2065	41	40	investigator	investigator	NOUN
ajlm-2065	41	41	.	.	PUNCT
ajlm-2065	42	1	study	study	NOUN
ajlm-2065	42	2	design	design	VERB
ajlm-2065	42	3	the	the	DET
ajlm-2065	42	4	authors	author	NOUN
ajlm-2065	42	5	retrospectively	retrospectively	ADV
ajlm-2065	42	6	tested	test	VERB
ajlm-2065	42	7	residual	residual	ADJ
ajlm-2065	42	8	clinical	clinical	ADJ
ajlm-2065	42	9	sera	sera	NOUN
ajlm-2065	42	10	and	and	CCONJ
ajlm-2065	42	11	plasma	plasma	NOUN
ajlm-2065	42	12	specimens	specimen	NOUN
ajlm-2065	42	13	submitted	submit	VERB
ajlm-2065	42	14	to	to	ADP
ajlm-2065	42	15	the	the	DET
ajlm-2065	42	16	department	department	NOUN
ajlm-2065	42	17	of	of	ADP
ajlm-2065	42	18	virology	virology	NOUN
ajlm-2065	42	19	at	at	ADP
ajlm-2065	42	20	inkosi	inkosi	PROPN
ajlm-2065	42	21	albert	albert	PROPN
ajlm-2065	42	22	luthuli	luthuli	PROPN
ajlm-2065	42	23	central	central	PROPN
ajlm-2065	42	24	hospital	hospital	NOUN
ajlm-2065	42	25	,	,	PUNCT
ajlm-2065	42	26	durban	durban	NOUN
ajlm-2065	42	27	,	,	PUNCT
ajlm-2065	42	28	for	for	ADP
ajlm-2065	42	29	diagnostic	diagnostic	ADJ
ajlm-2065	42	30	testing	testing	NOUN
ajlm-2065	42	31	unrelated	unrelated	ADJ
ajlm-2065	42	32	to	to	ADP
ajlm-2065	42	33	covid-19	covid-19	PROPN
ajlm-2065	42	34	from	from	ADP
ajlm-2065	42	35	10	10	NUM
ajlm-2065	42	36	november	november	PROPN
ajlm-2065	42	37	2020	2020	NUM
ajlm-2065	42	38	to	to	ADP
ajlm-2065	42	39	09	09	NUM
ajlm-2065	42	40	february	february	NOUN
ajlm-2065	42	41	2021	2021	NUM
ajlm-2065	42	42	,	,	PUNCT
ajlm-2065	42	43	representing	represent	VERB
ajlm-2065	42	44	the	the	DET
ajlm-2065	42	45	period	period	NOUN
ajlm-2065	42	46	before	before	ADP
ajlm-2065	42	47	and	and	CCONJ
ajlm-2065	42	48	during	during	ADP
ajlm-2065	42	49	the	the	DET
ajlm-2065	42	50	second	second	ADJ
ajlm-2065	42	51	wave	wave	NOUN
ajlm-2065	42	52	(	(	PUNCT
ajlm-2065	42	53	22	22	NUM
ajlm-2065	42	54	november	november	PROPN
ajlm-2065	42	55	2020	2020	NUM
ajlm-2065	42	56	to	to	ADP
ajlm-2065	42	57	27	27	NUM
ajlm-2065	42	58	march	march	NOUN
ajlm-2065	42	59	2021	2021	NUM
ajlm-2065	42	60	)	)	PUNCT
ajlm-2065	42	61	of	of	ADP
ajlm-2065	42	62	the	the	DET
ajlm-2065	42	63	sars	sar	NOUN
ajlm-2065	42	64	-	-	PUNCT
ajlm-2065	42	65	cov-2	cov-2	NOUN
ajlm-2065	42	66	epidemic	epidemic	NOUN
ajlm-2065	42	67	in	in	ADP
ajlm-2065	42	68	kwazulu	kwazulu	PROPN
ajlm-2065	42	69	-	-	PUNCT
ajlm-2065	42	70	natal	natal	NOUN
ajlm-2065	42	71	.	.	PUNCT
ajlm-2065	43	1	sample	sample	NOUN
ajlm-2065	43	2	size	size	NOUN
ajlm-2065	43	3	a	a	DET
ajlm-2065	43	4	minimum	minimum	NOUN
ajlm-2065	43	5	sample	sample	NOUN
ajlm-2065	43	6	size	size	NOUN
ajlm-2065	43	7	of	of	ADP
ajlm-2065	43	8	7294	7294	NUM
ajlm-2065	43	9	was	be	AUX
ajlm-2065	43	10	estimated	estimate	VERB
ajlm-2065	43	11	using	use	VERB
ajlm-2065	43	12	openepi	openepi	PROPN
ajlm-2065	43	13	(	(	PUNCT
ajlm-2065	43	14	version	version	NOUN
ajlm-2065	43	15	3.1	3.1	NUM
ajlm-2065	43	16	;	;	PUNCT
ajlm-2065	43	17	http://www.openepi.com/)21	http://www.openepi.com/)21	NOUN
ajlm-2065	43	18	based	base	VERB
ajlm-2065	43	19	on	on	ADP
ajlm-2065	43	20	a	a	DET
ajlm-2065	43	21	sars	sar	NOUN
ajlm-2065	43	22	-	-	PUNCT
ajlm-2065	43	23	cov-2	cov-2	NOUN
ajlm-2065	43	24	prevalence	prevalence	NOUN
ajlm-2065	43	25	of	of	ADP
ajlm-2065	43	26	5	5	NUM
ajlm-2065	43	27	%	%	NOUN
ajlm-2065	43	28	to	to	PART
ajlm-2065	43	29	10	10	NUM
ajlm-2065	43	30	%	%	NOUN
ajlm-2065	43	31	before	before	ADP
ajlm-2065	43	32	the	the	DET
ajlm-2065	43	33	second	second	ADJ
ajlm-2065	43	34	wave	wave	NOUN
ajlm-2065	43	35	peak	peak	NOUN
ajlm-2065	43	36	with	with	ADP
ajlm-2065	43	37	a	a	DET
ajlm-2065	43	38	maximum	maximum	ADJ
ajlm-2065	43	39	1	1	NUM
ajlm-2065	43	40	%	%	NOUN
ajlm-2065	43	41	margin	margin	NOUN
ajlm-2065	43	42	error	error	NOUN
ajlm-2065	43	43	and	and	CCONJ
ajlm-2065	43	44	using	use	VERB
ajlm-2065	43	45	published	publish	VERB
ajlm-2065	43	46	seroprevalence	seroprevalence	NOUN
ajlm-2065	43	47	data	datum	NOUN
ajlm-2065	43	48	from	from	ADP
ajlm-2065	43	49	studies	study	NOUN
ajlm-2065	43	50	done	do	VERB
ajlm-2065	43	51	globally	globally	ADV
ajlm-2065	43	52	(	(	PUNCT
ajlm-2065	43	53	5%,10	5%,10	NUM
ajlm-2065	43	54	1	1	NUM
ajlm-2065	43	55	%	%	NOUN
ajlm-2065	43	56	–	–	PUNCT
ajlm-2065	43	57	6.9%22	6.9%22	NUM
ajlm-2065	43	58	and	and	CCONJ
ajlm-2065	43	59	1	1	NUM
ajlm-2065	43	60	%	%	NOUN
ajlm-2065	43	61	–	–	PUNCT
ajlm-2065	43	62	10%8	10%8	NUM
ajlm-2065	43	63	)	)	PUNCT
ajlm-2065	43	64	,	,	PUNCT
ajlm-2065	43	65	the	the	DET
ajlm-2065	43	66	assumed	assumed	ADJ
ajlm-2065	43	67	point	point	NOUN
ajlm-2065	43	68	prevalence	prevalence	NOUN
ajlm-2065	43	69	was	be	AUX
ajlm-2065	43	70	calculated	calculate	VERB
ajlm-2065	43	71	.	.	PUNCT
ajlm-2065	44	1	using	use	VERB
ajlm-2065	44	2	the	the	DET
ajlm-2065	44	3	stata	stata	NOUN
ajlm-2065	44	4	®	®	PROPN
ajlm-2065	44	5	(	(	PUNCT
ajlm-2065	44	6	statacorp	statacorp	PROPN
ajlm-2065	44	7	,	,	PUNCT
ajlm-2065	44	8	college	college	NOUN
ajlm-2065	44	9	station	station	NOUN
ajlm-2065	44	10	,	,	PUNCT
ajlm-2065	44	11	texas	texas	PROPN
ajlm-2065	44	12	,	,	PUNCT
ajlm-2065	44	13	united	united	PROPN
ajlm-2065	44	14	staes	staes	PROPN
ajlm-2065	44	15	)	)	PUNCT
ajlm-2065	44	16	sampsi	sampsi	NOUN
ajlm-2065	44	17	function	function	NOUN
ajlm-2065	44	18	,	,	PUNCT
ajlm-2065	44	19	the	the	DET
ajlm-2065	44	20	sample	sample	NOUN
ajlm-2065	44	21	size	size	NOUN
ajlm-2065	44	22	was	be	AUX
ajlm-2065	44	23	calculated	calculate	VERB
ajlm-2065	44	24	to	to	PART
ajlm-2065	44	25	compare	compare	VERB
ajlm-2065	44	26	sars	sar	NOUN
ajlm-2065	44	27	-	-	PUNCT
ajlm-2065	44	28	cov-2	cov-2	NOUN
ajlm-2065	44	29	seropositivity	seropositivity	NOUN
ajlm-2065	44	30	in	in	ADP
ajlm-2065	44	31	hiv	hiv	PROPN
ajlm-2065	44	32	-	-	PUNCT
ajlm-2065	44	33	positive	positive	ADJ
ajlm-2065	44	34	and	and	CCONJ
ajlm-2065	44	35	hiv	hiv	NOUN
ajlm-2065	44	36	-	-	PUNCT
ajlm-2065	44	37	negative	negative	ADJ
ajlm-2065	44	38	individuals	individual	NOUN
ajlm-2065	44	39	with	with	ADP
ajlm-2065	44	40	a	a	DET
ajlm-2065	44	41	power	power	NOUN
ajlm-2065	44	42	of	of	ADP
ajlm-2065	44	43	80	80	NUM
ajlm-2065	44	44	%	%	NOUN
ajlm-2065	44	45	,	,	PUNCT
ajlm-2065	44	46	two	two	NUM
ajlm-2065	44	47	-	-	PUNCT
ajlm-2065	44	48	sided	sided	ADJ
ajlm-2065	44	49	alpha	alpha	NOUN
ajlm-2065	44	50	of	of	ADP
ajlm-2065	44	51	0.05	0.05	NUM
ajlm-2065	44	52	and	and	CCONJ
ajlm-2065	44	53	equal	equal	ADJ
ajlm-2065	44	54	size	size	NOUN
ajlm-2065	44	55	in	in	ADP
ajlm-2065	44	56	each	each	DET
ajlm-2065	44	57	group	group	NOUN
ajlm-2065	44	58	.	.	PUNCT
ajlm-2065	45	1	a	a	DET
ajlm-2065	45	2	sample	sample	NOUN
ajlm-2065	45	3	size	size	NOUN
ajlm-2065	45	4	of	of	ADP
ajlm-2065	45	5	3682	3682	NUM
ajlm-2065	45	6	would	would	AUX
ajlm-2065	45	7	be	be	AUX
ajlm-2065	45	8	sufficient	sufficient	ADJ
ajlm-2065	45	9	to	to	PART
ajlm-2065	45	10	detect	detect	VERB
ajlm-2065	45	11	a	a	DET
ajlm-2065	45	12	1	1	NUM
ajlm-2065	45	13	%	%	NOUN
ajlm-2065	45	14	difference	difference	NOUN
ajlm-2065	45	15	if	if	SCONJ
ajlm-2065	45	16	the	the	DET
ajlm-2065	45	17	prevalence	prevalence	NOUN
ajlm-2065	45	18	is	be	AUX
ajlm-2065	45	19	low	low	ADJ
ajlm-2065	45	20	(	(	PUNCT
ajlm-2065	45	21	1	1	NUM
ajlm-2065	45	22	%	%	NOUN
ajlm-2065	45	23	)	)	PUNCT
ajlm-2065	45	24	and	and	CCONJ
ajlm-2065	45	25	a	a	DET
ajlm-2065	45	26	3	3	NUM
ajlm-2065	45	27	%	%	NOUN
ajlm-2065	45	28	difference	difference	NOUN
ajlm-2065	45	29	if	if	SCONJ
ajlm-2065	45	30	the	the	DET
ajlm-2065	45	31	prevalence	prevalence	NOUN
ajlm-2065	45	32	is	be	AUX
ajlm-2065	45	33	high	high	ADJ
ajlm-2065	45	34	(	(	PUNCT
ajlm-2065	45	35	13%).8,13,22	13%).8,13,22	NUM
ajlm-2065	45	36	specimen	speciman	NOUN
ajlm-2065	45	37	selection	selection	NOUN
ajlm-2065	45	38	sera	sera	NOUN
ajlm-2065	45	39	and	and	CCONJ
ajlm-2065	45	40	plasma	plasma	NOUN
ajlm-2065	45	41	specimens	specimen	NOUN
ajlm-2065	45	42	with	with	ADP
ajlm-2065	45	43	sufficient	sufficient	ADJ
ajlm-2065	45	44	volumes	volume	NOUN
ajlm-2065	45	45	from	from	ADP
ajlm-2065	45	46	the	the	DET
ajlm-2065	45	47	viral	viral	ADJ
ajlm-2065	45	48	serology	serology	NOUN
ajlm-2065	45	49	(	(	PUNCT
ajlm-2065	45	50	hiv	hiv	NOUN
ajlm-2065	45	51	and	and	CCONJ
ajlm-2065	45	52	hepatitis	hepatitis	PROPN
ajlm-2065	45	53	b	b	NOUN
ajlm-2065	45	54	enzyme	enzyme	NOUN
ajlm-2065	45	55	-	-	PUNCT
ajlm-2065	45	56	linked	link	VERB
ajlm-2065	45	57	immunosorbent	immunosorbent	NOUN
ajlm-2065	45	58	assay	assay	NOUN
ajlm-2065	45	59	and	and	CCONJ
ajlm-2065	45	60	hiv	hiv	PROPN
ajlm-2065	45	61	viral	viral	ADJ
ajlm-2065	45	62	load	load	NOUN
ajlm-2065	45	63	laboratory	laboratory	NOUN
ajlm-2065	45	64	sections	section	NOUN
ajlm-2065	45	65	)	)	PUNCT
ajlm-2065	45	66	were	be	AUX
ajlm-2065	45	67	selected	select	VERB
ajlm-2065	45	68	for	for	ADP
ajlm-2065	45	69	sars	sar	NOUN
ajlm-2065	45	70	-	-	PUNCT
ajlm-2065	45	71	cov-2	cov-2	NOUN
ajlm-2065	45	72	igg	igg	PROPN
ajlm-2065	45	73	testing	testing	NOUN
ajlm-2065	45	74	.	.	PUNCT
ajlm-2065	46	1	specimens	specimen	NOUN
ajlm-2065	46	2	with	with	ADP
ajlm-2065	46	3	inadequate	inadequate	ADJ
ajlm-2065	46	4	volumes	volume	NOUN
ajlm-2065	46	5	(	(	PUNCT
ajlm-2065	46	6	<	<	X
ajlm-2065	46	7	100	100	NUM
ajlm-2065	46	8	µl	µl	NOUN
ajlm-2065	46	9	)	)	PUNCT
ajlm-2065	46	10	were	be	AUX
ajlm-2065	46	11	excluded	exclude	VERB
ajlm-2065	46	12	.	.	PUNCT
ajlm-2065	47	1	the	the	DET
ajlm-2065	47	2	selected	select	VERB
ajlm-2065	47	3	specimen	speciman	NOUN
ajlm-2065	47	4	results	result	NOUN
ajlm-2065	47	5	were	be	AUX
ajlm-2065	47	6	linked	link	VERB
ajlm-2065	47	7	to	to	ADP
ajlm-2065	47	8	demographic	demographic	ADJ
ajlm-2065	47	9	information	information	NOUN
ajlm-2065	47	10	extracted	extract	VERB
ajlm-2065	47	11	from	from	ADP
ajlm-2065	47	12	the	the	DET
ajlm-2065	47	13	laboratory	laboratory	NOUN
ajlm-2065	47	14	information	information	NOUN
ajlm-2065	47	15	system	system	NOUN
ajlm-2065	47	16	.	.	PUNCT
ajlm-2065	48	1	specimens	specimen	NOUN
ajlm-2065	48	2	from	from	ADP
ajlm-2065	48	3	the	the	DET
ajlm-2065	48	4	same	same	ADJ
ajlm-2065	48	5	patient	patient	NOUN
ajlm-2065	48	6	were	be	AUX
ajlm-2065	48	7	tested	test	VERB
ajlm-2065	48	8	once	once	ADV
ajlm-2065	48	9	only	only	ADV
ajlm-2065	48	10	.	.	PUNCT
ajlm-2065	49	1	laboratory	laboratory	NOUN
ajlm-2065	49	2	methods	method	NOUN
ajlm-2065	49	3	testing	test	VERB
ajlm-2065	49	4	for	for	ADP
ajlm-2065	49	5	sars	sar	NOUN
ajlm-2065	49	6	-	-	PUNCT
ajlm-2065	49	7	cov-2	cov-2	NOUN
ajlm-2065	49	8	igg	igg	PROPN
ajlm-2065	49	9	was	be	AUX
ajlm-2065	49	10	performed	perform	VERB
ajlm-2065	49	11	on	on	ADP
ajlm-2065	49	12	the	the	DET
ajlm-2065	49	13	abbott	abbott	PROPN
ajlm-2065	49	14	architect	architect	NOUN
ajlm-2065	49	15	using	use	VERB
ajlm-2065	49	16	the	the	DET
ajlm-2065	49	17	abbott	abbott	PROPN
ajlm-2065	49	18	architect	architect	PROPN
ajlm-2065	49	19	sars	sar	NOUN
ajlm-2065	49	20	-	-	PUNCT
ajlm-2065	49	21	cov-2	cov-2	NOUN
ajlm-2065	49	22	igg	igg	PROPN
ajlm-2065	49	23	assay	assay	PROPN
ajlm-2065	49	24	(	(	PUNCT
ajlm-2065	49	25	abbott	abbott	PROPN
ajlm-2065	49	26	diagnostics	diagnostics	PROPN
ajlm-2065	49	27	,	,	PUNCT
ajlm-2065	49	28	abbott	abbott	PROPN
ajlm-2065	49	29	park	park	PROPN
ajlm-2065	49	30	,	,	PUNCT
ajlm-2065	49	31	illinois	illinois	PROPN
ajlm-2065	49	32	,	,	PUNCT
ajlm-2065	49	33	united	united	PROPN
ajlm-2065	49	34	states).23	states).23	PROPN
ajlm-2065	49	35	sera	sera	PROPN
ajlm-2065	49	36	and	and	CCONJ
ajlm-2065	49	37	plasma	plasma	NOUN
ajlm-2065	49	38	specimens	specimen	NOUN
ajlm-2065	49	39	were	be	AUX
ajlm-2065	49	40	stored	store	VERB
ajlm-2065	49	41	at	at	ADP
ajlm-2065	49	42	2	2	NUM
ajlm-2065	49	43	°	°	ADP
ajlm-2065	49	44	c	c	NOUN
ajlm-2065	49	45	–	–	PUNCT
ajlm-2065	49	46	8	8	NUM
ajlm-2065	49	47	°	°	ADP
ajlm-2065	49	48	c	c	NOUN
ajlm-2065	49	49	for	for	ADP
ajlm-2065	49	50	not	not	PART
ajlm-2065	49	51	more	more	ADJ
ajlm-2065	49	52	than	than	ADP
ajlm-2065	49	53	7	7	NUM
ajlm-2065	49	54	days	day	NOUN
ajlm-2065	49	55	and	and	CCONJ
ajlm-2065	49	56	−20	−20	NOUN
ajlm-2065	49	57	°	°	CCONJ
ajlm-2065	49	58	c	c	NOUN
ajlm-2065	49	59	for	for	ADP
ajlm-2065	49	60	long	long	ADJ
ajlm-2065	49	61	-	-	PUNCT
ajlm-2065	49	62	term	term	NOUN
ajlm-2065	49	63	(	(	PUNCT
ajlm-2065	49	64	>	>	X
ajlm-2065	49	65	7	7	NUM
ajlm-2065	49	66	days	day	NOUN
ajlm-2065	49	67	)	)	PUNCT
ajlm-2065	49	68	storage	storage	NOUN
ajlm-2065	49	69	.	.	PUNCT
ajlm-2065	50	1	the	the	DET
ajlm-2065	50	2	assay	assay	NOUN
ajlm-2065	50	3	is	be	AUX
ajlm-2065	50	4	an	an	DET
ajlm-2065	50	5	automated	automate	VERB
ajlm-2065	50	6	two	two	NUM
ajlm-2065	50	7	-	-	PUNCT
ajlm-2065	50	8	step	step	NOUN
ajlm-2065	50	9	chemiluminescent	chemiluminescent	PROPN
ajlm-2065	50	10	microparticle	microparticle	PROPN
ajlm-2065	50	11	immunoassay	immunoassay	PROPN
ajlm-2065	50	12	for	for	ADP
ajlm-2065	50	13	qualitative	qualitative	ADJ
ajlm-2065	50	14	detection	detection	NOUN
ajlm-2065	50	15	of	of	ADP
ajlm-2065	50	16	sars	sar	NOUN
ajlm-2065	50	17	-	-	PUNCT
ajlm-2065	50	18	cov-2	cov-2	NOUN
ajlm-2065	50	19	igg	igg	PROPN
ajlm-2065	50	20	antibodies	antibodie	VERB
ajlm-2065	50	21	against	against	ADP
ajlm-2065	50	22	the	the	DET
ajlm-2065	50	23	sars	sar	NOUN
ajlm-2065	50	24	-	-	PUNCT
ajlm-2065	50	25	cov-2	cov-2	NOUN
ajlm-2065	50	26	nucleocapsid	nucleocapsid	ADJ
ajlm-2065	50	27	protein	protein	NOUN
ajlm-2065	50	28	.	.	PUNCT
ajlm-2065	51	1	the	the	DET
ajlm-2065	51	2	assay	assay	NOUN
ajlm-2065	51	3	was	be	AUX
ajlm-2065	51	4	performed	perform	VERB
ajlm-2065	51	5	and	and	CCONJ
ajlm-2065	51	6	interpreted	interpret	VERB
ajlm-2065	51	7	according	accord	VERB
ajlm-2065	51	8	to	to	ADP
ajlm-2065	51	9	the	the	DET
ajlm-2065	51	10	manufacturer	manufacturer	NOUN
ajlm-2065	51	11	’s	’s	PART
ajlm-2065	51	12	instructions.24	instructions.24	NOUN
ajlm-2065	51	13	statistical	statistical	ADJ
ajlm-2065	51	14	analysis	analysis	NOUN
ajlm-2065	51	15	statistical	statistical	ADJ
ajlm-2065	51	16	analysis	analysis	NOUN
ajlm-2065	51	17	was	be	AUX
ajlm-2065	51	18	done	do	VERB
ajlm-2065	51	19	using	use	VERB
ajlm-2065	51	20	stata	stata	PROPN
ajlm-2065	51	21	®	®	NOUN
ajlm-2065	51	22	version	version	NOUN
ajlm-2065	51	23	15	15	NUM
ajlm-2065	51	24	(	(	PUNCT
ajlm-2065	51	25	statacorp	statacorp	PROPN
ajlm-2065	51	26	,	,	PUNCT
ajlm-2065	51	27	college	college	NOUN
ajlm-2065	51	28	station	station	NOUN
ajlm-2065	51	29	,	,	PUNCT
ajlm-2065	51	30	texas	texas	PROPN
ajlm-2065	51	31	,	,	PUNCT
ajlm-2065	51	32	united	united	PROPN
ajlm-2065	51	33	states	states	PROPN
ajlm-2065	51	34	)	)	PUNCT
ajlm-2065	51	35	.	.	PUNCT
ajlm-2065	52	1	we	we	PRON
ajlm-2065	52	2	performed	perform	VERB
ajlm-2065	52	3	a	a	DET
ajlm-2065	52	4	logistic	logistic	ADJ
ajlm-2065	52	5	regression	regression	NOUN
ajlm-2065	52	6	analysis	analysis	NOUN
ajlm-2065	52	7	to	to	PART
ajlm-2065	52	8	determine	determine	VERB
ajlm-2065	52	9	whether	whether	SCONJ
ajlm-2065	52	10	age	age	NOUN
ajlm-2065	52	11	,	,	PUNCT
ajlm-2065	52	12	gender	gender	NOUN
ajlm-2065	52	13	,	,	PUNCT
ajlm-2065	52	14	hiv	hiv	PROPN
ajlm-2065	52	15	seropositivity	seropositivity	NOUN
ajlm-2065	52	16	,	,	PUNCT
ajlm-2065	52	17	and	and	CCONJ
ajlm-2065	52	18	hiv	hiv	PROPN
ajlm-2065	52	19	viral	viral	ADJ
ajlm-2065	52	20	load	load	NOUN
ajlm-2065	52	21	were	be	AUX
ajlm-2065	52	22	associated	associate	VERB
ajlm-2065	52	23	with	with	ADP
ajlm-2065	52	24	sars	sar	NOUN
ajlm-2065	52	25	-	-	PUNCT
ajlm-2065	52	26	cov-2	cov-2	NOUN
ajlm-2065	52	27	seropositivity	seropositivity	NOUN
ajlm-2065	52	28	,	,	PUNCT
ajlm-2065	52	29	with	with	ADP
ajlm-2065	52	30	significance	significance	NOUN
ajlm-2065	52	31	level	level	NOUN
ajlm-2065	52	32	set	set	VERB
ajlm-2065	52	33	to	to	ADP
ajlm-2065	52	34	0.05	0.05	NUM
ajlm-2065	52	35	.	.	PUNCT
ajlm-2065	53	1	results	result	VERB
ajlm-2065	53	2	a	a	DET
ajlm-2065	53	3	total	total	NOUN
ajlm-2065	53	4	of	of	ADP
ajlm-2065	53	5	9083	9083	NUM
ajlm-2065	53	6	specimens	specimen	NOUN
ajlm-2065	53	7	were	be	AUX
ajlm-2065	53	8	tested	test	VERB
ajlm-2065	53	9	.	.	PUNCT
ajlm-2065	54	1	however	however	ADV
ajlm-2065	54	2	,	,	PUNCT
ajlm-2065	54	3	254	254	NUM
ajlm-2065	54	4	specimens	specimen	NOUN
ajlm-2065	54	5	were	be	AUX
ajlm-2065	54	6	excluded	exclude	VERB
ajlm-2065	54	7	from	from	ADP
ajlm-2065	54	8	the	the	DET
ajlm-2065	54	9	analysis	analysis	NOUN
ajlm-2065	54	10	due	due	ADJ
ajlm-2065	54	11	to	to	ADP
ajlm-2065	54	12	existing	exist	VERB
ajlm-2065	54	13	sars	sar	NOUN
ajlm-2065	54	14	-	-	PUNCT
ajlm-2065	54	15	cov-2	cov-2	NOUN
ajlm-2065	54	16	igg	igg	PROPN
ajlm-2065	54	17	test	test	NOUN
ajlm-2065	54	18	requests	request	NOUN
ajlm-2065	54	19	(	(	PUNCT
ajlm-2065	54	20	n	n	NOUN
ajlm-2065	54	21	=	=	NUM
ajlm-2065	54	22	248	248	NUM
ajlm-2065	54	23	)	)	PUNCT
ajlm-2065	54	24	or	or	CCONJ
ajlm-2065	54	25	mismatched	mismatch	VERB
ajlm-2065	54	26	laboratory	laboratory	NOUN
ajlm-2065	54	27	information	information	NOUN
ajlm-2065	54	28	(	(	PUNCT
ajlm-2065	54	29	n	n	NOUN
ajlm-2065	54	30	=	=	SYM
ajlm-2065	54	31	6	6	NUM
ajlm-2065	54	32	)	)	PUNCT
ajlm-2065	54	33	.	.	PUNCT
ajlm-2065	55	1	a	a	DET
ajlm-2065	55	2	total	total	NOUN
ajlm-2065	55	3	of	of	ADP
ajlm-2065	55	4	8829	8829	NUM
ajlm-2065	55	5	(	(	PUNCT
ajlm-2065	55	6	table	table	NOUN
ajlm-2065	55	7	1	1	NUM
ajlm-2065	55	8	)	)	PUNCT
ajlm-2065	55	9	specimen	speciman	NOUN
ajlm-2065	55	10	results	result	NOUN
ajlm-2065	55	11	were	be	AUX
ajlm-2065	55	12	analysed	analyse	VERB
ajlm-2065	55	13	:	:	PUNCT
ajlm-2065	55	14	5724	5724	NUM
ajlm-2065	55	15	(	(	PUNCT
ajlm-2065	55	16	64.8	64.8	NUM
ajlm-2065	55	17	%	%	NOUN
ajlm-2065	55	18	)	)	PUNCT
ajlm-2065	55	19	of	of	ADP
ajlm-2065	55	20	the	the	DET
ajlm-2065	55	21	specimens	specimen	NOUN
ajlm-2065	55	22	were	be	AUX
ajlm-2065	55	23	from	from	ADP
ajlm-2065	55	24	female	female	ADJ
ajlm-2065	55	25	and	and	CCONJ
ajlm-2065	55	26	2865	2865	NUM
ajlm-2065	55	27	(	(	PUNCT
ajlm-2065	55	28	32.5	32.5	NUM
ajlm-2065	55	29	%	%	NOUN
ajlm-2065	55	30	)	)	PUNCT
ajlm-2065	55	31	from	from	ADP
ajlm-2065	55	32	male	male	ADJ
ajlm-2065	55	33	patients	patient	NOUN
ajlm-2065	55	34	,	,	PUNCT
ajlm-2065	55	35	while	while	SCONJ
ajlm-2065	55	36	240	240	NUM
ajlm-2065	55	37	(	(	PUNCT
ajlm-2065	55	38	2.7	2.7	NUM
ajlm-2065	55	39	%	%	NOUN
ajlm-2065	55	40	)	)	PUNCT
ajlm-2065	55	41	had	have	VERB
ajlm-2065	55	42	no	no	DET
ajlm-2065	55	43	specified	specify	VERB
ajlm-2065	55	44	gender	gender	NOUN
ajlm-2065	55	45	;	;	PUNCT
ajlm-2065	55	46	1309	1309	NUM
ajlm-2065	55	47	(	(	PUNCT
ajlm-2065	55	48	14.8	14.8	NUM
ajlm-2065	55	49	%	%	NOUN
ajlm-2065	55	50	)	)	PUNCT
ajlm-2065	55	51	of	of	ADP
ajlm-2065	55	52	sera	sera	NOUN
ajlm-2065	55	53	specimens	specimen	NOUN
ajlm-2065	55	54	had	have	VERB
ajlm-2065	55	55	hiv	hiv	PROPN
ajlm-2065	55	56	enzyme	enzyme	NOUN
ajlm-2065	55	57	-	-	PUNCT
ajlm-2065	55	58	linked	link	VERB
ajlm-2065	55	59	immunosorbent	immunosorbent	NOUN
ajlm-2065	55	60	assay	assay	NOUN
ajlm-2065	55	61	results	result	NOUN
ajlm-2065	55	62	,	,	PUNCT
ajlm-2065	55	63	and	and	CCONJ
ajlm-2065	56	1	5522	5522	NUM
ajlm-2065	56	2	(	(	PUNCT
ajlm-2065	56	3	62.5	62.5	NUM
ajlm-2065	56	4	%	%	NOUN
ajlm-2065	56	5	)	)	PUNCT
ajlm-2065	56	6	of	of	ADP
ajlm-2065	56	7	plasma	plasma	NOUN
ajlm-2065	56	8	specimens	specimen	NOUN
ajlm-2065	56	9	had	have	VERB
ajlm-2065	56	10	hiv	hiv	PROPN
ajlm-2065	56	11	viral	viral	ADJ
ajlm-2065	56	12	load	load	NOUN
ajlm-2065	56	13	results	result	NOUN
ajlm-2065	56	14	.	.	PUNCT
ajlm-2065	57	1	table	table	NOUN
ajlm-2065	57	2	1	1	NUM
ajlm-2065	57	3	:	:	PUNCT
ajlm-2065	57	4	 	 	SPACE
ajlm-2065	57	5	demographic	demographic	ADJ
ajlm-2065	57	6	characteristics	characteristic	NOUN
ajlm-2065	57	7	of	of	ADP
ajlm-2065	57	8	specimens	specimen	NOUN
ajlm-2065	57	9	collected	collect	VERB
ajlm-2065	57	10	in	in	ADP
ajlm-2065	57	11	kwazulu	kwazulu	PROPN
ajlm-2065	57	12	-	-	PUNCT
ajlm-2065	57	13	natal	natal	ADJ
ajlm-2065	57	14	,	,	PUNCT
ajlm-2065	57	15	south	south	PROPN
ajlm-2065	57	16	africa	africa	PROPN
ajlm-2065	57	17	,	,	PUNCT
ajlm-2065	57	18	from	from	ADP
ajlm-2065	57	19	10	10	NUM
ajlm-2065	57	20	november	november	PROPN
ajlm-2065	57	21	2020	2020	NUM
ajlm-2065	57	22	to	to	ADP
ajlm-2065	57	23	09	09	NUM
ajlm-2065	57	24	february	february	NOUN
ajlm-2065	57	25	2021	2021	NUM
ajlm-2065	57	26	.	.	PUNCT
ajlm-2065	58	1	the	the	DET
ajlm-2065	58	2	average	average	ADJ
ajlm-2065	58	3	sars	sar	NOUN
ajlm-2065	58	4	-	-	PUNCT
ajlm-2065	58	5	cov-2	cov-2	NOUN
ajlm-2065	58	6	seropositivity	seropositivity	NOUN
ajlm-2065	58	7	across	across	ADP
ajlm-2065	58	8	11	11	NUM
ajlm-2065	58	9	health	health	NOUN
ajlm-2065	58	10	districts	district	NOUN
ajlm-2065	58	11	(	(	PUNCT
ajlm-2065	58	12	figure	figure	NOUN
ajlm-2065	58	13	1	1	NUM
ajlm-2065	58	14	)	)	PUNCT
ajlm-2065	58	15	during	during	ADP
ajlm-2065	58	16	the	the	DET
ajlm-2065	58	17	second	second	ADJ
ajlm-2065	58	18	wave	wave	NOUN
ajlm-2065	58	19	was	be	AUX
ajlm-2065	58	20	22.4	22.4	NUM
ajlm-2065	58	21	%	%	NOUN
ajlm-2065	58	22	;	;	PUNCT
ajlm-2065	58	23	the	the	DET
ajlm-2065	58	24	ilembe	ilembe	NOUN
ajlm-2065	58	25	district	district	NOUN
ajlm-2065	58	26	had	have	VERB
ajlm-2065	58	27	the	the	DET
ajlm-2065	58	28	highest	high	ADJ
ajlm-2065	58	29	seropositivity	seropositivity	NOUN
ajlm-2065	58	30	(	(	PUNCT
ajlm-2065	58	31	37.3	37.3	NUM
ajlm-2065	58	32	%	%	NOUN
ajlm-2065	58	33	)	)	PUNCT
ajlm-2065	58	34	,	,	PUNCT
ajlm-2065	58	35	followed	follow	VERB
ajlm-2065	58	36	by	by	ADP
ajlm-2065	58	37	king	king	NOUN
ajlm-2065	58	38	cetshwayo	cetshwayo	NOUN
ajlm-2065	58	39	(	(	PUNCT
ajlm-2065	58	40	35.1	35.1	NUM
ajlm-2065	58	41	%	%	NOUN
ajlm-2065	58	42	)	)	PUNCT
ajlm-2065	58	43	,	,	PUNCT
ajlm-2065	58	44	and	and	CCONJ
ajlm-2065	58	45	umkhanyakude	umkhanyakude	ADJ
ajlm-2065	58	46	(	(	PUNCT
ajlm-2065	58	47	32	32	NUM
ajlm-2065	58	48	%	%	NOUN
ajlm-2065	58	49	)	)	PUNCT
ajlm-2065	58	50	.	.	PUNCT
ajlm-2065	59	1	weekly	weekly	ADJ
ajlm-2065	59	2	seropositivity	seropositivity	NOUN
ajlm-2065	59	3	increased	increase	VERB
ajlm-2065	59	4	with	with	ADP
ajlm-2065	59	5	increasing	increase	VERB
ajlm-2065	59	6	sars	sar	NOUN
ajlm-2065	59	7	-	-	PUNCT
ajlm-2065	59	8	cov-2	cov-2	PART
ajlm-2065	59	9	cases	case	NOUN
ajlm-2065	59	10	(	(	PUNCT
ajlm-2065	59	11	figure	figure	NOUN
ajlm-2065	59	12	2	2	NUM
ajlm-2065	59	13	)	)	PUNCT
ajlm-2065	59	14	,	,	PUNCT
ajlm-2065	59	15	reaching	reach	VERB
ajlm-2065	59	16	43	43	NUM
ajlm-2065	59	17	%	%	NOUN
ajlm-2065	59	18	during	during	ADP
ajlm-2065	59	19	the	the	DET
ajlm-2065	59	20	second	second	ADJ
ajlm-2065	59	21	wave	wave	NOUN
ajlm-2065	59	22	in	in	ADP
ajlm-2065	59	23	kwazulu	kwazulu	NOUN
ajlm-2065	59	24	-	-	PUNCT
ajlm-2065	59	25	natal	natal	NOUN
ajlm-2065	59	26	.	.	PUNCT
ajlm-2065	60	1	figure	figure	NOUN
ajlm-2065	60	2	1	1	NUM
ajlm-2065	60	3	:	:	PUNCT
ajlm-2065	60	4	sars	sar	NOUN
ajlm-2065	60	5	-	-	PUNCT
ajlm-2065	60	6	cov-2	cov-2	NOUN
ajlm-2065	60	7	immunoglobulin	immunoglobulin	NOUN
ajlm-2065	60	8	g	g	PROPN
ajlm-2065	60	9	seropositivity	seropositivity	NOUN
ajlm-2065	60	10	per	per	ADP
ajlm-2065	60	11	district	district	NOUN
ajlm-2065	60	12	in	in	ADP
ajlm-2065	60	13	kwazulu	kwazulu	PROPN
ajlm-2065	60	14	-	-	PUNCT
ajlm-2065	60	15	natal	natal	ADJ
ajlm-2065	60	16	,	,	PUNCT
ajlm-2065	60	17	south	south	PROPN
ajlm-2065	60	18	africa	africa	PROPN
ajlm-2065	60	19	,	,	PUNCT
ajlm-2065	60	20	from	from	ADP
ajlm-2065	60	21	10	10	NUM
ajlm-2065	60	22	november	november	PROPN
ajlm-2065	60	23	2020	2020	NUM
ajlm-2065	60	24	to	to	ADP
ajlm-2065	60	25	09	09	NUM
ajlm-2065	60	26	february	february	NOUN
ajlm-2065	60	27	2021	2021	NUM
ajlm-2065	60	28	.	.	PUNCT
ajlm-2065	61	1	figure	figure	VERB
ajlm-2065	61	2	2	2	NUM
ajlm-2065	61	3	:	:	PUNCT
ajlm-2065	61	4	temporal	temporal	ADJ
ajlm-2065	61	5	relationship	relationship	NOUN
ajlm-2065	61	6	between	between	ADP
ajlm-2065	61	7	seropositivity	seropositivity	NOUN
ajlm-2065	61	8	and	and	CCONJ
ajlm-2065	61	9	polymerase	polymerase	NOUN
ajlm-2065	61	10	chain	chain	NOUN
ajlm-2065	61	11	reaction	reaction	NOUN
ajlm-2065	61	12	positivity	positivity	NOUN
ajlm-2065	61	13	of	of	ADP
ajlm-2065	61	14	specimens	specimen	NOUN
ajlm-2065	61	15	collected	collect	VERB
ajlm-2065	61	16	in	in	ADP
ajlm-2065	61	17	kwazulu	kwazulu	PROPN
ajlm-2065	61	18	-	-	PUNCT
ajlm-2065	61	19	natal	natal	ADJ
ajlm-2065	61	20	,	,	PUNCT
ajlm-2065	61	21	south	south	PROPN
ajlm-2065	61	22	africa	africa	PROPN
ajlm-2065	61	23	,	,	PUNCT
ajlm-2065	61	24	from	from	ADP
ajlm-2065	61	25	10	10	NUM
ajlm-2065	61	26	november	november	PROPN
ajlm-2065	61	27	2020	2020	NUM
ajlm-2065	61	28	to	to	ADP
ajlm-2065	61	29	09	09	NUM
ajlm-2065	61	30	february	february	NOUN
ajlm-2065	61	31	2021	2021	NUM
ajlm-2065	61	32	.	.	PUNCT
ajlm-2065	62	1	seropositivity	seropositivity	NOUN
ajlm-2065	62	2	among	among	ADP
ajlm-2065	62	3	female	female	ADJ
ajlm-2065	62	4	patients	patient	NOUN
ajlm-2065	62	5	was	be	AUX
ajlm-2065	62	6	23.6	23.6	NUM
ajlm-2065	62	7	%	%	NOUN
ajlm-2065	62	8	(	(	PUNCT
ajlm-2065	62	9	odds	odd	NOUN
ajlm-2065	62	10	ratio	ratio	NOUN
ajlm-2065	62	11	:	:	PUNCT
ajlm-2065	62	12	0.705	0.705	NUM
ajlm-2065	62	13	,	,	PUNCT
ajlm-2065	62	14	95	95	NUM
ajlm-2065	62	15	%	%	NOUN
ajlm-2065	62	16	confidence	confidence	NOUN
ajlm-2065	62	17	interval	interval	NOUN
ajlm-2065	62	18	:	:	PUNCT
ajlm-2065	62	19	0.617–0.806	0.617–0.806	NUM
ajlm-2065	62	20	)	)	PUNCT
ajlm-2065	62	21	while	while	SCONJ
ajlm-2065	62	22	male	male	ADJ
ajlm-2065	62	23	patients	patient	NOUN
ajlm-2065	62	24	had	have	VERB
ajlm-2065	62	25	lower	low	ADJ
ajlm-2065	62	26	odds	odd	NOUN
ajlm-2065	62	27	of	of	ADP
ajlm-2065	62	28	seropositivity	seropositivity	NOUN
ajlm-2065	62	29	(	(	PUNCT
ajlm-2065	62	30	p	p	X
ajlm-2065	62	31	<	<	X
ajlm-2065	62	32	0.0001	0.0001	NUM
ajlm-2065	62	33	)	)	PUNCT
ajlm-2065	62	34	(	(	PUNCT
ajlm-2065	62	35	table	table	NOUN
ajlm-2065	62	36	1	1	NUM
ajlm-2065	62	37	)	)	PUNCT
ajlm-2065	62	38	.	.	PUNCT
ajlm-2065	63	1	seropositivity	seropositivity	PROPN
ajlm-2065	63	2	increased	increase	VERB
ajlm-2065	63	3	with	with	ADP
ajlm-2065	63	4	increasing	increase	VERB
ajlm-2065	63	5	age	age	NOUN
ajlm-2065	63	6	,	,	PUNCT
ajlm-2065	63	7	with	with	ADP
ajlm-2065	63	8	a	a	DET
ajlm-2065	63	9	1.012	1.012	NUM
ajlm-2065	63	10	increase	increase	NOUN
ajlm-2065	63	11	in	in	ADP
ajlm-2065	63	12	odds	odd	NOUN
ajlm-2065	63	13	for	for	ADP
ajlm-2065	63	14	every	every	DET
ajlm-2065	63	15	year	year	NOUN
ajlm-2065	63	16	increase	increase	NOUN
ajlm-2065	63	17	in	in	ADP
ajlm-2065	63	18	age	age	NOUN
ajlm-2065	63	19	(	(	PUNCT
ajlm-2065	63	20	p	p	X
ajlm-2065	63	21	<	<	X
ajlm-2065	63	22	0.0001	0.0001	NUM
ajlm-2065	63	23	)	)	PUNCT
ajlm-2065	63	24	(	(	PUNCT
ajlm-2065	63	25	figure	figure	NOUN
ajlm-2065	63	26	3	3	NUM
ajlm-2065	63	27	)	)	PUNCT
ajlm-2065	63	28	.	.	PUNCT
ajlm-2065	64	1	seropositivity	seropositivity	PROPN
ajlm-2065	64	2	was	be	AUX
ajlm-2065	64	3	highest	high	ADJ
ajlm-2065	64	4	in	in	ADP
ajlm-2065	64	5	the	the	DET
ajlm-2065	64	6	70–79	70–79	ADJ
ajlm-2065	64	7	year	year	NOUN
ajlm-2065	64	8	age	age	NOUN
ajlm-2065	64	9	group	group	NOUN
ajlm-2065	64	10	and	and	CCONJ
ajlm-2065	64	11	lowest	low	ADJ
ajlm-2065	64	12	in	in	ADP
ajlm-2065	64	13	those	those	PRON
ajlm-2065	64	14	under	under	ADP
ajlm-2065	64	15	9	9	NUM
ajlm-2065	64	16	years	year	NOUN
ajlm-2065	64	17	of	of	ADP
ajlm-2065	64	18	age	age	NOUN
ajlm-2065	64	19	.	.	PUNCT
ajlm-2065	65	1	seropositivity	seropositivity	NOUN
ajlm-2065	65	2	(	(	PUNCT
ajlm-2065	65	3	table	table	NOUN
ajlm-2065	65	4	1	1	NUM
ajlm-2065	65	5	)	)	PUNCT
ajlm-2065	65	6	was	be	AUX
ajlm-2065	65	7	higher	high	ADJ
ajlm-2065	65	8	in	in	ADP
ajlm-2065	65	9	the	the	DET
ajlm-2065	65	10	hiv	hiv	NOUN
ajlm-2065	65	11	-	-	PUNCT
ajlm-2065	65	12	negative	negative	ADJ
ajlm-2065	65	13	compared	compare	VERB
ajlm-2065	65	14	to	to	ADP
ajlm-2065	65	15	the	the	DET
ajlm-2065	65	16	hiv	hiv	NOUN
ajlm-2065	65	17	-	-	PUNCT
ajlm-2065	65	18	positive	positive	ADJ
ajlm-2065	65	19	(	(	PUNCT
ajlm-2065	65	20	35.3	35.3	NUM
ajlm-2065	65	21	%	%	NOUN
ajlm-2065	65	22	vs	vs	ADP
ajlm-2065	65	23	19	19	NUM
ajlm-2065	65	24	%	%	NOUN
ajlm-2065	65	25	;	;	PUNCT
ajlm-2065	65	26	odds	odd	NOUN
ajlm-2065	65	27	ratio	ratio	NOUN
ajlm-2065	65	28	:	:	PUNCT
ajlm-2065	65	29	0.402	0.402	NUM
ajlm-2065	65	30	;	;	PUNCT
ajlm-2065	65	31	95	95	NUM
ajlm-2065	65	32	%	%	NOUN
ajlm-2065	65	33	confidence	confidence	NOUN
ajlm-2065	65	34	interval	interval	NOUN
ajlm-2065	65	35	:	:	PUNCT
ajlm-2065	65	36	0.349–0.463	0.349–0.463	NOUN
ajlm-2065	65	37	)	)	PUNCT
ajlm-2065	65	38	.	.	PUNCT
ajlm-2065	66	1	hiv	hiv	PROPN
ajlm-2065	66	2	positivity	positivity	NOUN
ajlm-2065	66	3	with	with	ADP
ajlm-2065	66	4	a	a	DET
ajlm-2065	66	5	viral	viral	ADJ
ajlm-2065	66	6	load	load	NOUN
ajlm-2065	66	7	greater	great	ADJ
ajlm-2065	66	8	than	than	ADP
ajlm-2065	66	9	1000	1000	NUM
ajlm-2065	66	10	copies	copy	NOUN
ajlm-2065	66	11	/	/	PUNCT
ajlm-2065	66	12	ml	ml	PROPN
ajlm-2065	66	13	was	be	AUX
ajlm-2065	66	14	associated	associate	VERB
ajlm-2065	66	15	with	with	ADP
ajlm-2065	66	16	lower	low	ADJ
ajlm-2065	66	17	odds	odd	NOUN
ajlm-2065	66	18	of	of	ADP
ajlm-2065	66	19	sars	sar	NOUN
ajlm-2065	66	20	-	-	PUNCT
ajlm-2065	66	21	cov-2	cov-2	NOUN
ajlm-2065	66	22	seropositivity	seropositivity	NOUN
ajlm-2065	66	23	(	(	PUNCT
ajlm-2065	66	24	odds	odd	NOUN
ajlm-2065	66	25	ratio	ratio	NOUN
ajlm-2065	66	26	:	:	PUNCT
ajlm-2065	66	27	0.518	0.518	NUM
ajlm-2065	66	28	;	;	PUNCT
ajlm-2065	66	29	95	95	NUM
ajlm-2065	66	30	%	%	NOUN
ajlm-2065	66	31	confidence	confidence	NOUN
ajlm-2065	66	32	interval	interval	NOUN
ajlm-2065	66	33	:	:	PUNCT
ajlm-2065	66	34	0.401–0.669	0.401–0.669	NUM
ajlm-2065	66	35	)	)	PUNCT
ajlm-2065	66	36	.	.	PUNCT
ajlm-2065	67	1	no	no	DET
ajlm-2065	67	2	statistically	statistically	ADV
ajlm-2065	67	3	significant	significant	ADJ
ajlm-2065	67	4	interaction	interaction	NOUN
ajlm-2065	67	5	(	(	PUNCT
ajlm-2065	67	6	at	at	ADP
ajlm-2065	67	7	a	a	DET
ajlm-2065	67	8	10	10	NUM
ajlm-2065	67	9	%	%	NOUN
ajlm-2065	67	10	level	level	NOUN
ajlm-2065	67	11	)	)	PUNCT
ajlm-2065	67	12	was	be	AUX
ajlm-2065	67	13	noted	note	VERB
ajlm-2065	67	14	between	between	ADP
ajlm-2065	67	15	hiv	hiv	PROPN
ajlm-2065	67	16	status	status	NOUN
ajlm-2065	67	17	and	and	CCONJ
ajlm-2065	67	18	age	age	NOUN
ajlm-2065	67	19	or	or	CCONJ
ajlm-2065	67	20	gender	gender	NOUN
ajlm-2065	67	21	.	.	PUNCT
ajlm-2065	68	1	figure	figure	NOUN
ajlm-2065	68	2	3	3	NUM
ajlm-2065	68	3	:	:	PUNCT
ajlm-2065	68	4	age	age	NOUN
ajlm-2065	68	5	and	and	CCONJ
ajlm-2065	68	6	seropositivity	seropositivity	NOUN
ajlm-2065	68	7	of	of	ADP
ajlm-2065	68	8	specimens	specimen	NOUN
ajlm-2065	68	9	collected	collect	VERB
ajlm-2065	68	10	in	in	ADP
ajlm-2065	68	11	kwazulu	kwazulu	PROPN
ajlm-2065	68	12	-	-	PUNCT
ajlm-2065	68	13	natal	natal	ADJ
ajlm-2065	68	14	,	,	PUNCT
ajlm-2065	68	15	south	south	PROPN
ajlm-2065	68	16	africa	africa	PROPN
ajlm-2065	68	17	,	,	PUNCT
ajlm-2065	68	18	from	from	ADP
ajlm-2065	68	19	10	10	NUM
ajlm-2065	68	20	november	november	PROPN
ajlm-2065	68	21	2020	2020	NUM
ajlm-2065	68	22	to	to	ADP
ajlm-2065	68	23	09	09	NUM
ajlm-2065	68	24	february	february	NOUN
ajlm-2065	68	25	2021	2021	NUM
ajlm-2065	68	26	.	.	PUNCT
ajlm-2065	69	1	discussion	discussion	NOUN
ajlm-2065	69	2	we	we	PRON
ajlm-2065	69	3	assessed	assess	VERB
ajlm-2065	69	4	the	the	DET
ajlm-2065	69	5	sars	sar	NOUN
ajlm-2065	69	6	-	-	PUNCT
ajlm-2065	69	7	cov-2	cov-2	NOUN
ajlm-2065	69	8	igg	igg	NOUN
ajlm-2065	69	9	seropositivity	seropositivity	NOUN
ajlm-2065	69	10	in	in	ADP
ajlm-2065	69	11	convenience	convenience	NOUN
ajlm-2065	69	12	specimens	specimen	NOUN
ajlm-2065	69	13	submitted	submit	VERB
ajlm-2065	69	14	to	to	ADP
ajlm-2065	69	15	the	the	DET
ajlm-2065	69	16	department	department	NOUN
ajlm-2065	69	17	of	of	ADP
ajlm-2065	69	18	virology	virology	NOUN
ajlm-2065	69	19	at	at	ADP
ajlm-2065	69	20	inkosi	inkosi	PROPN
ajlm-2065	69	21	albert	albert	PROPN
ajlm-2065	69	22	luthuli	luthuli	PROPN
ajlm-2065	69	23	central	central	PROPN
ajlm-2065	69	24	hospital	hospital	NOUN
ajlm-2065	69	25	,	,	PUNCT
ajlm-2065	69	26	durban	durban	NOUN
ajlm-2065	69	27	,	,	PUNCT
ajlm-2065	69	28	before	before	ADP
ajlm-2065	69	29	and	and	CCONJ
ajlm-2065	69	30	during	during	ADP
ajlm-2065	69	31	the	the	DET
ajlm-2065	69	32	peak	peak	NOUN
ajlm-2065	69	33	of	of	ADP
ajlm-2065	69	34	the	the	DET
ajlm-2065	69	35	second	second	ADJ
ajlm-2065	69	36	covid-19	covid-19	PROPN
ajlm-2065	69	37	wave	wave	NOUN
ajlm-2065	69	38	caused	cause	VERB
ajlm-2065	69	39	by	by	ADP
ajlm-2065	69	40	the	the	DET
ajlm-2065	69	41	beta	beta	ADJ
ajlm-2065	69	42	variant	variant	NOUN
ajlm-2065	69	43	.	.	PUNCT
ajlm-2065	70	1	we	we	PRON
ajlm-2065	70	2	observed	observe	VERB
ajlm-2065	70	3	an	an	DET
ajlm-2065	70	4	increase	increase	NOUN
ajlm-2065	70	5	in	in	ADP
ajlm-2065	70	6	seropositivity	seropositivity	NOUN
ajlm-2065	70	7	from	from	ADP
ajlm-2065	70	8	17	17	NUM
ajlm-2065	70	9	%	%	NOUN
ajlm-2065	70	10	before	before	ADP
ajlm-2065	70	11	to	to	ADP
ajlm-2065	70	12	43	43	NUM
ajlm-2065	70	13	%	%	NOUN
ajlm-2065	70	14	during	during	ADP
ajlm-2065	70	15	the	the	DET
ajlm-2065	70	16	second	second	ADJ
ajlm-2065	70	17	wave	wave	NOUN
ajlm-2065	70	18	in	in	ADP
ajlm-2065	70	19	kwazulu	kwazulu	NOUN
ajlm-2065	70	20	-	-	PUNCT
ajlm-2065	70	21	natal	natal	ADJ
ajlm-2065	70	22	,	,	PUNCT
ajlm-2065	70	23	reflective	reflective	ADJ
ajlm-2065	70	24	of	of	ADP
ajlm-2065	70	25	the	the	DET
ajlm-2065	70	26	increase	increase	NOUN
ajlm-2065	70	27	in	in	ADP
ajlm-2065	70	28	the	the	DET
ajlm-2065	70	29	number	number	NOUN
ajlm-2065	70	30	of	of	ADP
ajlm-2065	70	31	infected	infected	ADJ
ajlm-2065	70	32	individuals	individual	NOUN
ajlm-2065	70	33	during	during	ADP
ajlm-2065	70	34	the	the	DET
ajlm-2065	70	35	second	second	ADJ
ajlm-2065	70	36	wave	wave	NOUN
ajlm-2065	70	37	,	,	PUNCT
ajlm-2065	70	38	with	with	ADP
ajlm-2065	70	39	a	a	DET
ajlm-2065	70	40	mean	mean	NOUN
ajlm-2065	70	41	sars	sar	NOUN
ajlm-2065	70	42	-	-	PUNCT
ajlm-2065	70	43	cov-2	cov-2	NOUN
ajlm-2065	70	44	seropositivity	seropositivity	NOUN
ajlm-2065	70	45	of	of	ADP
ajlm-2065	70	46	22.4	22.4	NUM
ajlm-2065	70	47	%	%	NOUN
ajlm-2065	70	48	across	across	ADP
ajlm-2065	70	49	the	the	DET
ajlm-2065	70	50	study	study	NOUN
ajlm-2065	70	51	period	period	NOUN
ajlm-2065	70	52	.	.	PUNCT
ajlm-2065	71	1	there	there	PRON
ajlm-2065	71	2	were	be	VERB
ajlm-2065	71	3	statistically	statistically	ADV
ajlm-2065	71	4	significant	significant	ADJ
ajlm-2065	71	5	associations	association	NOUN
ajlm-2065	71	6	between	between	ADP
ajlm-2065	71	7	sars	sar	NOUN
ajlm-2065	71	8	-	-	PUNCT
ajlm-2065	71	9	cov-2	cov-2	NOUN
ajlm-2065	71	10	seropositivity	seropositivity	NOUN
ajlm-2065	71	11	,	,	PUNCT
ajlm-2065	71	12	age	age	NOUN
ajlm-2065	71	13	,	,	PUNCT
ajlm-2065	71	14	gender	gender	NOUN
ajlm-2065	71	15	,	,	PUNCT
ajlm-2065	71	16	and	and	CCONJ
ajlm-2065	71	17	hiv	hiv	PROPN
ajlm-2065	71	18	status	status	NOUN
ajlm-2065	71	19	.	.	PUNCT
ajlm-2065	72	1	our	our	PRON
ajlm-2065	72	2	results	result	NOUN
ajlm-2065	72	3	indicate	indicate	VERB
ajlm-2065	72	4	that	that	SCONJ
ajlm-2065	72	5	the	the	DET
ajlm-2065	72	6	true	true	ADJ
ajlm-2065	72	7	extent	extent	NOUN
ajlm-2065	72	8	of	of	ADP
ajlm-2065	72	9	the	the	DET
ajlm-2065	72	10	sars	sar	NOUN
ajlm-2065	72	11	-	-	PUNCT
ajlm-2065	72	12	cov-2	cov-2	NOUN
ajlm-2065	72	13	epidemic	epidemic	NOUN
ajlm-2065	72	14	in	in	ADP
ajlm-2065	72	15	kwazulu	kwazulu	PROPN
ajlm-2065	72	16	-	-	PUNCT
ajlm-2065	72	17	natal	natal	NOUN
ajlm-2065	72	18	may	may	AUX
ajlm-2065	72	19	have	have	AUX
ajlm-2065	72	20	been	be	AUX
ajlm-2065	72	21	underestimated	underestimate	VERB
ajlm-2065	72	22	due	due	ADJ
ajlm-2065	72	23	to	to	ADP
ajlm-2065	72	24	reporting	reporting	NOUN
ajlm-2065	72	25	of	of	ADP
ajlm-2065	72	26	pcr	pcr	ADJ
ajlm-2065	72	27	results	result	NOUN
ajlm-2065	72	28	alone	alone	ADV
ajlm-2065	72	29	.	.	PUNCT
ajlm-2065	73	1	this	this	PRON
ajlm-2065	73	2	is	be	AUX
ajlm-2065	73	3	similar	similar	ADJ
ajlm-2065	73	4	to	to	ADP
ajlm-2065	73	5	other	other	ADJ
ajlm-2065	73	6	local	local	ADJ
ajlm-2065	73	7	seroprevalence	seroprevalence	NOUN
ajlm-2065	73	8	studies	study	NOUN
ajlm-2065	73	9	that	that	PRON
ajlm-2065	73	10	report	report	VERB
ajlm-2065	73	11	higher	high	ADJ
ajlm-2065	73	12	seroprevalence	seroprevalence	NOUN
ajlm-2065	73	13	compared	compare	VERB
ajlm-2065	73	14	to	to	ADP
ajlm-2065	73	15	the	the	DET
ajlm-2065	73	16	number	number	NOUN
ajlm-2065	73	17	of	of	ADP
ajlm-2065	73	18	reported	report	VERB
ajlm-2065	73	19	pcr	pcr	PROPN
ajlm-2065	73	20	cases.10,11,12,25	cases.10,11,12,25	PROPN
ajlm-2065	73	21	the	the	DET
ajlm-2065	73	22	seropositivity	seropositivity	NOUN
ajlm-2065	73	23	in	in	ADP
ajlm-2065	73	24	our	our	PRON
ajlm-2065	73	25	study	study	NOUN
ajlm-2065	73	26	was	be	AUX
ajlm-2065	73	27	lower	low	ADJ
ajlm-2065	73	28	than	than	ADP
ajlm-2065	73	29	the	the	DET
ajlm-2065	73	30	seroprevalence	seroprevalence	NOUN
ajlm-2065	73	31	reported	report	VERB
ajlm-2065	73	32	by	by	ADP
ajlm-2065	73	33	surveillance	surveillance	NOUN
ajlm-2065	73	34	studies	study	NOUN
ajlm-2065	73	35	in	in	ADP
ajlm-2065	73	36	cape	cape	NOUN
ajlm-2065	73	37	town	town	NOUN
ajlm-2065	73	38	(	(	PUNCT
ajlm-2065	73	39	40	40	NUM
ajlm-2065	73	40	%	%	NOUN
ajlm-2065	73	41	)	)	PUNCT
ajlm-2065	73	42	and	and	CCONJ
ajlm-2065	73	43	gauteng	gauteng	PROPN
ajlm-2065	73	44	(	(	PUNCT
ajlm-2065	73	45	27.8%).12,18	27.8%).12,18	NUM
ajlm-2065	73	46	the	the	DET
ajlm-2065	73	47	lower	low	ADJ
ajlm-2065	73	48	prevalence	prevalence	NOUN
ajlm-2065	73	49	may	may	AUX
ajlm-2065	73	50	be	be	AUX
ajlm-2065	73	51	because	because	SCONJ
ajlm-2065	73	52	the	the	DET
ajlm-2065	73	53	specimens	specimen	NOUN
ajlm-2065	73	54	were	be	AUX
ajlm-2065	73	55	not	not	PART
ajlm-2065	73	56	collected	collect	VERB
ajlm-2065	73	57	immediately	immediately	ADV
ajlm-2065	73	58	after	after	ADP
ajlm-2065	73	59	the	the	DET
ajlm-2065	73	60	first	first	ADJ
ajlm-2065	73	61	wave	wave	NOUN
ajlm-2065	73	62	in	in	ADP
ajlm-2065	73	63	kwazulu	kwazulu	NOUN
ajlm-2065	73	64	-	-	NOUN
ajlm-2065	73	65	natal	natal	NOUN
ajlm-2065	73	66	;	;	PUNCT
ajlm-2065	73	67	they	they	PRON
ajlm-2065	73	68	were	be	AUX
ajlm-2065	73	69	collected	collect	VERB
ajlm-2065	73	70	4	4	NUM
ajlm-2065	73	71	months	month	NOUN
ajlm-2065	73	72	later	later	ADV
ajlm-2065	73	73	,	,	PUNCT
ajlm-2065	73	74	thus	thus	ADV
ajlm-2065	73	75	affecting	affect	VERB
ajlm-2065	73	76	the	the	DET
ajlm-2065	73	77	detection	detection	NOUN
ajlm-2065	73	78	of	of	ADP
ajlm-2065	73	79	igg	igg	PROPN
ajlm-2065	73	80	,	,	PUNCT
ajlm-2065	73	81	which	which	PRON
ajlm-2065	73	82	wanes	wane	VERB
ajlm-2065	73	83	over	over	ADP
ajlm-2065	73	84	time	time	NOUN
ajlm-2065	73	85	.	.	PUNCT
ajlm-2065	74	1	the	the	DET
ajlm-2065	74	2	sentinel	sentinel	ADJ
ajlm-2065	74	3	surveillance	surveillance	NOUN
ajlm-2065	74	4	studies	study	NOUN
ajlm-2065	74	5	were	be	AUX
ajlm-2065	74	6	started	start	VERB
ajlm-2065	74	7	directly	directly	ADV
ajlm-2065	74	8	after	after	ADP
ajlm-2065	74	9	the	the	DET
ajlm-2065	74	10	first	first	ADJ
ajlm-2065	74	11	wave	wave	NOUN
ajlm-2065	74	12	in	in	ADP
ajlm-2065	74	13	both	both	DET
ajlm-2065	74	14	cape	cape	NOUN
ajlm-2065	74	15	town	town	NOUN
ajlm-2065	74	16	and	and	CCONJ
ajlm-2065	74	17	gauteng	gauteng	PROPN
ajlm-2065	74	18	.	.	PUNCT
ajlm-2065	75	1	furthermore	furthermore	ADV
ajlm-2065	75	2	,	,	PUNCT
ajlm-2065	75	3	the	the	DET
ajlm-2065	75	4	majority	majority	NOUN
ajlm-2065	75	5	(	(	PUNCT
ajlm-2065	75	6	63	63	NUM
ajlm-2065	75	7	%	%	NOUN
ajlm-2065	75	8	)	)	PUNCT
ajlm-2065	75	9	of	of	ADP
ajlm-2065	75	10	the	the	DET
ajlm-2065	75	11	specimens	specimen	NOUN
ajlm-2065	75	12	in	in	ADP
ajlm-2065	75	13	our	our	PRON
ajlm-2065	75	14	study	study	NOUN
ajlm-2065	75	15	were	be	AUX
ajlm-2065	75	16	from	from	ADP
ajlm-2065	75	17	hiv	hiv	PROPN
ajlm-2065	75	18	-	-	PUNCT
ajlm-2065	75	19	positive	positive	ADJ
ajlm-2065	75	20	individuals	individual	NOUN
ajlm-2065	75	21	;	;	PUNCT
ajlm-2065	75	22	10	10	NUM
ajlm-2065	75	23	%	%	NOUN
ajlm-2065	75	24	of	of	ADP
ajlm-2065	75	25	these	these	DET
ajlm-2065	75	26	specimens	specimen	NOUN
ajlm-2065	75	27	had	have	VERB
ajlm-2065	75	28	an	an	DET
ajlm-2065	75	29	hiv	hiv	PROPN
ajlm-2065	75	30	viral	viral	ADJ
ajlm-2065	75	31	load	load	NOUN
ajlm-2065	75	32	greater	great	ADJ
ajlm-2065	75	33	than	than	ADP
ajlm-2065	75	34	1000	1000	NUM
ajlm-2065	75	35	copies	copy	NOUN
ajlm-2065	75	36	/	/	SYM
ajlm-2065	75	37	ml	ml	PROPN
ajlm-2065	75	38	and	and	CCONJ
ajlm-2065	75	39	reduced	reduce	VERB
ajlm-2065	75	40	sars	sar	NOUN
ajlm-2065	75	41	-	-	PUNCT
ajlm-2065	75	42	cov-2	cov-2	NOUN
ajlm-2065	75	43	seropositivity	seropositivity	NOUN
ajlm-2065	75	44	.	.	PUNCT
ajlm-2065	76	1	hiv	hiv	PROPN
ajlm-2065	76	2	viral	viral	ADJ
ajlm-2065	76	3	load	load	NOUN
ajlm-2065	76	4	greater	great	ADJ
ajlm-2065	76	5	than	than	ADP
ajlm-2065	76	6	1000	1000	NUM
ajlm-2065	76	7	copies	copy	NOUN
ajlm-2065	76	8	/	/	PUNCT
ajlm-2065	76	9	ml	ml	PROPN
ajlm-2065	76	10	had	have	VERB
ajlm-2065	76	11	a	a	DET
ajlm-2065	76	12	statistically	statistically	ADV
ajlm-2065	76	13	significant	significant	ADJ
ajlm-2065	76	14	association	association	NOUN
ajlm-2065	76	15	with	with	ADP
ajlm-2065	76	16	lower	low	ADJ
ajlm-2065	76	17	odds	odd	NOUN
ajlm-2065	76	18	of	of	ADP
ajlm-2065	76	19	sars	sar	NOUN
ajlm-2065	76	20	-	-	PUNCT
ajlm-2065	76	21	cov-2	cov-2	NOUN
ajlm-2065	76	22	igg	igg	NOUN
ajlm-2065	76	23	positivity	positivity	NOUN
ajlm-2065	76	24	.	.	PUNCT
ajlm-2065	77	1	hiv	hiv	PROPN
ajlm-2065	77	2	infection	infection	NOUN
ajlm-2065	77	3	is	be	AUX
ajlm-2065	77	4	associated	associate	VERB
ajlm-2065	77	5	with	with	ADP
ajlm-2065	77	6	a	a	DET
ajlm-2065	77	7	reduced	reduce	VERB
ajlm-2065	77	8	immune	immune	ADJ
ajlm-2065	77	9	response	response	NOUN
ajlm-2065	77	10	to	to	ADP
ajlm-2065	77	11	infectious	infectious	ADJ
ajlm-2065	77	12	pathogens.26	pathogens.26	PROPN
ajlm-2065	77	13	however	however	ADV
ajlm-2065	77	14	,	,	PUNCT
ajlm-2065	77	15	in	in	ADP
ajlm-2065	77	16	individuals	individual	NOUN
ajlm-2065	77	17	on	on	ADP
ajlm-2065	77	18	antiretroviral	antiretroviral	ADJ
ajlm-2065	77	19	therapy	therapy	NOUN
ajlm-2065	77	20	,	,	PUNCT
ajlm-2065	77	21	immune	immune	ADJ
ajlm-2065	77	22	responses	response	NOUN
ajlm-2065	77	23	to	to	ADP
ajlm-2065	77	24	sars	sar	NOUN
ajlm-2065	77	25	-	-	PUNCT
ajlm-2065	77	26	cov-2	cov-2	PART
ajlm-2065	77	27	are	be	AUX
ajlm-2065	77	28	reported	report	VERB
ajlm-2065	77	29	to	to	PART
ajlm-2065	77	30	be	be	AUX
ajlm-2065	77	31	similar	similar	ADJ
ajlm-2065	77	32	to	to	ADP
ajlm-2065	77	33	that	that	PRON
ajlm-2065	77	34	in	in	SCONJ
ajlm-2065	77	35	hiv	hiv	PROPN
ajlm-2065	77	36	-	-	PUNCT
ajlm-2065	77	37	negative	negative	ADJ
ajlm-2065	77	38	individuals.27,28	individuals.27,28	NOUN
ajlm-2065	77	39	people	people	NOUN
ajlm-2065	77	40	on	on	ADP
ajlm-2065	77	41	antiretroviral	antiretroviral	ADJ
ajlm-2065	77	42	therapy	therapy	NOUN
ajlm-2065	77	43	may	may	AUX
ajlm-2065	77	44	display	display	VERB
ajlm-2065	77	45	immune	immune	ADJ
ajlm-2065	77	46	reconstitution;26	reconstitution;26	NOUN
ajlm-2065	77	47	however	however	ADV
ajlm-2065	77	48	,	,	PUNCT
ajlm-2065	77	49	chronic	chronic	ADJ
ajlm-2065	77	50	immune	immune	ADJ
ajlm-2065	77	51	activation	activation	NOUN
ajlm-2065	77	52	and	and	CCONJ
ajlm-2065	77	53	impaired	impaired	ADJ
ajlm-2065	77	54	b	b	X
ajlm-2065	77	55	-	-	PUNCT
ajlm-2065	77	56	cell	cell	NOUN
ajlm-2065	77	57	responses	response	NOUN
ajlm-2065	77	58	in	in	ADP
ajlm-2065	77	59	individuals	individual	NOUN
ajlm-2065	77	60	on	on	ADP
ajlm-2065	77	61	antiretroviral	antiretroviral	ADJ
ajlm-2065	77	62	therapy	therapy	NOUN
ajlm-2065	77	63	with	with	ADP
ajlm-2065	77	64	virologic	virologic	ADJ
ajlm-2065	77	65	failure	failure	NOUN
ajlm-2065	77	66	may	may	AUX
ajlm-2065	77	67	result	result	VERB
ajlm-2065	77	68	in	in	ADP
ajlm-2065	77	69	reduced	reduced	ADJ
ajlm-2065	77	70	antibody	antibody	NOUN
ajlm-2065	77	71	responses26,28	responses26,28	PROPN
ajlm-2065	77	72	and	and	CCONJ
ajlm-2065	77	73	lower	low	ADJ
ajlm-2065	77	74	igg	igg	PROPN
ajlm-2065	77	75	concentrations,29	concentrations,29	NOUN
ajlm-2065	77	76	accounting	account	VERB
ajlm-2065	77	77	for	for	ADP
ajlm-2065	77	78	the	the	DET
ajlm-2065	77	79	lower	low	ADJ
ajlm-2065	77	80	seropositivity	seropositivity	NOUN
ajlm-2065	77	81	in	in	ADP
ajlm-2065	77	82	those	those	PRON
ajlm-2065	77	83	with	with	ADP
ajlm-2065	77	84	hiv	hiv	PROPN
ajlm-2065	77	85	infection	infection	NOUN
ajlm-2065	77	86	.	.	PUNCT
ajlm-2065	78	1	lower	low	ADJ
ajlm-2065	78	2	sars	sar	NOUN
ajlm-2065	78	3	-	-	PUNCT
ajlm-2065	78	4	cov-2	cov-2	NOUN
ajlm-2065	78	5	igg	igg	NOUN
ajlm-2065	78	6	concentrations	concentration	NOUN
ajlm-2065	78	7	may	may	AUX
ajlm-2065	78	8	affect	affect	VERB
ajlm-2065	78	9	the	the	DET
ajlm-2065	78	10	detectability	detectability	NOUN
ajlm-2065	78	11	of	of	ADP
ajlm-2065	78	12	igg,30	igg,30	PROPN
ajlm-2065	78	13	which	which	PRON
ajlm-2065	78	14	may	may	AUX
ajlm-2065	78	15	be	be	AUX
ajlm-2065	78	16	lower	low	ADJ
ajlm-2065	78	17	than	than	ADP
ajlm-2065	78	18	the	the	DET
ajlm-2065	78	19	detectable	detectable	ADJ
ajlm-2065	78	20	limit	limit	NOUN
ajlm-2065	78	21	of	of	ADP
ajlm-2065	78	22	the	the	DET
ajlm-2065	78	23	assay	assay	NOUN
ajlm-2065	78	24	.	.	PUNCT
ajlm-2065	79	1	based	base	VERB
ajlm-2065	79	2	on	on	ADP
ajlm-2065	79	3	a	a	DET
ajlm-2065	79	4	local	local	ADJ
ajlm-2065	79	5	evaluation	evaluation	NOUN
ajlm-2065	79	6	of	of	ADP
ajlm-2065	79	7	the	the	DET
ajlm-2065	79	8	performance	performance	NOUN
ajlm-2065	79	9	of	of	ADP
ajlm-2065	79	10	the	the	DET
ajlm-2065	79	11	abbott	abbott	PROPN
ajlm-2065	79	12	architect	architect	PROPN
ajlm-2065	79	13	sars	sar	NOUN
ajlm-2065	79	14	-	-	PUNCT
ajlm-2065	79	15	cov-2	cov-2	NOUN
ajlm-2065	79	16	igg	igg	PROPN
ajlm-2065	79	17	assay	assay	NOUN
ajlm-2065	79	18	,	,	PUNCT
ajlm-2065	79	19	sensitivity	sensitivity	NOUN
ajlm-2065	79	20	is	be	AUX
ajlm-2065	79	21	highest	high	ADJ
ajlm-2065	79	22	30–41	30–41	NUM
ajlm-2065	79	23	days	day	NOUN
ajlm-2065	79	24	after	after	ADP
ajlm-2065	79	25	a	a	DET
ajlm-2065	79	26	positive	positive	ADJ
ajlm-2065	79	27	pcr	pcr	NOUN
ajlm-2065	79	28	,	,	PUNCT
ajlm-2065	79	29	following	follow	VERB
ajlm-2065	79	30	moderate	moderate	ADJ
ajlm-2065	79	31	to	to	ADP
ajlm-2065	79	32	severe	severe	ADJ
ajlm-2065	79	33	infection.23	infection.23	PROPN
ajlm-2065	79	34	however	however	ADV
ajlm-2065	79	35	in	in	ADP
ajlm-2065	79	36	our	our	PRON
ajlm-2065	79	37	study	study	NOUN
ajlm-2065	79	38	reduced	reduce	VERB
ajlm-2065	79	39	seropositivity	seropositivity	NOUN
ajlm-2065	79	40	was	be	AUX
ajlm-2065	79	41	most	most	ADV
ajlm-2065	79	42	likely	likely	ADJ
ajlm-2065	79	43	due	due	ADJ
ajlm-2065	79	44	to	to	ADP
ajlm-2065	79	45	reduced	reduce	VERB
ajlm-2065	79	46	immunity	immunity	NOUN
ajlm-2065	79	47	in	in	ADP
ajlm-2065	79	48	people	people	NOUN
ajlm-2065	79	49	with	with	ADP
ajlm-2065	79	50	uncontrolled	uncontrolled	ADJ
ajlm-2065	79	51	hiv	hiv	PROPN
ajlm-2065	79	52	and	and	CCONJ
ajlm-2065	79	53	the	the	DET
ajlm-2065	79	54	timing	timing	NOUN
ajlm-2065	79	55	of	of	ADP
ajlm-2065	79	56	sampling	sample	VERB
ajlm-2065	79	57	in	in	ADP
ajlm-2065	79	58	relation	relation	NOUN
ajlm-2065	79	59	to	to	ADP
ajlm-2065	79	60	the	the	DET
ajlm-2065	79	61	epidemic	epidemic	NOUN
ajlm-2065	79	62	waves.23	waves.23	NOUN
ajlm-2065	79	63	we	we	PRON
ajlm-2065	79	64	have	have	AUX
ajlm-2065	79	65	demonstrated	demonstrate	VERB
ajlm-2065	79	66	that	that	SCONJ
ajlm-2065	79	67	sars	sar	NOUN
ajlm-2065	79	68	-	-	PUNCT
ajlm-2065	79	69	cov-2	cov-2	PART
ajlm-2065	79	70	seropositivity	seropositivity	NOUN
ajlm-2065	79	71	increased	increase	VERB
ajlm-2065	79	72	with	with	ADP
ajlm-2065	79	73	age	age	NOUN
ajlm-2065	79	74	,	,	PUNCT
ajlm-2065	79	75	with	with	ADP
ajlm-2065	79	76	children	child	NOUN
ajlm-2065	79	77	under	under	ADP
ajlm-2065	79	78	10	10	NUM
ajlm-2065	79	79	years	year	NOUN
ajlm-2065	79	80	having	have	VERB
ajlm-2065	79	81	the	the	DET
ajlm-2065	79	82	lowest	low	ADJ
ajlm-2065	79	83	seropositivity	seropositivity	NOUN
ajlm-2065	79	84	(	(	PUNCT
ajlm-2065	79	85	11.1	11.1	NUM
ajlm-2065	79	86	%	%	NOUN
ajlm-2065	79	87	)	)	PUNCT
ajlm-2065	79	88	.	.	PUNCT
ajlm-2065	80	1	similar	similar	ADJ
ajlm-2065	80	2	patterns	pattern	NOUN
ajlm-2065	80	3	have	have	AUX
ajlm-2065	80	4	been	be	AUX
ajlm-2065	80	5	described	describe	VERB
ajlm-2065	80	6	locally25	locally25	NOUN
ajlm-2065	80	7	and	and	CCONJ
ajlm-2065	80	8	internationally.15	internationally.15	PROPN
ajlm-2065	80	9	our	our	PRON
ajlm-2065	80	10	reported	report	VERB
ajlm-2065	80	11	seropositivity	seropositivity	NOUN
ajlm-2065	80	12	(	(	PUNCT
ajlm-2065	80	13	10	10	NUM
ajlm-2065	80	14	%	%	NOUN
ajlm-2065	80	15	)	)	PUNCT
ajlm-2065	80	16	in	in	ADP
ajlm-2065	80	17	children	child	NOUN
ajlm-2065	80	18	under	under	ADP
ajlm-2065	80	19	10	10	NUM
ajlm-2065	80	20	years	year	NOUN
ajlm-2065	80	21	during	during	ADP
ajlm-2065	80	22	the	the	DET
ajlm-2065	80	23	second	second	ADJ
ajlm-2065	80	24	wave	wave	NOUN
ajlm-2065	80	25	in	in	ADP
ajlm-2065	80	26	kwazulu	kwazulu	PROPN
ajlm-2065	80	27	-	-	PUNCT
ajlm-2065	80	28	natal	natal	NOUN
ajlm-2065	80	29	indicated	indicate	VERB
ajlm-2065	80	30	that	that	SCONJ
ajlm-2065	80	31	these	these	DET
ajlm-2065	80	32	children	child	NOUN
ajlm-2065	80	33	may	may	AUX
ajlm-2065	80	34	have	have	AUX
ajlm-2065	80	35	been	be	AUX
ajlm-2065	80	36	more	more	ADV
ajlm-2065	80	37	vulnerable	vulnerable	ADJ
ajlm-2065	80	38	to	to	ADP
ajlm-2065	80	39	sars	sar	NOUN
ajlm-2065	80	40	-	-	PUNCT
ajlm-2065	80	41	cov-2	cov-2	PART
ajlm-2065	80	42	infection	infection	NOUN
ajlm-2065	80	43	.	.	PUNCT
ajlm-2065	81	1	however	however	ADV
ajlm-2065	81	2	,	,	PUNCT
ajlm-2065	81	3	the	the	DET
ajlm-2065	81	4	rate	rate	NOUN
ajlm-2065	81	5	of	of	ADP
ajlm-2065	81	6	infections	infection	NOUN
ajlm-2065	81	7	in	in	ADP
ajlm-2065	81	8	south	south	PROPN
ajlm-2065	81	9	africa	africa	PROPN
ajlm-2065	81	10	among	among	ADP
ajlm-2065	81	11	these	these	DET
ajlm-2065	81	12	children	child	NOUN
ajlm-2065	81	13	was	be	AUX
ajlm-2065	81	14	1.4%,31	1.4%,31	NUM
ajlm-2065	81	15	suggesting	suggest	VERB
ajlm-2065	81	16	that	that	SCONJ
ajlm-2065	81	17	pcr	pcr	NOUN
ajlm-2065	81	18	testing	testing	NOUN
ajlm-2065	81	19	alone	alone	ADV
ajlm-2065	81	20	may	may	AUX
ajlm-2065	81	21	have	have	AUX
ajlm-2065	81	22	underestimated	underestimate	VERB
ajlm-2065	81	23	infection	infection	NOUN
ajlm-2065	81	24	rates	rate	NOUN
ajlm-2065	81	25	or	or	CCONJ
ajlm-2065	81	26	that	that	SCONJ
ajlm-2065	81	27	these	these	DET
ajlm-2065	81	28	children	child	NOUN
ajlm-2065	81	29	were	be	AUX
ajlm-2065	81	30	asymptomatic	asymptomatic	ADJ
ajlm-2065	81	31	.	.	PUNCT
ajlm-2065	82	1	however	however	ADV
ajlm-2065	82	2	,	,	PUNCT
ajlm-2065	82	3	a	a	DET
ajlm-2065	82	4	seroprevalence	seroprevalence	NOUN
ajlm-2065	82	5	in	in	ADP
ajlm-2065	82	6	children	child	NOUN
ajlm-2065	82	7	under	under	ADP
ajlm-2065	82	8	9	9	NUM
ajlm-2065	82	9	years	year	NOUN
ajlm-2065	82	10	during	during	ADP
ajlm-2065	82	11	the	the	DET
ajlm-2065	82	12	first	first	ADJ
ajlm-2065	82	13	wave	wave	NOUN
ajlm-2065	82	14	in	in	ADP
ajlm-2065	82	15	gauteng	gauteng	PROPN
ajlm-2065	82	16	was	be	AUX
ajlm-2065	82	17	reported	report	VERB
ajlm-2065	82	18	to	to	PART
ajlm-2065	82	19	be	be	AUX
ajlm-2065	82	20	about	about	ADP
ajlm-2065	82	21	20%,18	20%,18	NUM
ajlm-2065	82	22	most	most	ADV
ajlm-2065	82	23	likely	likely	ADJ
ajlm-2065	82	24	due	due	ADJ
ajlm-2065	82	25	to	to	ADP
ajlm-2065	82	26	gauteng	gauteng	PROPN
ajlm-2065	82	27	having	have	VERB
ajlm-2065	82	28	the	the	DET
ajlm-2065	82	29	highest	high	ADJ
ajlm-2065	82	30	infection	infection	NOUN
ajlm-2065	82	31	rate	rate	NOUN
ajlm-2065	82	32	nationally	nationally	ADV
ajlm-2065	82	33	during	during	ADP
ajlm-2065	82	34	the	the	DET
ajlm-2065	82	35	entire	entire	ADJ
ajlm-2065	82	36	epidemic.1	epidemic.1	PROPN
ajlm-2065	82	37	we	we	PRON
ajlm-2065	82	38	found	find	VERB
ajlm-2065	82	39	no	no	DET
ajlm-2065	82	40	discernible	discernible	ADJ
ajlm-2065	82	41	pattern	pattern	NOUN
ajlm-2065	82	42	in	in	ADP
ajlm-2065	82	43	the	the	DET
ajlm-2065	82	44	district	district	NOUN
ajlm-2065	82	45	seroprevalence	seroprevalence	NOUN
ajlm-2065	82	46	during	during	ADP
ajlm-2065	82	47	the	the	DET
ajlm-2065	82	48	second	second	ADJ
ajlm-2065	82	49	wave	wave	NOUN
ajlm-2065	82	50	.	.	PUNCT
ajlm-2065	83	1	however	however	ADV
ajlm-2065	83	2	,	,	PUNCT
ajlm-2065	83	3	the	the	DET
ajlm-2065	83	4	rate	rate	NOUN
ajlm-2065	83	5	of	of	ADP
ajlm-2065	83	6	infections	infection	NOUN
ajlm-2065	83	7	in	in	ADP
ajlm-2065	83	8	the	the	DET
ajlm-2065	83	9	ethekwini	ethekwini	NOUN
ajlm-2065	83	10	,	,	PUNCT
ajlm-2065	83	11	ilembe	ilembe	NOUN
ajlm-2065	83	12	,	,	PUNCT
ajlm-2065	83	13	ugu	ugu	PROPN
ajlm-2065	83	14	,	,	PUNCT
ajlm-2065	83	15	and	and	CCONJ
ajlm-2065	83	16	uthukela	uthukela	PROPN
ajlm-2065	83	17	districts	district	NOUN
ajlm-2065	83	18	were	be	AUX
ajlm-2065	83	19	subsequently	subsequently	ADV
ajlm-2065	83	20	lower	low	ADJ
ajlm-2065	83	21	in	in	ADP
ajlm-2065	83	22	the	the	DET
ajlm-2065	83	23	third	third	ADJ
ajlm-2065	83	24	wave.1	wave.1	ADJ
ajlm-2065	83	25	limitations	limitation	NOUN
ajlm-2065	83	26	firstly	firstly	ADV
ajlm-2065	83	27	,	,	PUNCT
ajlm-2065	83	28	the	the	DET
ajlm-2065	83	29	specimens	specimen	NOUN
ajlm-2065	83	30	tested	test	VERB
ajlm-2065	83	31	were	be	AUX
ajlm-2065	83	32	from	from	ADP
ajlm-2065	83	33	individuals	individual	NOUN
ajlm-2065	83	34	accessing	access	VERB
ajlm-2065	83	35	public	public	ADJ
ajlm-2065	83	36	healthcare	healthcare	NOUN
ajlm-2065	83	37	and	and	CCONJ
ajlm-2065	83	38	thus	thus	ADV
ajlm-2065	83	39	may	may	AUX
ajlm-2065	83	40	not	not	PART
ajlm-2065	83	41	represent	represent	VERB
ajlm-2065	83	42	the	the	DET
ajlm-2065	83	43	general	general	ADJ
ajlm-2065	83	44	population	population	NOUN
ajlm-2065	83	45	.	.	PUNCT
ajlm-2065	84	1	however	however	ADV
ajlm-2065	84	2	,	,	PUNCT
ajlm-2065	84	3	it	it	PRON
ajlm-2065	84	4	potentially	potentially	ADV
ajlm-2065	84	5	represents	represent	VERB
ajlm-2065	84	6	people	people	NOUN
ajlm-2065	84	7	living	live	VERB
ajlm-2065	84	8	with	with	ADP
ajlm-2065	84	9	hiv	hiv	PROPN
ajlm-2065	84	10	accessing	access	VERB
ajlm-2065	84	11	antiretroviral	antiretroviral	ADJ
ajlm-2065	84	12	therapy	therapy	NOUN
ajlm-2065	84	13	in	in	ADP
ajlm-2065	84	14	our	our	PRON
ajlm-2065	84	15	province	province	NOUN
ajlm-2065	84	16	.	.	PUNCT
ajlm-2065	85	1	secondly	secondly	ADV
ajlm-2065	85	2	,	,	PUNCT
ajlm-2065	85	3	surveillance	surveillance	NOUN
ajlm-2065	85	4	using	use	VERB
ajlm-2065	85	5	residual	residual	ADJ
ajlm-2065	85	6	clinical	clinical	ADJ
ajlm-2065	85	7	specimens	specimen	NOUN
ajlm-2065	85	8	without	without	ADP
ajlm-2065	85	9	exposure	exposure	NOUN
ajlm-2065	85	10	time	time	NOUN
ajlm-2065	85	11	data	datum	NOUN
ajlm-2065	85	12	,	,	PUNCT
ajlm-2065	85	13	as	as	SCONJ
ajlm-2065	85	14	done	do	VERB
ajlm-2065	85	15	in	in	ADP
ajlm-2065	85	16	this	this	DET
ajlm-2065	85	17	study	study	NOUN
ajlm-2065	85	18	,	,	PUNCT
ajlm-2065	85	19	may	may	AUX
ajlm-2065	85	20	underestimate	underestimate	VERB
ajlm-2065	85	21	seropositivity.32	seropositivity.32	VERB
ajlm-2065	85	22	thirdly	thirdly	ADV
ajlm-2065	85	23	,	,	PUNCT
ajlm-2065	85	24	seropositivity	seropositivity	NOUN
ajlm-2065	85	25	may	may	AUX
ajlm-2065	85	26	be	be	AUX
ajlm-2065	85	27	underestimated	underestimate	VERB
ajlm-2065	85	28	since	since	SCONJ
ajlm-2065	85	29	sars	sar	NOUN
ajlm-2065	85	30	-	-	PUNCT
ajlm-2065	85	31	cov-2	cov-2	NOUN
ajlm-2065	85	32	igg	igg	NOUN
ajlm-2065	85	33	detection	detection	NOUN
ajlm-2065	85	34	and	and	CCONJ
ajlm-2065	85	35	durability	durability	NOUN
ajlm-2065	85	36	is	be	AUX
ajlm-2065	85	37	directly	directly	ADV
ajlm-2065	85	38	proportional	proportional	ADJ
ajlm-2065	85	39	to	to	ADP
ajlm-2065	85	40	disease	disease	NOUN
ajlm-2065	85	41	severity.33,34	severity.33,34	NOUN
ajlm-2065	85	42	although	although	SCONJ
ajlm-2065	85	43	antibody	antibody	NOUN
ajlm-2065	85	44	positivity	positivity	NOUN
ajlm-2065	85	45	was	be	AUX
ajlm-2065	85	46	still	still	ADV
ajlm-2065	85	47	high	high	ADJ
ajlm-2065	85	48	in	in	ADP
ajlm-2065	85	49	another	another	DET
ajlm-2065	85	50	study	study	NOUN
ajlm-2065	85	51	at	at	ADP
ajlm-2065	85	52	8	8	NUM
ajlm-2065	85	53	months	month	NOUN
ajlm-2065	85	54	after	after	ADP
ajlm-2065	85	55	mild	mild	ADJ
ajlm-2065	85	56	and	and	CCONJ
ajlm-2065	85	57	asymptomatic	asymptomatic	ADJ
ajlm-2065	85	58	infection,35	infection,35	NOUN
ajlm-2065	85	59	overall	overall	ADJ
ajlm-2065	85	60	detectability	detectability	NOUN
ajlm-2065	85	61	and	and	CCONJ
ajlm-2065	85	62	durability	durability	NOUN
ajlm-2065	85	63	may	may	AUX
ajlm-2065	85	64	be	be	AUX
ajlm-2065	85	65	reduced	reduce	VERB
ajlm-2065	85	66	in	in	ADP
ajlm-2065	85	67	hiv	hiv	PROPN
ajlm-2065	85	68	-	-	PUNCT
ajlm-2065	85	69	positive	positive	ADJ
ajlm-2065	85	70	persons.36	persons.36	NOUN
ajlm-2065	85	71	fourthly	fourthly	ADV
ajlm-2065	85	72	,	,	PUNCT
ajlm-2065	85	73	the	the	DET
ajlm-2065	85	74	abbott	abbott	PROPN
ajlm-2065	85	75	architect	architect	PROPN
ajlm-2065	85	76	sars	sar	NOUN
ajlm-2065	85	77	-	-	PUNCT
ajlm-2065	85	78	cov-2	cov-2	NOUN
ajlm-2065	85	79	igg	igg	PROPN
ajlm-2065	85	80	assay	assay	PROPN
ajlm-2065	85	81	detects	detect	NOUN
ajlm-2065	85	82	igg	igg	PROPN
ajlm-2065	85	83	to	to	PART
ajlm-2065	85	84	nucleocapsid	nucleocapsid	VERB
ajlm-2065	85	85	antigens	antigen	NOUN
ajlm-2065	85	86	only	only	ADV
ajlm-2065	85	87	and	and	CCONJ
ajlm-2065	85	88	at	at	ADP
ajlm-2065	85	89	the	the	DET
ajlm-2065	85	90	time	time	NOUN
ajlm-2065	85	91	was	be	AUX
ajlm-2065	85	92	the	the	DET
ajlm-2065	85	93	only	only	ADV
ajlm-2065	85	94	approved	approve	VERB
ajlm-2065	85	95	commercial	commercial	ADJ
ajlm-2065	85	96	serological	serological	ADJ
ajlm-2065	85	97	assay	assay	NOUN
ajlm-2065	85	98	by	by	ADP
ajlm-2065	85	99	the	the	DET
ajlm-2065	85	100	south	south	ADJ
ajlm-2065	85	101	african	african	ADJ
ajlm-2065	85	102	health	health	NOUN
ajlm-2065	85	103	products	product	NOUN
ajlm-2065	85	104	regulatory	regulatory	ADJ
ajlm-2065	85	105	authority.37	authority.37	ADP
ajlm-2065	85	106	the	the	DET
ajlm-2065	85	107	use	use	NOUN
ajlm-2065	85	108	of	of	ADP
ajlm-2065	85	109	nucleocapsid	nucleocapsid	ADJ
ajlm-2065	85	110	igg	igg	NOUN
ajlm-2065	85	111	solely	solely	ADV
ajlm-2065	85	112	to	to	PART
ajlm-2065	85	113	determine	determine	VERB
ajlm-2065	85	114	seroprevalence	seroprevalence	NOUN
ajlm-2065	85	115	may	may	AUX
ajlm-2065	85	116	underestimate	underestimate	VERB
ajlm-2065	85	117	the	the	DET
ajlm-2065	85	118	true	true	ADJ
ajlm-2065	85	119	rate	rate	NOUN
ajlm-2065	85	120	of	of	ADP
ajlm-2065	85	121	past	past	ADJ
ajlm-2065	85	122	infections.32	infections.32	PROPN
ajlm-2065	85	123	nucleocapsid	nucleocapsid	PROPN
ajlm-2065	85	124	igg	igg	PROPN
ajlm-2065	85	125	declines	decline	VERB
ajlm-2065	85	126	more	more	ADV
ajlm-2065	85	127	rapidly	rapidly	ADV
ajlm-2065	85	128	than	than	ADP
ajlm-2065	85	129	spike	spike	PROPN
ajlm-2065	85	130	igg	igg	PROPN
ajlm-2065	85	131	.	.	PUNCT
ajlm-2065	86	1	however	however	ADV
ajlm-2065	86	2	,	,	PUNCT
ajlm-2065	86	3	nucleocapsid	nucleocapsid	ADJ
ajlm-2065	86	4	igg	igg	PROPN
ajlm-2065	86	5	is	be	AUX
ajlm-2065	86	6	more	more	ADV
ajlm-2065	86	7	sensitive	sensitive	ADJ
ajlm-2065	86	8	within	within	ADP
ajlm-2065	86	9	the	the	DET
ajlm-2065	86	10	first	first	ADJ
ajlm-2065	86	11	14	14	NUM
ajlm-2065	86	12	days	day	NOUN
ajlm-2065	86	13	of	of	ADP
ajlm-2065	86	14	sars	sar	NOUN
ajlm-2065	86	15	-	-	PUNCT
ajlm-2065	86	16	cov-2	cov-2	NOUN
ajlm-2065	86	17	infection	infection	NOUN
ajlm-2065	86	18	as	as	SCONJ
ajlm-2065	86	19	compared	compare	VERB
ajlm-2065	86	20	to	to	PART
ajlm-2065	86	21	spike	spike	VERB
ajlm-2065	86	22	igg.34	igg.34	ADV
ajlm-2065	86	23	lastly	lastly	ADV
ajlm-2065	86	24	,	,	PUNCT
ajlm-2065	86	25	antibody	antibody	NOUN
ajlm-2065	86	26	cross	cross	NOUN
ajlm-2065	86	27	-	-	NOUN
ajlm-2065	86	28	reactivity	reactivity	NOUN
ajlm-2065	86	29	with	with	ADP
ajlm-2065	86	30	other	other	ADJ
ajlm-2065	86	31	betacoronaviruses	betacoronaviruse	NOUN
ajlm-2065	86	32	may	may	AUX
ajlm-2065	86	33	lead	lead	VERB
ajlm-2065	86	34	to	to	ADP
ajlm-2065	86	35	false	false	ADJ
ajlm-2065	86	36	positives.23,38	positives.23,38	NOUN
ajlm-2065	86	37	however	however	ADV
ajlm-2065	86	38	,	,	PUNCT
ajlm-2065	86	39	the	the	DET
ajlm-2065	86	40	abbott	abbott	PROPN
ajlm-2065	86	41	architect	architect	PROPN
ajlm-2065	86	42	sars	sar	NOUN
ajlm-2065	86	43	-	-	PUNCT
ajlm-2065	86	44	cov-2	cov-2	NOUN
ajlm-2065	86	45	igg	igg	PROPN
ajlm-2065	86	46	has	have	VERB
ajlm-2065	86	47	a	a	DET
ajlm-2065	86	48	specificity	specificity	NOUN
ajlm-2065	86	49	of	of	ADP
ajlm-2065	86	50	99%.23,38	99%.23,38	NUM
ajlm-2065	86	51	conclusion	conclusion	NOUN
ajlm-2065	86	52	our	our	PRON
ajlm-2065	86	53	results	result	NOUN
ajlm-2065	86	54	highlight	highlight	VERB
ajlm-2065	86	55	that	that	SCONJ
ajlm-2065	86	56	after	after	ADP
ajlm-2065	86	57	the	the	DET
ajlm-2065	86	58	second	second	ADJ
ajlm-2065	86	59	wave	wave	NOUN
ajlm-2065	86	60	in	in	ADP
ajlm-2065	86	61	kwazulu	kwazulu	NOUN
ajlm-2065	86	62	-	-	PUNCT
ajlm-2065	86	63	natal	natal	ADJ
ajlm-2065	86	64	,	,	PUNCT
ajlm-2065	86	65	many	many	ADJ
ajlm-2065	86	66	people	people	NOUN
ajlm-2065	86	67	accessing	access	VERB
ajlm-2065	86	68	public	public	ADJ
ajlm-2065	86	69	healthcare	healthcare	NOUN
ajlm-2065	86	70	were	be	AUX
ajlm-2065	86	71	immunologically	immunologically	ADV
ajlm-2065	86	72	susceptible	susceptible	ADJ
ajlm-2065	86	73	.	.	PUNCT
ajlm-2065	87	1	furthermore	furthermore	ADV
ajlm-2065	87	2	,	,	PUNCT
ajlm-2065	87	3	reduced	reduce	VERB
ajlm-2065	87	4	seropositivity	seropositivity	NOUN
ajlm-2065	87	5	in	in	ADP
ajlm-2065	87	6	hiv	hiv	PROPN
ajlm-2065	87	7	-	-	PUNCT
ajlm-2065	87	8	positive	positive	ADJ
ajlm-2065	87	9	individuals	individual	NOUN
ajlm-2065	87	10	with	with	ADP
ajlm-2065	87	11	hiv	hiv	PROPN
ajlm-2065	87	12	viral	viral	ADJ
ajlm-2065	87	13	loads	load	NOUN
ajlm-2065	87	14	greater	great	ADJ
ajlm-2065	87	15	than	than	ADP
ajlm-2065	87	16	1000	1000	NUM
ajlm-2065	87	17	copies	copy	NOUN
ajlm-2065	87	18	/	/	SYM
ajlm-2065	87	19	ml	ml	VERB
ajlm-2065	87	20	further	far	ADV
ajlm-2065	87	21	emphasised	emphasise	VERB
ajlm-2065	87	22	the	the	DET
ajlm-2065	87	23	importance	importance	NOUN
ajlm-2065	87	24	of	of	ADP
ajlm-2065	87	25	targeted	target	VERB
ajlm-2065	87	26	vaccination	vaccination	NOUN
ajlm-2065	87	27	of	of	ADP
ajlm-2065	87	28	people	people	NOUN
ajlm-2065	87	29	living	live	VERB
ajlm-2065	87	30	with	with	ADP
ajlm-2065	87	31	hiv	hiv	PROPN
ajlm-2065	87	32	and	and	CCONJ
ajlm-2065	87	33	monitoring	monitor	VERB
ajlm-2065	87	34	response	response	NOUN
ajlm-2065	87	35	to	to	ADP
ajlm-2065	87	36	vaccination	vaccination	NOUN
ajlm-2065	87	37	in	in	ADP
ajlm-2065	87	38	these	these	DET
ajlm-2065	87	39	individuals.39,40	individuals.39,40	NOUN
ajlm-2065	87	40	acknowledgements	acknowledgement	NOUN
ajlm-2065	87	41	the	the	DET
ajlm-2065	87	42	authors	author	NOUN
ajlm-2065	87	43	would	would	AUX
ajlm-2065	87	44	like	like	VERB
ajlm-2065	87	45	to	to	PART
ajlm-2065	87	46	acknowledge	acknowledge	VERB
ajlm-2065	87	47	and	and	CCONJ
ajlm-2065	87	48	thank	thank	VERB
ajlm-2065	87	49	the	the	DET
ajlm-2065	87	50	staff	staff	NOUN
ajlm-2065	87	51	from	from	ADP
ajlm-2065	87	52	the	the	DET
ajlm-2065	87	53	department	department	NOUN
ajlm-2065	87	54	of	of	ADP
ajlm-2065	87	55	virology	virology	NOUN
ajlm-2065	87	56	at	at	ADP
ajlm-2065	87	57	inkosi	inkosi	PROPN
ajlm-2065	87	58	albert	albert	PROPN
ajlm-2065	87	59	luthuli	luthuli	PROPN
ajlm-2065	87	60	central	central	PROPN
ajlm-2065	87	61	hospital	hospital	NOUN
ajlm-2065	87	62	for	for	ADP
ajlm-2065	87	63	their	their	PRON
ajlm-2065	87	64	assistance	assistance	NOUN
ajlm-2065	87	65	and	and	CCONJ
ajlm-2065	87	66	dedication	dedication	NOUN
ajlm-2065	87	67	to	to	ADP
ajlm-2065	87	68	the	the	DET
ajlm-2065	87	69	research	research	NOUN
ajlm-2065	87	70	project	project	NOUN
ajlm-2065	87	71	,	,	PUNCT
ajlm-2065	87	72	as	as	ADV
ajlm-2065	87	73	well	well	ADV
ajlm-2065	87	74	as	as	ADP
ajlm-2065	87	75	the	the	DET
ajlm-2065	87	76	national	national	PROPN
ajlm-2065	87	77	health	health	PROPN
ajlm-2065	87	78	laboratory	laboratory	PROPN
ajlm-2065	87	79	service	service	NOUN
ajlm-2065	87	80	for	for	ADP
ajlm-2065	87	81	providing	provide	VERB
ajlm-2065	87	82	the	the	DET
ajlm-2065	87	83	kits	kit	NOUN
ajlm-2065	87	84	used	use	VERB
ajlm-2065	87	85	for	for	ADP
ajlm-2065	87	86	this	this	DET
ajlm-2065	87	87	research	research	NOUN
ajlm-2065	87	88	.	.	PUNCT
ajlm-2065	88	1	competing	compete	VERB
ajlm-2065	88	2	interests	interest	NOUN
ajlm-2065	88	3	the	the	DET
ajlm-2065	88	4	authors	author	NOUN
ajlm-2065	88	5	declare	declare	VERB
ajlm-2065	88	6	that	that	SCONJ
ajlm-2065	88	7	they	they	PRON
ajlm-2065	88	8	have	have	VERB
ajlm-2065	88	9	no	no	DET
ajlm-2065	88	10	financial	financial	ADJ
ajlm-2065	88	11	or	or	CCONJ
ajlm-2065	88	12	personal	personal	ADJ
ajlm-2065	88	13	relationships	relationship	NOUN
ajlm-2065	88	14	that	that	PRON
ajlm-2065	88	15	may	may	AUX
ajlm-2065	88	16	have	have	AUX
ajlm-2065	88	17	inappropriately	inappropriately	ADV
ajlm-2065	88	18	influenced	influence	VERB
ajlm-2065	88	19	them	they	PRON
ajlm-2065	88	20	in	in	ADP
ajlm-2065	88	21	writing	write	VERB
ajlm-2065	88	22	this	this	DET
ajlm-2065	88	23	article	article	NOUN
ajlm-2065	88	24	.	.	PUNCT
ajlm-2065	89	1	authors	author	NOUN
ajlm-2065	89	2	’	'	PUNCT
ajlm-2065	89	3	contributions	contribution	NOUN
ajlm-2065	89	4	k.-l.a.f	k.-l.a.f	PROPN
ajlm-2065	89	5	.	.	PUNCT
ajlm-2065	89	6	,	,	PUNCT
ajlm-2065	89	7	n.m	n.m	PROPN
ajlm-2065	89	8	.	.	PROPN
ajlm-2065	89	9	,	,	PUNCT
ajlm-2065	89	10	k.g	k.g	PROPN
ajlm-2065	89	11	.	.	PROPN
ajlm-2065	89	12	,	,	PUNCT
ajlm-2065	89	13	l.g	l.g	PROPN
ajlm-2065	89	14	.	.	PROPN
ajlm-2065	89	15	,	,	PUNCT
ajlm-2065	89	16	p.m.	p.m.	NOUN
ajlm-2065	89	17	,	,	PUNCT
ajlm-2065	89	18	r.p	r.p	PROPN
ajlm-2065	89	19	.	.	PROPN
ajlm-2065	89	20	,	,	PUNCT
ajlm-2065	89	21	i.c	i.c	PROPN
ajlm-2065	89	22	.	.	PROPN
ajlm-2065	89	23	,	,	PUNCT
ajlm-2065	89	24	l.x	l.x	PROPN
ajlm-2065	89	25	.	.	PROPN
ajlm-2065	90	1	and	and	CCONJ
ajlm-2065	90	2	a.k	a.k	PROPN
ajlm-2065	90	3	.	.	PROPN
ajlm-2065	90	4	contributed	contribute	VERB
ajlm-2065	90	5	to	to	ADP
ajlm-2065	90	6	the	the	DET
ajlm-2065	90	7	conceptualisation	conceptualisation	NOUN
ajlm-2065	90	8	,	,	PUNCT
ajlm-2065	90	9	ethics	ethic	NOUN
ajlm-2065	90	10	application	application	NOUN
ajlm-2065	90	11	,	,	PUNCT
ajlm-2065	90	12	writing	writing	NOUN
ajlm-2065	90	13	of	of	ADP
ajlm-2065	90	14	the	the	DET
ajlm-2065	90	15	manuscript	manuscript	NOUN
ajlm-2065	90	16	,	,	PUNCT
ajlm-2065	90	17	data	datum	NOUN
ajlm-2065	90	18	collection	collection	NOUN
ajlm-2065	90	19	and	and	CCONJ
ajlm-2065	90	20	analysis	analysis	NOUN
ajlm-2065	90	21	,	,	PUNCT
ajlm-2065	90	22	and	and	CCONJ
ajlm-2065	90	23	have	have	AUX
ajlm-2065	90	24	read	read	VERB
ajlm-2065	90	25	and	and	CCONJ
ajlm-2065	90	26	agreed	agree	VERB
ajlm-2065	90	27	to	to	ADP
ajlm-2065	90	28	the	the	DET
ajlm-2065	90	29	published	publish	VERB
ajlm-2065	90	30	version	version	NOUN
ajlm-2065	90	31	of	of	ADP
ajlm-2065	90	32	the	the	DET
ajlm-2065	90	33	manuscript	manuscript	NOUN
ajlm-2065	90	34	.	.	PUNCT
ajlm-2065	91	1	sources	source	NOUN
ajlm-2065	91	2	of	of	ADP
ajlm-2065	91	3	support	support	NOUN
ajlm-2065	91	4	this	this	DET
ajlm-2065	91	5	research	research	NOUN
ajlm-2065	91	6	did	do	AUX
ajlm-2065	91	7	not	not	PART
ajlm-2065	91	8	receive	receive	VERB
ajlm-2065	91	9	a	a	DET
ajlm-2065	91	10	grant	grant	NOUN
ajlm-2065	91	11	from	from	ADP
ajlm-2065	91	12	any	any	DET
ajlm-2065	91	13	funding	funding	NOUN
ajlm-2065	91	14	agency	agency	NOUN
ajlm-2065	91	15	in	in	ADP
ajlm-2065	91	16	the	the	DET
ajlm-2065	91	17	public	public	ADJ
ajlm-2065	91	18	,	,	PUNCT
ajlm-2065	91	19	commercial	commercial	ADJ
ajlm-2065	91	20	,	,	PUNCT
ajlm-2065	91	21	or	or	CCONJ
ajlm-2065	91	22	non	non	ADJ
ajlm-2065	91	23	-	-	ADJ
ajlm-2065	91	24	profit	profit	ADJ
ajlm-2065	91	25	sectors	sector	NOUN
ajlm-2065	91	26	.	.	PUNCT
ajlm-2065	92	1	we	we	PRON
ajlm-2065	92	2	would	would	AUX
ajlm-2065	92	3	like	like	VERB
ajlm-2065	92	4	to	to	PART
ajlm-2065	92	5	express	express	VERB
ajlm-2065	92	6	gratitude	gratitude	NOUN
ajlm-2065	92	7	to	to	ADP
ajlm-2065	92	8	the	the	DET
ajlm-2065	92	9	national	national	PROPN
ajlm-2065	92	10	health	health	PROPN
ajlm-2065	92	11	laboratory	laboratory	PROPN
ajlm-2065	92	12	service	service	NOUN
ajlm-2065	92	13	for	for	ADP
ajlm-2065	92	14	providing	provide	VERB
ajlm-2065	92	15	kits	kit	NOUN
ajlm-2065	92	16	used	use	VERB
ajlm-2065	92	17	for	for	ADP
ajlm-2065	92	18	this	this	DET
ajlm-2065	92	19	research	research	NOUN
ajlm-2065	92	20	.	.	PUNCT
ajlm-2065	93	1	data	datum	NOUN
ajlm-2065	93	2	availability	availability	NOUN
ajlm-2065	93	3	the	the	DET
ajlm-2065	93	4	authors	author	NOUN
ajlm-2065	93	5	confirm	confirm	VERB
ajlm-2065	93	6	that	that	SCONJ
ajlm-2065	93	7	the	the	DET
ajlm-2065	93	8	data	datum	NOUN
ajlm-2065	93	9	supporting	support	VERB
ajlm-2065	93	10	the	the	DET
ajlm-2065	93	11	findings	finding	NOUN
ajlm-2065	93	12	of	of	ADP
ajlm-2065	93	13	this	this	DET
ajlm-2065	93	14	study	study	NOUN
ajlm-2065	93	15	are	be	AUX
ajlm-2065	93	16	available	available	ADJ
ajlm-2065	93	17	within	within	ADP
ajlm-2065	93	18	the	the	DET
ajlm-2065	93	19	article	article	NOUN
ajlm-2065	93	20	.	.	PUNCT
ajlm-2065	94	1	disclaimer	disclaimer	VERB
ajlm-2065	94	2	the	the	DET
ajlm-2065	94	3	views	view	NOUN
ajlm-2065	94	4	and	and	CCONJ
ajlm-2065	94	5	opinions	opinion	NOUN
ajlm-2065	94	6	expressed	express	VERB
ajlm-2065	94	7	in	in	ADP
ajlm-2065	94	8	this	this	DET
ajlm-2065	94	9	article	article	NOUN
ajlm-2065	94	10	are	be	AUX
ajlm-2065	94	11	those	those	PRON
ajlm-2065	94	12	of	of	ADP
ajlm-2065	94	13	the	the	DET
ajlm-2065	94	14	authors	author	NOUN
ajlm-2065	94	15	and	and	CCONJ
ajlm-2065	94	16	do	do	AUX
ajlm-2065	94	17	not	not	PART
ajlm-2065	94	18	necessarily	necessarily	ADV
ajlm-2065	94	19	reflect	reflect	VERB
ajlm-2065	94	20	the	the	DET
ajlm-2065	94	21	official	official	ADJ
ajlm-2065	94	22	policy	policy	NOUN
ajlm-2065	94	23	or	or	CCONJ
ajlm-2065	94	24	position	position	NOUN
ajlm-2065	94	25	of	of	ADP
ajlm-2065	94	26	any	any	PRON
ajlm-2065	94	27	of	of	ADP
ajlm-2065	94	28	the	the	DET
ajlm-2065	94	29	affiliated	affiliate	VERB
ajlm-2065	94	30	institutions	institution	NOUN
ajlm-2065	94	31	of	of	ADP
ajlm-2065	94	32	the	the	DET
ajlm-2065	94	33	authors	author	NOUN
ajlm-2065	94	34	.	.	PUNCT
ajlm-2065	95	1	references	reference	NOUN
ajlm-2065	95	2	bapela	bapela	PROPN
ajlm-2065	95	3	mp	mp	PROPN
ajlm-2065	95	4	,	,	PUNCT
ajlm-2065	95	5	ngcobo	ngcobo	VERB
ajlm-2065	95	6	a	a	PRON
ajlm-2065	95	7	,	,	PUNCT
ajlm-2065	95	8	sosibo	sosibo	PROPN
ajlm-2065	95	9	c	c	PROPN
ajlm-2065	95	10	,	,	PUNCT
ajlm-2065	95	11	mhlongo	mhlongo	PROPN
ajlm-2065	95	12	b.	b.	PROPN
ajlm-2065	96	1	kwazulu	kwazulu	PROPN
ajlm-2065	96	2	-	-	PUNCT
ajlm-2065	96	3	natal	natal	PROPN
ajlm-2065	96	4	department	department	PROPN
ajlm-2065	96	5	of	of	ADP
ajlm-2065	96	6	health	health	PROPN
ajlm-2065	96	7	covid-19	covid-19	PROPN
ajlm-2065	96	8	situation	situation	NOUN
ajlm-2065	96	9	report	report	NOUN
ajlm-2065	96	10	.	.	PUNCT
ajlm-2065	97	1	9	9	NUM
ajlm-2065	97	2	june	june	PROPN
ajlm-2065	97	3	2022	2022	NUM
ajlm-2065	97	4	.	.	PUNCT
ajlm-2065	98	1	durban	durban	PROPN
ajlm-2065	98	2	:	:	PUNCT
ajlm-2065	98	3	doh	doh	PROPN
ajlm-2065	98	4	;	;	PUNCT
ajlm-2065	98	5	2022	2022	NUM
ajlm-2065	98	6	.	.	PUNCT
ajlm-2065	99	1	abdool	abdool	NOUN
ajlm-2065	99	2	karim	karim	PROPN
ajlm-2065	99	3	ss	ss	PROPN
ajlm-2065	99	4	,	,	PUNCT
ajlm-2065	99	5	baxter	baxter	PROPN
ajlm-2065	99	6	c.	c.	PROPN
ajlm-2065	99	7	impact	impact	NOUN
ajlm-2065	99	8	of	of	ADP
ajlm-2065	99	9	sars	sar	NOUN
ajlm-2065	99	10	-	-	PUNCT
ajlm-2065	99	11	cov-2	cov-2	NOUN
ajlm-2065	99	12	variants	variant	NOUN
ajlm-2065	99	13	of	of	ADP
ajlm-2065	99	14	concern	concern	NOUN
ajlm-2065	99	15	on	on	ADP
ajlm-2065	99	16	covid-19	covid-19	PROPN
ajlm-2065	99	17	epidemic	epidemic	NOUN
ajlm-2065	99	18	in	in	ADP
ajlm-2065	99	19	south	south	PROPN
ajlm-2065	99	20	africa	africa	PROPN
ajlm-2065	99	21	.	.	PUNCT
ajlm-2065	100	1	trans	trans	PROPN
ajlm-2065	100	2	r	r	NOUN
ajlm-2065	100	3	soc	soc	NOUN
ajlm-2065	100	4	s	s	VERB
ajlm-2065	100	5	afr	afr	NOUN
ajlm-2065	100	6	.	.	PUNCT
ajlm-2065	101	1	2022;77(1):101–104	2022;77(1):101–104	PROPN
ajlm-2065	101	2	.	.	PUNCT
ajlm-2065	102	1	https://doi.org/10.1080/0035919x.2021.2011801	https://doi.org/10.1080/0035919x.2021.2011801	X
ajlm-2065	102	2	tegally	tegally	ADV
ajlm-2065	102	3	h	h	PROPN
ajlm-2065	102	4	,	,	PUNCT
ajlm-2065	102	5	wilkinson	wilkinson	PROPN
ajlm-2065	102	6	e	e	PROPN
ajlm-2065	102	7	,	,	PUNCT
ajlm-2065	102	8	giovanetti	giovanetti	PROPN
ajlm-2065	102	9	m	m	PROPN
ajlm-2065	102	10	,	,	PUNCT
ajlm-2065	102	11	et	et	PROPN
ajlm-2065	102	12	al	al	PROPN
ajlm-2065	102	13	.	.	PUNCT
ajlm-2065	103	1	detection	detection	NOUN
ajlm-2065	103	2	of	of	ADP
ajlm-2065	103	3	a	a	DET
ajlm-2065	103	4	sars	sar	NOUN
ajlm-2065	103	5	-	-	PUNCT
ajlm-2065	103	6	cov-2	cov-2	NOUN
ajlm-2065	103	7	variant	variant	NOUN
ajlm-2065	103	8	of	of	ADP
ajlm-2065	103	9	concern	concern	NOUN
ajlm-2065	103	10	in	in	ADP
ajlm-2065	103	11	south	south	PROPN
ajlm-2065	103	12	africa	africa	PROPN
ajlm-2065	103	13	.	.	PUNCT
ajlm-2065	104	1	nature	nature	NOUN
ajlm-2065	104	2	.	.	PUNCT
ajlm-2065	105	1	2021;592(7854):438–443	2021;592(7854):438–443	X
ajlm-2065	105	2	.	.	PUNCT
ajlm-2065	105	3	https://doi.org/10.1038/s41586-021-03402-9	https://doi.org/10.1038/s41586-021-03402-9	X
ajlm-2065	105	4	subramoney	subramoney	PROPN
ajlm-2065	105	5	k	k	PROPN
ajlm-2065	105	6	,	,	PUNCT
ajlm-2065	105	7	mtileni	mtileni	NOUN
ajlm-2065	105	8	n	n	CCONJ
ajlm-2065	105	9	,	,	PUNCT
ajlm-2065	105	10	bharuthram	bharuthram	PROPN
ajlm-2065	105	11	a	a	X
ajlm-2065	105	12	,	,	PUNCT
ajlm-2065	105	13	et	et	PROPN
ajlm-2065	105	14	al	al	PROPN
ajlm-2065	105	15	.	.	PUNCT
ajlm-2065	105	16	identification	identification	NOUN
ajlm-2065	105	17	of	of	ADP
ajlm-2065	105	18	sars	sar	NOUN
ajlm-2065	105	19	-	-	PUNCT
ajlm-2065	105	20	cov-2	cov-2	NOUN
ajlm-2065	105	21	omicron	omicron	PROPN
ajlm-2065	105	22	variant	variant	NOUN
ajlm-2065	105	23	using	use	VERB
ajlm-2065	105	24	spike	spike	ADJ
ajlm-2065	105	25	gene	gene	NOUN
ajlm-2065	105	26	target	target	NOUN
ajlm-2065	105	27	failure	failure	NOUN
ajlm-2065	105	28	and	and	CCONJ
ajlm-2065	105	29	genotyping	genotype	VERB
ajlm-2065	105	30	assays	assay	NOUN
ajlm-2065	105	31	,	,	PUNCT
ajlm-2065	105	32	gauteng	gauteng	PROPN
ajlm-2065	105	33	,	,	PUNCT
ajlm-2065	105	34	south	south	PROPN
ajlm-2065	105	35	africa	africa	PROPN
ajlm-2065	105	36	,	,	PUNCT
ajlm-2065	105	37	2021	2021	NUM
ajlm-2065	105	38	.	.	PUNCT
ajlm-2065	106	1	j	j	PROPN
ajlm-2065	106	2	med	med	PROPN
ajlm-2065	106	3	virol	virol	NOUN
ajlm-2065	106	4	.	.	PUNCT
ajlm-2065	107	1	2022;94(8):3676–3684	2022;94(8):3676–3684	NUM
ajlm-2065	107	2	.	.	PUNCT
ajlm-2065	108	1	https://doi.org/10.1002/jmv.27797	https://doi.org/10.1002/jmv.27797	PRON
ajlm-2065	108	2	burgess	burgess	PROPN
ajlm-2065	108	3	s	s	PROPN
ajlm-2065	108	4	,	,	PUNCT
ajlm-2065	108	5	ponsford	ponsford	PROPN
ajlm-2065	108	6	mj	mj	PROPN
ajlm-2065	108	7	,	,	PUNCT
ajlm-2065	108	8	gill	gill	PROPN
ajlm-2065	108	9	d.	d.	PROPN
ajlm-2065	108	10	are	be	AUX
ajlm-2065	108	11	we	we	PRON
ajlm-2065	108	12	underestimating	underestimate	VERB
ajlm-2065	108	13	seroprevalence	seroprevalence	NOUN
ajlm-2065	108	14	of	of	ADP
ajlm-2065	108	15	sars	sar	NOUN
ajlm-2065	108	16	-	-	PUNCT
ajlm-2065	108	17	cov-2	cov-2	NOUN
ajlm-2065	108	18	?	?	PUNCT
ajlm-2065	109	1	london	london	PROPN
ajlm-2065	109	2	:	:	PUNCT
ajlm-2065	109	3	british	british	PROPN
ajlm-2065	109	4	medical	medical	PROPN
ajlm-2065	109	5	journal	journal	PROPN
ajlm-2065	109	6	publishing	publishing	NOUN
ajlm-2065	109	7	group	group	NOUN
ajlm-2065	109	8	;	;	PUNCT
ajlm-2065	109	9	2020	2020	NUM
ajlm-2065	109	10	.	.	PUNCT
ajlm-2065	110	1	alter	alter	VERB
ajlm-2065	110	2	g	g	NOUN
ajlm-2065	110	3	,	,	PUNCT
ajlm-2065	110	4	seder	seder	PROPN
ajlm-2065	110	5	r.	r.	PROPN
ajlm-2065	110	6	the	the	DET
ajlm-2065	110	7	power	power	NOUN
ajlm-2065	110	8	of	of	ADP
ajlm-2065	110	9	antibody	antibody	NOUN
ajlm-2065	110	10	-	-	PUNCT
ajlm-2065	110	11	based	base	VERB
ajlm-2065	110	12	surveillance	surveillance	NOUN
ajlm-2065	110	13	.	.	PUNCT
ajlm-2065	111	1	n	n	PROPN
ajlm-2065	111	2	engl	engl	PROPN
ajlm-2065	111	3	j	j	PROPN
ajlm-2065	111	4	med	med	PROPN
ajlm-2065	111	5	.	.	PUNCT
ajlm-2065	112	1	2020;383(18):1782–1784	2020;383(18):1782–1784	NUM
ajlm-2065	112	2	.	.	PUNCT
ajlm-2065	112	3	mayne	mayne	PROPN
ajlm-2065	112	4	e	e	PROPN
ajlm-2065	112	5	,	,	PUNCT
ajlm-2065	112	6	scott	scott	PROPN
ajlm-2065	112	7	l	l	PROPN
ajlm-2065	112	8	,	,	PUNCT
ajlm-2065	112	9	semete	semete	ADJ
ajlm-2065	112	10	b	b	NOUN
ajlm-2065	112	11	,	,	PUNCT
ajlm-2065	112	12	et	et	PROPN
ajlm-2065	112	13	al	al	PROPN
ajlm-2065	112	14	.	.	PUNCT
ajlm-2065	113	1	the	the	DET
ajlm-2065	113	2	role	role	NOUN
ajlm-2065	113	3	of	of	ADP
ajlm-2065	113	4	serological	serological	ADJ
ajlm-2065	113	5	testing	testing	NOUN
ajlm-2065	113	6	in	in	ADP
ajlm-2065	113	7	the	the	DET
ajlm-2065	113	8	sars	sar	NOUN
ajlm-2065	113	9	-	-	PUNCT
ajlm-2065	113	10	cov-2	cov-2	PART
ajlm-2065	113	11	outbreak	outbreak	NOUN
ajlm-2065	113	12	.	.	PUNCT
ajlm-2065	114	1	s	s	PROPN
ajlm-2065	114	2	afr	afr	PROPN
ajlm-2065	114	3	med	med	PROPN
ajlm-2065	114	4	j.	j.	PROPN
ajlm-2065	114	5	2020;110(9):842–845	2020;110(9):842–845	PROPN
ajlm-2065	114	6	.	.	PUNCT
ajlm-2065	115	1	https://doi.org/10.7196/samj.2020.v110i9.15098	https://doi.org/10.7196/samj.2020.v110i9.15098	PROPN
ajlm-2065	115	2	byambasuren	byambasuren	PROPN
ajlm-2065	115	3	o	o	PROPN
ajlm-2065	115	4	,	,	PUNCT
ajlm-2065	115	5	dobler	dobler	NOUN
ajlm-2065	115	6	cc	cc	PROPN
ajlm-2065	115	7	,	,	PUNCT
ajlm-2065	115	8	bell	bell	PROPN
ajlm-2065	115	9	k	k	PROPN
ajlm-2065	115	10	,	,	PUNCT
ajlm-2065	115	11	et	et	PROPN
ajlm-2065	115	12	al	al	PROPN
ajlm-2065	115	13	.	.	PROPN
ajlm-2065	115	14	comparison	comparison	NOUN
ajlm-2065	115	15	of	of	ADP
ajlm-2065	115	16	seroprevalence	seroprevalence	NOUN
ajlm-2065	115	17	of	of	ADP
ajlm-2065	115	18	sars	sar	NOUN
ajlm-2065	115	19	-	-	PUNCT
ajlm-2065	115	20	cov-2	cov-2	NOUN
ajlm-2065	115	21	infections	infection	NOUN
ajlm-2065	115	22	with	with	ADP
ajlm-2065	115	23	cumulative	cumulative	ADJ
ajlm-2065	115	24	and	and	CCONJ
ajlm-2065	115	25	imputed	impute	VERB
ajlm-2065	115	26	covid-19	covid-19	PROPN
ajlm-2065	115	27	cases	case	NOUN
ajlm-2065	115	28	:	:	PUNCT
ajlm-2065	115	29	systematic	systematic	ADJ
ajlm-2065	115	30	review	review	NOUN
ajlm-2065	115	31	.	.	PUNCT
ajlm-2065	116	1	plos	plos	PROPN
ajlm-2065	116	2	one	one	NUM
ajlm-2065	116	3	.	.	PUNCT
ajlm-2065	117	1	2021;16(4):e0248946	2021;16(4):e0248946	X
ajlm-2065	117	2	.	.	X
ajlm-2065	118	1	rostami	rostami	PROPN
ajlm-2065	118	2	a	a	PRON
ajlm-2065	118	3	,	,	PUNCT
ajlm-2065	118	4	sepidarkish	sepidarkish	PROPN
ajlm-2065	118	5	m	m	PROPN
ajlm-2065	118	6	,	,	PUNCT
ajlm-2065	118	7	leeflang	leeflang	PROPN
ajlm-2065	118	8	mmmg	mmmg	PROPN
ajlm-2065	118	9	,	,	PUNCT
ajlm-2065	118	10	et	et	PROPN
ajlm-2065	118	11	al	al	PROPN
ajlm-2065	118	12	.	.	PUNCT
ajlm-2065	119	1	sars	sars	PROPN
ajlm-2065	119	2	-	-	PUNCT
ajlm-2065	119	3	cov-2	cov-2	PART
ajlm-2065	119	4	seroprevalence	seroprevalence	NOUN
ajlm-2065	119	5	worldwide	worldwide	ADV
ajlm-2065	119	6	:	:	PUNCT
ajlm-2065	119	7	a	a	DET
ajlm-2065	119	8	systematic	systematic	ADJ
ajlm-2065	119	9	review	review	NOUN
ajlm-2065	119	10	and	and	CCONJ
ajlm-2065	119	11	meta	meta	ADJ
ajlm-2065	119	12	-	-	PUNCT
ajlm-2065	119	13	analysis	analysis	NOUN
ajlm-2065	119	14	.	.	PUNCT
ajlm-2065	120	1	clin	clin	PROPN
ajlm-2065	120	2	microbiol	microbiol	PROPN
ajlm-2065	120	3	infect	infect	PROPN
ajlm-2065	120	4	.	.	PUNCT
ajlm-2065	121	1	2021;27(3):331–340	2021;27(3):331–340	NUM
ajlm-2065	121	2	.	.	PUNCT
ajlm-2065	122	1	https://doi.org/10.1016/j.cmi.2020.10.020	https://doi.org/10.1016/j.cmi.2020.10.020	NOUN
ajlm-2065	122	2	mutevedzi	mutevedzi	VERB
ajlm-2065	122	3	pc	pc	NOUN
ajlm-2065	122	4	,	,	PUNCT
ajlm-2065	122	5	kawonga	kawonga	PROPN
ajlm-2065	122	6	m	m	PROPN
ajlm-2065	122	7	,	,	PUNCT
ajlm-2065	122	8	kwatra	kwatra	PROPN
ajlm-2065	122	9	g	g	PROPN
ajlm-2065	122	10	,	,	PUNCT
ajlm-2065	122	11	et	et	PROPN
ajlm-2065	122	12	al	al	PROPN
ajlm-2065	122	13	.	.	PUNCT
ajlm-2065	123	1	estimated	estimate	VERB
ajlm-2065	123	2	sars	sar	NOUN
ajlm-2065	123	3	-	-	PUNCT
ajlm-2065	123	4	cov-2	cov-2	NOUN
ajlm-2065	123	5	infection	infection	NOUN
ajlm-2065	123	6	rate	rate	NOUN
ajlm-2065	123	7	and	and	CCONJ
ajlm-2065	123	8	fatality	fatality	NOUN
ajlm-2065	123	9	risk	risk	NOUN
ajlm-2065	123	10	in	in	ADP
ajlm-2065	123	11	gauteng	gauteng	PROPN
ajlm-2065	123	12	province	province	PROPN
ajlm-2065	123	13	,	,	PUNCT
ajlm-2065	123	14	south	south	PROPN
ajlm-2065	123	15	africa	africa	PROPN
ajlm-2065	123	16	:	:	PUNCT
ajlm-2065	123	17	a	a	DET
ajlm-2065	123	18	population	population	NOUN
ajlm-2065	123	19	-	-	PUNCT
ajlm-2065	123	20	based	base	VERB
ajlm-2065	123	21	seroepidemiological	seroepidemiological	ADJ
ajlm-2065	123	22	survey	survey	NOUN
ajlm-2065	123	23	.	.	PUNCT
ajlm-2065	124	1	int	int	NOUN
ajlm-2065	124	2	j	j	PROPN
ajlm-2065	124	3	epidemiol	epidemiol	PROPN
ajlm-2065	124	4	.	.	PUNCT
ajlm-2065	125	1	2021;51(2):404–417	2021;51(2):404–417	PUNCT
ajlm-2065	125	2	.	.	PUNCT
ajlm-2065	126	1	https://doi.org/10.1093/ije/dyab217	https://doi.org/10.1093/ije/dyab217	PROPN
ajlm-2065	126	2	sykes	syke	VERB
ajlm-2065	126	3	w	w	PROPN
ajlm-2065	126	4	,	,	PUNCT
ajlm-2065	126	5	mhlanga	mhlanga	PROPN
ajlm-2065	126	6	l	l	NOUN
ajlm-2065	126	7	,	,	PUNCT
ajlm-2065	126	8	swanevelder	swanevelder	ADJ
ajlm-2065	126	9	r	r	NOUN
ajlm-2065	126	10	,	,	PUNCT
ajlm-2065	126	11	et	et	PROPN
ajlm-2065	126	12	al	al	PROPN
ajlm-2065	126	13	.	.	PUNCT
ajlm-2065	127	1	prevalence	prevalence	NOUN
ajlm-2065	127	2	of	of	ADP
ajlm-2065	127	3	anti	anti	ADJ
ajlm-2065	127	4	-	-	ADJ
ajlm-2065	127	5	sars	sar	NOUN
ajlm-2065	127	6	-	-	PUNCT
ajlm-2065	127	7	cov-2	cov-2	NOUN
ajlm-2065	127	8	antibodies	antibody	NOUN
ajlm-2065	127	9	among	among	ADP
ajlm-2065	127	10	blood	blood	NOUN
ajlm-2065	127	11	donors	donor	NOUN
ajlm-2065	127	12	in	in	ADP
ajlm-2065	127	13	northern	northern	ADJ
ajlm-2065	127	14	cape	cape	NOUN
ajlm-2065	127	15	,	,	PUNCT
ajlm-2065	127	16	kwazulu	kwazulu	NOUN
ajlm-2065	127	17	-	-	PUNCT
ajlm-2065	127	18	natal	natal	ADJ
ajlm-2065	127	19	,	,	PUNCT
ajlm-2065	127	20	eastern	eastern	ADJ
ajlm-2065	127	21	cape	cape	NOUN
ajlm-2065	127	22	,	,	PUNCT
ajlm-2065	127	23	and	and	CCONJ
ajlm-2065	127	24	free	free	ADJ
ajlm-2065	127	25	state	state	NOUN
ajlm-2065	127	26	provinces	province	NOUN
ajlm-2065	127	27	of	of	ADP
ajlm-2065	127	28	south	south	PROPN
ajlm-2065	127	29	africa	africa	PROPN
ajlm-2065	127	30	in	in	ADP
ajlm-2065	127	31	january	january	PROPN
ajlm-2065	127	32	2021	2021	NUM
ajlm-2065	127	33	.	.	PUNCT
ajlm-2065	128	1	research	research	NOUN
ajlm-2065	128	2	square	square	PROPN
ajlm-2065	128	3	.	.	PUNCT
ajlm-2065	129	1	2021	2021	NUM
ajlm-2065	129	2	;	;	PUNCT
ajlm-2065	130	1	preprint	preprint	NOUN
ajlm-2065	130	2	.	.	PUNCT
ajlm-2065	131	1	https://doi.org/10.21203/rs.3.rs-233375/v1	https://doi.org/10.21203/rs.3.rs-233375/v1	PUNCT
ajlm-2065	132	1	hsiao	hsiao	PROPN
ajlm-2065	132	2	m	m	PROPN
ajlm-2065	132	3	,	,	PUNCT
ajlm-2065	132	4	davies	davies	PROPN
ajlm-2065	132	5	m	m	PROPN
ajlm-2065	132	6	,	,	PUNCT
ajlm-2065	132	7	kalk	kalk	PROPN
ajlm-2065	132	8	e.	e.	PROPN
ajlm-2065	132	9	sars	sars	PROPN
ajlm-2065	132	10	-	-	PUNCT
ajlm-2065	132	11	cov-2	cov-2	PART
ajlm-2065	132	12	seroprevalence	seroprevalence	NOUN
ajlm-2065	132	13	in	in	ADP
ajlm-2065	132	14	the	the	DET
ajlm-2065	132	15	cape	cape	NOUN
ajlm-2065	132	16	town	town	NOUN
ajlm-2065	132	17	metropolitan	metropolitan	PROPN
ajlm-2065	132	18	sub	sub	NOUN
ajlm-2065	132	19	-	-	NOUN
ajlm-2065	132	20	districts	district	NOUN
ajlm-2065	132	21	after	after	ADP
ajlm-2065	132	22	the	the	DET
ajlm-2065	132	23	peak	peak	NOUN
ajlm-2065	132	24	of	of	ADP
ajlm-2065	132	25	infections	infection	NOUN
ajlm-2065	132	26	.	.	PUNCT
ajlm-2065	133	1	nicd	nicd	PROPN
ajlm-2065	133	2	covid-19	covid-19	PROPN
ajlm-2065	133	3	special	special	ADJ
ajlm-2065	133	4	public	public	ADJ
ajlm-2065	133	5	health	health	NOUN
ajlm-2065	133	6	surveill	surveill	NOUN
ajlm-2065	133	7	bull	bull	NOUN
ajlm-2065	133	8	.	.	PUNCT
ajlm-2065	134	1	2020;18:1–9	2020;18:1–9	NUM
ajlm-2065	134	2	.	.	PUNCT
ajlm-2065	135	1	pollán	pollán	PROPN
ajlm-2065	135	2	m	m	PROPN
ajlm-2065	135	3	,	,	PUNCT
ajlm-2065	135	4	pérez	pérez	NOUN
ajlm-2065	135	5	-	-	PUNCT
ajlm-2065	135	6	gómez	gómez	NOUN
ajlm-2065	135	7	b	b	PROPN
ajlm-2065	135	8	,	,	PUNCT
ajlm-2065	135	9	pastor	pastor	NOUN
ajlm-2065	135	10	-	-	PUNCT
ajlm-2065	135	11	barriuso	barriuso	NOUN
ajlm-2065	135	12	r	r	NOUN
ajlm-2065	135	13	,	,	PUNCT
ajlm-2065	135	14	et	et	PROPN
ajlm-2065	135	15	al	al	PROPN
ajlm-2065	135	16	.	.	PUNCT
ajlm-2065	136	1	prevalence	prevalence	NOUN
ajlm-2065	136	2	of	of	ADP
ajlm-2065	136	3	sars	sar	NOUN
ajlm-2065	136	4	-	-	PUNCT
ajlm-2065	136	5	cov-2	cov-2	NOUN
ajlm-2065	136	6	in	in	ADP
ajlm-2065	136	7	spain	spain	PROPN
ajlm-2065	136	8	(	(	PUNCT
ajlm-2065	136	9	ene	ene	PROPN
ajlm-2065	136	10	-	-	PUNCT
ajlm-2065	136	11	covid	covid	PROPN
ajlm-2065	136	12	):	):	PUNCT
ajlm-2065	136	13	a	a	DET
ajlm-2065	136	14	nationwide	nationwide	ADJ
ajlm-2065	136	15	,	,	PUNCT
ajlm-2065	136	16	population	population	NOUN
ajlm-2065	136	17	-	-	PUNCT
ajlm-2065	136	18	based	base	VERB
ajlm-2065	136	19	seroepidemiological	seroepidemiological	ADJ
ajlm-2065	136	20	study	study	NOUN
ajlm-2065	136	21	.	.	PUNCT
ajlm-2065	137	1	lancet	lancet	PROPN
ajlm-2065	137	2	.	.	PUNCT
ajlm-2065	138	1	2020;396(10250):535–544	2020;396(10250):535–544	NUM
ajlm-2065	138	2	.	.	PUNCT
ajlm-2065	139	1	https://doi.org/10.1016/s0140-6736(20)31483-5	https://doi.org/10.1016/s0140-6736(20)31483-5	PROPN
ajlm-2065	139	2	alfego	alfego	PROPN
ajlm-2065	139	3	d	d	PROPN
ajlm-2065	139	4	,	,	PUNCT
ajlm-2065	139	5	sullivan	sullivan	PROPN
ajlm-2065	139	6	a	a	PROPN
ajlm-2065	139	7	,	,	PUNCT
ajlm-2065	139	8	poirier	poirier	PROPN
ajlm-2065	139	9	b	b	PROPN
ajlm-2065	139	10	,	,	PUNCT
ajlm-2065	139	11	williams	williams	PROPN
ajlm-2065	139	12	j	j	PROPN
ajlm-2065	139	13	,	,	PUNCT
ajlm-2065	139	14	adcock	adcock	PROPN
ajlm-2065	139	15	d	d	PROPN
ajlm-2065	139	16	,	,	PUNCT
ajlm-2065	139	17	letovsky	letovsky	PROPN
ajlm-2065	139	18	s.	s.	PROPN
ajlm-2065	140	1	a	a	DET
ajlm-2065	140	2	population	population	NOUN
ajlm-2065	140	3	-	-	PUNCT
ajlm-2065	140	4	based	base	VERB
ajlm-2065	140	5	analysis	analysis	NOUN
ajlm-2065	140	6	of	of	ADP
ajlm-2065	140	7	the	the	DET
ajlm-2065	140	8	longevity	longevity	NOUN
ajlm-2065	140	9	of	of	ADP
ajlm-2065	140	10	sars	sar	NOUN
ajlm-2065	140	11	-	-	PUNCT
ajlm-2065	140	12	cov-2	cov-2	NOUN
ajlm-2065	140	13	antibody	antibody	NOUN
ajlm-2065	140	14	seropositivity	seropositivity	NOUN
ajlm-2065	140	15	in	in	ADP
ajlm-2065	140	16	the	the	DET
ajlm-2065	140	17	united	united	PROPN
ajlm-2065	140	18	states	states	PROPN
ajlm-2065	140	19	.	.	PUNCT
ajlm-2065	141	1	eclinicalmedicine	eclinicalmedicine	PROPN
ajlm-2065	141	2	.	.	PUNCT
ajlm-2065	142	1	2021;36:100902	2021;36:100902	X
ajlm-2065	142	2	.	.	PUNCT
ajlm-2065	143	1	https://doi.org/10.1016/j.eclinm.2021.100902	https://doi.org/10.1016/j.eclinm.2021.100902	PROPN
ajlm-2065	143	2	pagani	pagani	PROPN
ajlm-2065	143	3	g	g	PROPN
ajlm-2065	143	4	,	,	PUNCT
ajlm-2065	143	5	conti	conti	PROPN
ajlm-2065	143	6	f	f	PROPN
ajlm-2065	143	7	,	,	PUNCT
ajlm-2065	143	8	giacomelli	giacomelli	PROPN
ajlm-2065	143	9	a	a	X
ajlm-2065	143	10	,	,	PUNCT
ajlm-2065	143	11	et	et	PROPN
ajlm-2065	143	12	al	al	PROPN
ajlm-2065	143	13	.	.	PROPN
ajlm-2065	143	14	seroprevalence	seroprevalence	NOUN
ajlm-2065	143	15	of	of	ADP
ajlm-2065	143	16	sars	sar	NOUN
ajlm-2065	143	17	-	-	PUNCT
ajlm-2065	143	18	cov-2	cov-2	NOUN
ajlm-2065	143	19	significantly	significantly	ADV
ajlm-2065	143	20	varies	vary	VERB
ajlm-2065	143	21	with	with	ADP
ajlm-2065	143	22	age	age	NOUN
ajlm-2065	143	23	:	:	PUNCT
ajlm-2065	143	24	preliminary	preliminary	ADJ
ajlm-2065	143	25	results	result	NOUN
ajlm-2065	143	26	from	from	ADP
ajlm-2065	143	27	a	a	DET
ajlm-2065	143	28	mass	mass	ADJ
ajlm-2065	143	29	population	population	NOUN
ajlm-2065	143	30	screening	screening	NOUN
ajlm-2065	143	31	.	.	PUNCT
ajlm-2065	144	1	j	j	PROPN
ajlm-2065	144	2	infect	infect	VERB
ajlm-2065	144	3	.	.	PUNCT
ajlm-2065	145	1	2020;81(6):e10	2020;81(6):e10	NUM
ajlm-2065	145	2	.	.	PUNCT
ajlm-2065	145	3	https://doi.org/10.1016/j.jinf.2020.09.021	https://doi.org/10.1016/j.jinf.2020.09.021	NUM
ajlm-2065	145	4	chen	chen	PROPN
ajlm-2065	145	5	x	x	PROPN
ajlm-2065	145	6	,	,	PUNCT
ajlm-2065	145	7	chen	chen	PROPN
ajlm-2065	145	8	z	z	PROPN
ajlm-2065	145	9	,	,	PUNCT
ajlm-2065	145	10	azman	azman	PROPN
ajlm-2065	145	11	as	as	ADP
ajlm-2065	145	12	,	,	PUNCT
ajlm-2065	145	13	et	et	PROPN
ajlm-2065	145	14	al	al	PROPN
ajlm-2065	145	15	.	.	PROPN
ajlm-2065	145	16	serological	serological	ADJ
ajlm-2065	145	17	evidence	evidence	NOUN
ajlm-2065	145	18	of	of	ADP
ajlm-2065	145	19	human	human	ADJ
ajlm-2065	145	20	infection	infection	NOUN
ajlm-2065	145	21	with	with	ADP
ajlm-2065	145	22	sars	sar	NOUN
ajlm-2065	145	23	-	-	PUNCT
ajlm-2065	145	24	cov-2	cov-2	NUM
ajlm-2065	145	25	:	:	PUNCT
ajlm-2065	145	26	a	a	DET
ajlm-2065	145	27	systematic	systematic	ADJ
ajlm-2065	145	28	review	review	NOUN
ajlm-2065	145	29	and	and	CCONJ
ajlm-2065	145	30	meta	meta	ADJ
ajlm-2065	145	31	-	-	PUNCT
ajlm-2065	145	32	analysis	analysis	NOUN
ajlm-2065	145	33	.	.	PUNCT
ajlm-2065	146	1	lancet	lancet	NOUN
ajlm-2065	146	2	glob	glob	PROPN
ajlm-2065	146	3	.	.	PUNCT
ajlm-2065	147	1	health	health	NOUN
ajlm-2065	147	2	.	.	PUNCT
ajlm-2065	148	1	2021;9(5):e598	2021;9(5):e598	NOUN
ajlm-2065	148	2	–	–	PUNCT
ajlm-2065	148	3	e609	e609	PROPN
ajlm-2065	148	4	.	.	PUNCT
ajlm-2065	149	1	cheng	cheng	PROPN
ajlm-2065	149	2	mp	mp	PROPN
ajlm-2065	149	3	,	,	PUNCT
ajlm-2065	149	4	yansouni	yansouni	PROPN
ajlm-2065	149	5	cp	cp	PROPN
ajlm-2065	149	6	,	,	PUNCT
ajlm-2065	149	7	basta	basta	PROPN
ajlm-2065	149	8	ne	ne	PROPN
ajlm-2065	149	9	,	,	PUNCT
ajlm-2065	149	10	et	et	PROPN
ajlm-2065	149	11	al	al	PROPN
ajlm-2065	149	12	.	.	PROPN
ajlm-2065	149	13	serodiagnostics	serodiagnostic	NOUN
ajlm-2065	149	14	for	for	ADP
ajlm-2065	149	15	severe	severe	ADJ
ajlm-2065	149	16	acute	acute	ADJ
ajlm-2065	149	17	respiratory	respiratory	ADJ
ajlm-2065	149	18	syndrome	syndrome	NOUN
ajlm-2065	149	19	–	–	PUNCT
ajlm-2065	149	20	related	relate	VERB
ajlm-2065	149	21	coronavirus	coronavirus	NOUN
ajlm-2065	149	22	2	2	NUM
ajlm-2065	149	23	:	:	PUNCT
ajlm-2065	149	24	a	a	DET
ajlm-2065	149	25	narrative	narrative	NOUN
ajlm-2065	149	26	review	review	NOUN
ajlm-2065	149	27	.	.	PUNCT
ajlm-2065	150	1	ann	ann	PROPN
ajlm-2065	150	2	intern	intern	PROPN
ajlm-2065	150	3	med	me	VERB
ajlm-2065	150	4	.	.	PUNCT
ajlm-2065	151	1	2021;173(6):450–460	2021;173(6):450–460	NUM
ajlm-2065	151	2	.	.	PUNCT
ajlm-2065	152	1	george	george	PROPN
ajlm-2065	152	2	ja	ja	PROPN
ajlm-2065	152	3	,	,	PUNCT
ajlm-2065	152	4	khoza	khoza	PROPN
ajlm-2065	152	5	s	s	PROPN
ajlm-2065	152	6	,	,	PUNCT
ajlm-2065	152	7	mayne	mayne	PROPN
ajlm-2065	152	8	e	e	NOUN
ajlm-2065	152	9	,	,	PUNCT
ajlm-2065	152	10	et	et	PROPN
ajlm-2065	152	11	al	al	PROPN
ajlm-2065	152	12	.	.	PROPN
ajlm-2065	152	13	sentinel	sentinel	PROPN
ajlm-2065	152	14	seroprevalence	seroprevalence	NOUN
ajlm-2065	152	15	of	of	ADP
ajlm-2065	152	16	sars	sar	NOUN
ajlm-2065	152	17	-	-	PUNCT
ajlm-2065	152	18	cov-2	cov-2	NOUN
ajlm-2065	152	19	in	in	ADP
ajlm-2065	152	20	gauteng	gauteng	PROPN
ajlm-2065	152	21	province	province	PROPN
ajlm-2065	152	22	,	,	PUNCT
ajlm-2065	152	23	south	south	PROPN
ajlm-2065	152	24	africa	africa	PROPN
ajlm-2065	152	25	,	,	PUNCT
ajlm-2065	152	26	august	august	PROPN
ajlm-2065	152	27	–	–	PUNCT
ajlm-2065	152	28	october	october	PROPN
ajlm-2065	152	29	2020	2020	NUM
ajlm-2065	152	30	.	.	PUNCT
ajlm-2065	153	1	south	south	PROPN
ajlm-2065	153	2	afr	afr	PROPN
ajlm-2065	153	3	med	med	PROPN
ajlm-2065	153	4	j.	j.	PROPN
ajlm-2065	153	5	2021;111(11):1078–1083	2021;111(11):1078–1083	PROPN
ajlm-2065	153	6	.	.	PUNCT
ajlm-2065	154	1	simbayi	simbayi	ADJ
ajlm-2065	154	2	lczk	lczk	PROPN
ajlm-2065	154	3	,	,	PUNCT
ajlm-2065	154	4	zuma	zuma	PROPN
ajlm-2065	154	5	k	k	PROPN
ajlm-2065	154	6	,	,	PUNCT
ajlm-2065	154	7	zungu	zungu	PROPN
ajlm-2065	154	8	n	n	CCONJ
ajlm-2065	154	9	,	,	PUNCT
ajlm-2065	154	10	et	et	PROPN
ajlm-2065	154	11	al	al	PROPN
ajlm-2065	154	12	.	.	PROPN
ajlm-2065	154	13	south	south	PROPN
ajlm-2065	154	14	african	african	PROPN
ajlm-2065	154	15	national	national	PROPN
ajlm-2065	154	16	hiv	hiv	PROPN
ajlm-2065	154	17	prevalence	prevalence	NOUN
ajlm-2065	154	18	,	,	PUNCT
ajlm-2065	154	19	incidence	incidence	NOUN
ajlm-2065	154	20	,	,	PUNCT
ajlm-2065	154	21	behaviour	behaviour	NOUN
ajlm-2065	154	22	and	and	CCONJ
ajlm-2065	154	23	communication	communication	NOUN
ajlm-2065	154	24	survey	survey	NOUN
ajlm-2065	154	25	,	,	PUNCT
ajlm-2065	154	26	2017	2017	NUM
ajlm-2065	154	27	:	:	PUNCT
ajlm-2065	154	28	towards	towards	ADP
ajlm-2065	154	29	achieving	achieve	VERB
ajlm-2065	154	30	the	the	DET
ajlm-2065	154	31	unaids	unaid	NOUN
ajlm-2065	154	32	90	90	NUM
ajlm-2065	154	33	-	-	SYM
ajlm-2065	154	34	90	90	NUM
ajlm-2065	154	35	-	-	PUNCT
ajlm-2065	154	36	90	90	NUM
ajlm-2065	154	37	targets	target	NOUN
ajlm-2065	154	38	.	.	PUNCT
ajlm-2065	155	1	cape	cape	NOUN
ajlm-2065	155	2	town	town	NOUN
ajlm-2065	155	3	:	:	PUNCT
ajlm-2065	155	4	hsrc	hsrc	PROPN
ajlm-2065	155	5	press	press	NOUN
ajlm-2065	155	6	;	;	PUNCT
ajlm-2065	155	7	2019	2019	NUM
ajlm-2065	155	8	.	.	PUNCT
ajlm-2065	156	1	jassat	jassat	VERB
ajlm-2065	156	2	w	w	ADP
ajlm-2065	156	3	,	,	PUNCT
ajlm-2065	156	4	mudara	mudara	PROPN
ajlm-2065	156	5	c	c	NOUN
ajlm-2065	156	6	,	,	PUNCT
ajlm-2065	156	7	ozougwu	ozougwu	ADP
ajlm-2065	156	8	l	l	NOUN
ajlm-2065	156	9	,	,	PUNCT
ajlm-2065	156	10	et	et	PROPN
ajlm-2065	156	11	al	al	PROPN
ajlm-2065	156	12	.	.	PROPN
ajlm-2065	156	13	difference	difference	NOUN
ajlm-2065	156	14	in	in	ADP
ajlm-2065	156	15	mortality	mortality	NOUN
ajlm-2065	156	16	among	among	ADP
ajlm-2065	156	17	individuals	individual	NOUN
ajlm-2065	156	18	admitted	admit	VERB
ajlm-2065	156	19	to	to	ADP
ajlm-2065	156	20	hospital	hospital	NOUN
ajlm-2065	156	21	with	with	ADP
ajlm-2065	156	22	covid-19	covid-19	PROPN
ajlm-2065	156	23	during	during	ADP
ajlm-2065	156	24	the	the	DET
ajlm-2065	156	25	first	first	ADJ
ajlm-2065	156	26	and	and	CCONJ
ajlm-2065	156	27	second	second	ADJ
ajlm-2065	156	28	waves	wave	NOUN
ajlm-2065	156	29	in	in	ADP
ajlm-2065	156	30	south	south	PROPN
ajlm-2065	156	31	africa	africa	PROPN
ajlm-2065	156	32	:	:	PUNCT
ajlm-2065	156	33	a	a	DET
ajlm-2065	156	34	cohort	cohort	NOUN
ajlm-2065	156	35	study	study	NOUN
ajlm-2065	156	36	.	.	PUNCT
ajlm-2065	157	1	lancet	lancet	PROPN
ajlm-2065	157	2	glob	glob	PROPN
ajlm-2065	157	3	.	.	PUNCT
ajlm-2065	158	1	health	health	NOUN
ajlm-2065	158	2	.	.	PUNCT
ajlm-2065	159	1	2021;9(9):e1216	2021;9(9):e1216	NUM
ajlm-2065	159	2	–	–	PUNCT
ajlm-2065	159	3	e1225	e1225	NOUN
ajlm-2065	159	4	.	.	PUNCT
ajlm-2065	160	1	https://doi.org/10.1101/2021.03.09.21253184	https://doi.org/10.1101/2021.03.09.21253184	PROPN
ajlm-2065	160	2	dean	dean	PROPN
ajlm-2065	160	3	ag	ag	PROPN
ajlm-2065	160	4	,	,	PUNCT
ajlm-2065	160	5	sullivan	sullivan	PROPN
ajlm-2065	160	6	km	km	PROPN
ajlm-2065	160	7	,	,	PUNCT
ajlm-2065	161	1	soe	soe	PROPN
ajlm-2065	161	2	mm	mm	PROPN
ajlm-2065	161	3	.	.	PUNCT
ajlm-2065	161	4	openepi	openepi	PROPN
ajlm-2065	161	5	:	:	PUNCT
ajlm-2065	161	6	open	open	ADJ
ajlm-2065	161	7	source	source	NOUN
ajlm-2065	161	8	epidemiologic	epidemiologic	ADJ
ajlm-2065	161	9	statistics	statistic	NOUN
ajlm-2065	161	10	for	for	ADP
ajlm-2065	161	11	public	public	ADJ
ajlm-2065	161	12	health	health	NOUN
ajlm-2065	161	13	.	.	PUNCT
ajlm-2065	162	1	2013	2013	NUM
ajlm-2065	163	1	[	[	X
ajlm-2065	163	2	cited	cite	VERB
ajlm-2065	163	3	2020	2020	NUM
ajlm-2065	163	4	jul	jul	PROPN
ajlm-2065	163	5	29	29	NUM
ajlm-2065	163	6	]	]	PUNCT
ajlm-2065	163	7	.	.	PUNCT
ajlm-2065	164	1	available	available	ADJ
ajlm-2065	164	2	from	from	ADP
ajlm-2065	164	3	:	:	PUNCT
ajlm-2065	164	4	http://www.openepi.com	http://www.openepi.com	PROPN
ajlm-2065	164	5	havers	havers	PROPN
ajlm-2065	164	6	fp	fp	NOUN
ajlm-2065	164	7	,	,	PUNCT
ajlm-2065	164	8	reed	reed	NOUN
ajlm-2065	164	9	c	c	PROPN
ajlm-2065	164	10	,	,	PUNCT
ajlm-2065	164	11	lim	lim	PROPN
ajlm-2065	164	12	t	t	PROPN
ajlm-2065	164	13	,	,	PUNCT
ajlm-2065	164	14	et	et	PROPN
ajlm-2065	164	15	al	al	PROPN
ajlm-2065	164	16	.	.	PROPN
ajlm-2065	164	17	seroprevalence	seroprevalence	NOUN
ajlm-2065	164	18	of	of	ADP
ajlm-2065	164	19	antibodies	antibody	NOUN
ajlm-2065	164	20	to	to	ADP
ajlm-2065	164	21	sars	sar	NOUN
ajlm-2065	164	22	-	-	PUNCT
ajlm-2065	164	23	cov-2	cov-2	NOUN
ajlm-2065	164	24	in	in	ADP
ajlm-2065	164	25	10	10	NUM
ajlm-2065	164	26	sites	site	NOUN
ajlm-2065	164	27	in	in	ADP
ajlm-2065	164	28	the	the	DET
ajlm-2065	164	29	united	united	PROPN
ajlm-2065	164	30	states	states	PROPN
ajlm-2065	164	31	,	,	PUNCT
ajlm-2065	164	32	march	march	PROPN
ajlm-2065	164	33	23	23	NUM
ajlm-2065	164	34	-	-	PUNCT
ajlm-2065	164	35	may	may	PROPN
ajlm-2065	164	36	12	12	NUM
ajlm-2065	164	37	,	,	PUNCT
ajlm-2065	164	38	2020	2020	NUM
ajlm-2065	164	39	.	.	PUNCT
ajlm-2065	165	1	jama	jama	PROPN
ajlm-2065	165	2	intern	intern	PROPN
ajlm-2065	165	3	med	me	VERB
ajlm-2065	165	4	.	.	PUNCT
ajlm-2065	166	1	2020;180(12):1576–1586	2020;180(12):1576–1586	NUM
ajlm-2065	166	2	.	.	PUNCT
ajlm-2065	167	1	https://doi.org/10.1001/jamainternmed.2020.4130	https://doi.org/10.1001/jamainternmed.2020.4130	PROPN
ajlm-2065	167	2	jugwanth	jugwanth	PROPN
ajlm-2065	167	3	s	s	PROPN
ajlm-2065	167	4	,	,	PUNCT
ajlm-2065	167	5	gededzha	gededzha	PROPN
ajlm-2065	167	6	mp	mp	PROPN
ajlm-2065	167	7	,	,	PUNCT
ajlm-2065	167	8	mampeule	mampeule	NOUN
ajlm-2065	167	9	n	n	CCONJ
ajlm-2065	167	10	,	,	PUNCT
ajlm-2065	167	11	et	et	PROPN
ajlm-2065	167	12	al	al	PROPN
ajlm-2065	167	13	.	.	PUNCT
ajlm-2065	167	14	performance	performance	NOUN
ajlm-2065	167	15	of	of	ADP
ajlm-2065	167	16	the	the	DET
ajlm-2065	167	17	abbott	abbott	PROPN
ajlm-2065	167	18	sars	sars	PROPN
ajlm-2065	167	19	-	-	PUNCT
ajlm-2065	167	20	cov-2	cov-2	NOUN
ajlm-2065	167	21	igg	igg	PROPN
ajlm-2065	167	22	serological	serological	ADJ
ajlm-2065	167	23	assay	assay	NOUN
ajlm-2065	167	24	in	in	ADP
ajlm-2065	167	25	south	south	ADJ
ajlm-2065	167	26	african	african	ADJ
ajlm-2065	167	27	2	2	NUM
ajlm-2065	167	28	patients	patient	NOUN
ajlm-2065	167	29	.	.	PUNCT
ajlm-2065	168	1	plos	plos	PROPN
ajlm-2065	168	2	one	one	NUM
ajlm-2065	168	3	.	.	PUNCT
ajlm-2065	169	1	2022;17(2):e0262442	2022;17(2):e0262442	X
ajlm-2065	169	2	.	.	PUNCT
ajlm-2065	170	1	https://doi.org/10.1371/journal.pone.0262442	https://doi.org/10.1371/journal.pone.0262442	PROPN
ajlm-2065	170	2	sars	sars	PROPN
ajlm-2065	170	3	-	-	PUNCT
ajlm-2065	170	4	cov	cov	PROPN
ajlm-2065	170	5	abbott	abbott	PROPN
ajlm-2065	170	6	architect	architect	PROPN
ajlm-2065	170	7	.	.	PUNCT
ajlm-2065	171	1	igg	igg	PROPN
ajlm-2065	171	2	instructions	instruction	NOUN
ajlm-2065	171	3	for	for	ADP
ajlm-2065	171	4	use	use	NOUN
ajlm-2065	171	5	.	.	PUNCT
ajlm-2065	172	1	h07943r01	h07943r01	NOUN
ajlm-2065	172	2	.	.	PUNCT
ajlm-2065	173	1	available	available	ADJ
ajlm-2065	173	2	from	from	ADP
ajlm-2065	173	3	:	:	PUNCT
ajlm-2065	173	4	https://www.corelaboratory.abbott/int/en/home	https://www.corelaboratory.abbott/int/en/home	PROPN
ajlm-2065	173	5	kleynhans	kleynhans	PROPN
ajlm-2065	173	6	j	j	PROPN
ajlm-2065	173	7	,	,	PUNCT
ajlm-2065	173	8	tempia	tempia	PROPN
ajlm-2065	173	9	s	s	PROPN
ajlm-2065	173	10	,	,	PUNCT
ajlm-2065	173	11	wolter	wolter	PROPN
ajlm-2065	173	12	n	n	CCONJ
ajlm-2065	173	13	,	,	PUNCT
ajlm-2065	173	14	et	et	PROPN
ajlm-2065	173	15	al	al	PROPN
ajlm-2065	173	16	.	.	PUNCT
ajlm-2065	174	1	sars	sars	PROPN
ajlm-2065	174	2	-	-	PUNCT
ajlm-2065	174	3	cov-2	cov-2	PART
ajlm-2065	174	4	seroprevalence	seroprevalence	NOUN
ajlm-2065	174	5	in	in	ADP
ajlm-2065	174	6	a	a	DET
ajlm-2065	174	7	rural	rural	ADJ
ajlm-2065	174	8	and	and	CCONJ
ajlm-2065	174	9	urban	urban	ADJ
ajlm-2065	174	10	household	household	NOUN
ajlm-2065	174	11	cohort	cohort	NOUN
ajlm-2065	174	12	during	during	ADP
ajlm-2065	174	13	first	first	ADJ
ajlm-2065	174	14	and	and	CCONJ
ajlm-2065	174	15	second	second	ADJ
ajlm-2065	174	16	waves	wave	NOUN
ajlm-2065	174	17	of	of	ADP
ajlm-2065	174	18	infections	infection	NOUN
ajlm-2065	174	19	,	,	PUNCT
ajlm-2065	174	20	south	south	PROPN
ajlm-2065	174	21	africa	africa	PROPN
ajlm-2065	174	22	,	,	PUNCT
ajlm-2065	174	23	july	july	PROPN
ajlm-2065	174	24	2020	2020	NUM
ajlm-2065	174	25	–	–	PUNCT
ajlm-2065	174	26	march	march	NOUN
ajlm-2065	174	27	2021	2021	NUM
ajlm-2065	174	28	.	.	PUNCT
ajlm-2065	175	1	emerg	emerg	PROPN
ajlm-2065	175	2	infect	infect	PROPN
ajlm-2065	175	3	dis	dis	PROPN
ajlm-2065	175	4	.	.	PUNCT
ajlm-2065	176	1	2021;27(12):3020–3029	2021;27(12):3020–3029	NUM
ajlm-2065	176	2	.	.	PUNCT
ajlm-2065	177	1	https://doi.org/10.3201/eid2712.211465	https://doi.org/10.3201/eid2712.211465	NUM
ajlm-2065	177	2	moir	moir	PROPN
ajlm-2065	177	3	s	s	PROPN
ajlm-2065	177	4	,	,	PUNCT
ajlm-2065	177	5	fauci	fauci	X
ajlm-2065	177	6	as	as	ADP
ajlm-2065	177	7	.	.	PUNCT
ajlm-2065	178	1	b	b	X
ajlm-2065	178	2	-	-	PUNCT
ajlm-2065	178	3	cell	cell	NOUN
ajlm-2065	178	4	responses	response	NOUN
ajlm-2065	178	5	to	to	ADP
ajlm-2065	178	6	hiv	hiv	PROPN
ajlm-2065	178	7	infection	infection	NOUN
ajlm-2065	178	8	.	.	PUNCT
ajlm-2065	179	1	immunol	immunol	PROPN
ajlm-2065	179	2	rev	rev	PROPN
ajlm-2065	179	3	.	.	PROPN
ajlm-2065	179	4	2017;275(1):33–48	2017;275(1):33–48	NUM
ajlm-2065	179	5	.	.	PUNCT
ajlm-2065	180	1	https://doi.org/10.1111/imr.12502	https://doi.org/10.1111/imr.12502	VERB
ajlm-2065	180	2	pallikkuth	pallikkuth	PROPN
ajlm-2065	180	3	s	s	PROPN
ajlm-2065	180	4	,	,	PUNCT
ajlm-2065	180	5	sharkey	sharkey	PROPN
ajlm-2065	180	6	m	m	PROPN
ajlm-2065	180	7	,	,	PUNCT
ajlm-2065	180	8	beauchamps	beauchamps	PROPN
ajlm-2065	180	9	l	l	PROPN
ajlm-2065	180	10	,	,	PUNCT
ajlm-2065	180	11	et	et	PROPN
ajlm-2065	180	12	al	al	PROPN
ajlm-2065	180	13	.	.	PROPN
ajlm-2065	180	14	persistence	persistence	NOUN
ajlm-2065	180	15	of	of	ADP
ajlm-2065	180	16	sars	sar	NOUN
ajlm-2065	180	17	-	-	PUNCT
ajlm-2065	180	18	cov-2	cov-2	NOUN
ajlm-2065	180	19	-	-	PUNCT
ajlm-2065	180	20	specific	specific	ADJ
ajlm-2065	180	21	ab	ab	NOUN
ajlm-2065	180	22	response	response	NOUN
ajlm-2065	180	23	in	in	ADP
ajlm-2065	180	24	hiv+	hiv+	ADJ
ajlm-2065	180	25	individuals	individual	NOUN
ajlm-2065	180	26	on	on	ADP
ajlm-2065	180	27	art	art	NOUN
ajlm-2065	180	28	.	.	PUNCT
ajlm-2065	181	1	top	top	ADJ
ajlm-2065	181	2	antivir	antivir	PROPN
ajlm-2065	181	3	med	med	PROPN
ajlm-2065	181	4	.	.	PUNCT
ajlm-2065	182	1	2021:88–88	2021:88–88	NUM
ajlm-2065	182	2	.	.	PUNCT
ajlm-2065	183	1	ambrosioni	ambrosioni	PROPN
ajlm-2065	183	2	j	j	PROPN
ajlm-2065	183	3	,	,	PUNCT
ajlm-2065	183	4	blanco	blanco	PROPN
ajlm-2065	183	5	jl	jl	PROPN
ajlm-2065	183	6	,	,	PUNCT
ajlm-2065	183	7	reyes	reyes	PROPN
ajlm-2065	183	8	-	-	PUNCT
ajlm-2065	183	9	urueña	urueña	PROPN
ajlm-2065	183	10	jm	jm	PROPN
ajlm-2065	183	11	,	,	PUNCT
ajlm-2065	183	12	et	et	PROPN
ajlm-2065	183	13	al	al	PROPN
ajlm-2065	183	14	.	.	PROPN
ajlm-2065	183	15	overview	overview	NOUN
ajlm-2065	183	16	of	of	ADP
ajlm-2065	183	17	sars	sar	NOUN
ajlm-2065	183	18	-	-	PUNCT
ajlm-2065	183	19	cov-2	cov-2	PART
ajlm-2065	183	20	infection	infection	NOUN
ajlm-2065	183	21	in	in	ADP
ajlm-2065	183	22	adults	adult	NOUN
ajlm-2065	183	23	living	live	VERB
ajlm-2065	183	24	with	with	ADP
ajlm-2065	183	25	hiv	hiv	PROPN
ajlm-2065	183	26	.	.	PUNCT
ajlm-2065	184	1	lancet	lancet	PROPN
ajlm-2065	184	2	hiv	hiv	PROPN
ajlm-2065	184	3	.	.	PUNCT
ajlm-2065	185	1	2021;8(5):e294	2021;8(5):e294	NOUN
ajlm-2065	185	2	–	–	PUNCT
ajlm-2065	185	3	e305	e305	PROPN
ajlm-2065	185	4	.	.	PUNCT
ajlm-2065	186	1	https://doi.org/10.1016/s2352-3018(21)00070-9	https://doi.org/10.1016/s2352-3018(21)00070-9	PROPN
ajlm-2065	186	2	spinelli	spinelli	PROPN
ajlm-2065	186	3	ma	ma	PROPN
ajlm-2065	186	4	,	,	PUNCT
ajlm-2065	186	5	lynch	lynch	PROPN
ajlm-2065	186	6	kl	kl	PROPN
ajlm-2065	186	7	,	,	PUNCT
ajlm-2065	186	8	yun	yun	PROPN
ajlm-2065	186	9	c	c	PROPN
ajlm-2065	186	10	,	,	PUNCT
ajlm-2065	186	11	et	et	PROPN
ajlm-2065	186	12	al	al	PROPN
ajlm-2065	186	13	.	.	PUNCT
ajlm-2065	187	1	sars	sars	PROPN
ajlm-2065	187	2	-	-	PUNCT
ajlm-2065	187	3	cov-2	cov-2	PART
ajlm-2065	187	4	seroprevalence	seroprevalence	NOUN
ajlm-2065	187	5	,	,	PUNCT
ajlm-2065	187	6	and	and	CCONJ
ajlm-2065	187	7	igg	igg	PROPN
ajlm-2065	187	8	concentration	concentration	NOUN
ajlm-2065	187	9	and	and	CCONJ
ajlm-2065	187	10	pseudovirus	pseudovirus	NOUN
ajlm-2065	187	11	neutralising	neutralise	VERB
ajlm-2065	187	12	antibody	antibody	NOUN
ajlm-2065	187	13	titres	titre	NOUN
ajlm-2065	187	14	after	after	ADP
ajlm-2065	187	15	infection	infection	NOUN
ajlm-2065	187	16	,	,	PUNCT
ajlm-2065	187	17	compared	compare	VERB
ajlm-2065	187	18	by	by	ADP
ajlm-2065	187	19	hiv	hiv	PROPN
ajlm-2065	187	20	status	status	PROPN
ajlm-2065	187	21	:	:	PUNCT
ajlm-2065	187	22	a	a	DET
ajlm-2065	187	23	matched	match	VERB
ajlm-2065	187	24	case	case	NOUN
ajlm-2065	187	25	-	-	PUNCT
ajlm-2065	187	26	control	control	NOUN
ajlm-2065	187	27	observational	observational	ADJ
ajlm-2065	187	28	study	study	NOUN
ajlm-2065	187	29	.	.	PUNCT
ajlm-2065	188	1	lancet	lancet	PROPN
ajlm-2065	188	2	hiv	hiv	PROPN
ajlm-2065	188	3	.	.	PUNCT
ajlm-2065	189	1	2021;8(6):e334	2021;8(6):e334	PROPN
ajlm-2065	189	2	–	–	PUNCT
ajlm-2065	189	3	e341	e341	PROPN
ajlm-2065	189	4	.	.	PUNCT
ajlm-2065	190	1	https://doi.org/10.1016/s2352-3018(21)00072-2	https://doi.org/10.1016/s2352-3018(21)00072-2	PROPN
ajlm-2065	190	2	spinelli	spinelli	PROPN
ajlm-2065	190	3	m	m	PROPN
ajlm-2065	190	4	,	,	PUNCT
ajlm-2065	190	5	lynch	lynch	PROPN
ajlm-2065	190	6	k	k	PROPN
ajlm-2065	190	7	,	,	PUNCT
ajlm-2065	190	8	yun	yun	PROPN
ajlm-2065	190	9	c	c	PROPN
ajlm-2065	190	10	,	,	PUNCT
ajlm-2065	190	11	et	et	PROPN
ajlm-2065	190	12	al	al	PROPN
ajlm-2065	190	13	.	.	PUNCT
ajlm-2065	190	14	sars	sars	PROPN
ajlm-2065	190	15	-	-	PUNCT
ajlm-2065	190	16	cov-2	cov-2	PART
ajlm-2065	190	17	seroprevalence	seroprevalence	NOUN
ajlm-2065	190	18	and	and	CCONJ
ajlm-2065	190	19	igg	igg	PROPN
ajlm-2065	190	20	levels	level	NOUN
ajlm-2065	190	21	are	be	AUX
ajlm-2065	190	22	lower	low	ADJ
ajlm-2065	190	23	among	among	ADP
ajlm-2065	190	24	people	people	NOUN
ajlm-2065	190	25	living	live	VERB
ajlm-2065	190	26	with	with	ADP
ajlm-2065	190	27	hiv	hiv	PROPN
ajlm-2065	190	28	.	.	PUNCT
ajlm-2065	191	1	top	top	ADJ
ajlm-2065	191	2	antiviral	antiviral	PROPN
ajlm-2065	191	3	med	med	PROPN
ajlm-2065	191	4	.	.	PUNCT
ajlm-2065	192	1	2021:242–242	2021:242–242	PROPN
ajlm-2065	192	2	.	.	PUNCT
ajlm-2065	192	3	national	national	PROPN
ajlm-2065	192	4	institute	institute	PROPN
ajlm-2065	192	5	for	for	ADP
ajlm-2065	192	6	communicable	communicable	NOUN
ajlm-2065	192	7	diseases	disease	NOUN
ajlm-2065	192	8	(	(	PUNCT
ajlm-2065	192	9	nicd	nicd	NOUN
ajlm-2065	192	10	)	)	PUNCT
ajlm-2065	192	11	.	.	PUNCT
ajlm-2065	193	1	covid-19	covid-19	PROPN
ajlm-2065	193	2	in	in	ADP
ajlm-2065	193	3	children	child	NOUN
ajlm-2065	193	4	surveillance	surveillance	NOUN
ajlm-2065	193	5	report	report	NOUN
ajlm-2065	193	6	.	.	PUNCT
ajlm-2065	194	1	2021	2021	NUM
ajlm-2065	194	2	.	.	PUNCT
ajlm-2065	195	1	available	available	ADJ
ajlm-2065	195	2	from	from	ADP
ajlm-2065	195	3	:	:	PUNCT
ajlm-2065	195	4	https://www.nicd.ac.za/wp-content/uploads/2021/09/covid-19-in-children-surveillance-report.pdf	https://www.nicd.ac.za/wp-content/uploads/2021/09/covid-19-in-children-surveillance-report.pdf	PROPN
ajlm-2065	195	5	.	.	PUNCT
ajlm-2065	196	1	fenwick	fenwick	PROPN
ajlm-2065	196	2	c	c	PROPN
ajlm-2065	196	3	,	,	PUNCT
ajlm-2065	196	4	croxatto	croxatto	NOUN
ajlm-2065	196	5	a	a	NOUN
ajlm-2065	196	6	,	,	PUNCT
ajlm-2065	196	7	coste	coste	NOUN
ajlm-2065	196	8	at	at	ADP
ajlm-2065	196	9	,	,	PUNCT
ajlm-2065	196	10	et	et	PROPN
ajlm-2065	196	11	al	al	PROPN
ajlm-2065	196	12	.	.	PROPN
ajlm-2065	196	13	changes	change	NOUN
ajlm-2065	196	14	in	in	ADP
ajlm-2065	196	15	sars	sar	NOUN
ajlm-2065	196	16	-	-	PUNCT
ajlm-2065	196	17	cov-2	cov-2	NOUN
ajlm-2065	196	18	spike	spike	NOUN
ajlm-2065	196	19	versus	versus	ADP
ajlm-2065	196	20	nucleoprotein	nucleoprotein	NOUN
ajlm-2065	196	21	antibody	antibody	NOUN
ajlm-2065	196	22	responses	response	NOUN
ajlm-2065	196	23	impact	impact	VERB
ajlm-2065	196	24	the	the	DET
ajlm-2065	196	25	estimates	estimate	NOUN
ajlm-2065	196	26	of	of	ADP
ajlm-2065	196	27	infections	infection	NOUN
ajlm-2065	196	28	in	in	ADP
ajlm-2065	196	29	population	population	NOUN
ajlm-2065	196	30	-	-	PUNCT
ajlm-2065	196	31	based	base	VERB
ajlm-2065	196	32	seroprevalence	seroprevalence	NOUN
ajlm-2065	196	33	studies	study	NOUN
ajlm-2065	196	34	.	.	PUNCT
ajlm-2065	197	1	j	j	PROPN
ajlm-2065	197	2	virology	virology	NOUN
ajlm-2065	197	3	.	.	PUNCT
ajlm-2065	198	1	2021;95(3):e01828–20	2021;95(3):e01828–20	NUM
ajlm-2065	198	2	.	.	PUNCT
ajlm-2065	198	3	paleker	paleker	PROPN
ajlm-2065	198	4	m	m	PROPN
ajlm-2065	198	5	,	,	PUNCT
ajlm-2065	198	6	tembo	tembo	PROPN
ajlm-2065	198	7	y	y	PROPN
ajlm-2065	198	8	,	,	PUNCT
ajlm-2065	198	9	davies	davies	PROPN
ajlm-2065	198	10	m	m	PROPN
ajlm-2065	198	11	,	,	PUNCT
ajlm-2065	198	12	et	et	PROPN
ajlm-2065	198	13	al	al	PROPN
ajlm-2065	198	14	.	.	PROPN
ajlm-2065	198	15	asymptomatic	asymptomatic	PROPN
ajlm-2065	198	16	covid-19	covid-19	PROPN
ajlm-2065	198	17	–	–	PUNCT
ajlm-2065	198	18	implications	implication	NOUN
ajlm-2065	198	19	for	for	ADP
ajlm-2065	198	20	the	the	DET
ajlm-2065	198	21	control	control	NOUN
ajlm-2065	198	22	of	of	ADP
ajlm-2065	198	23	transmission	transmission	NOUN
ajlm-2065	198	24	in	in	ADP
ajlm-2065	198	25	south	south	PROPN
ajlm-2065	198	26	africa	africa	PROPN
ajlm-2065	198	27	.	.	PUNCT
ajlm-2065	199	1	public	public	ADJ
ajlm-2065	199	2	health	health	NOUN
ajlm-2065	199	3	action	action	NOUN
ajlm-2065	199	4	.	.	PUNCT
ajlm-2065	200	1	2021;11(2):58–60	2021;11(2):58–60	X
ajlm-2065	200	2	.	.	PUNCT
ajlm-2065	201	1	https://doi.org/10.5588/pha.20.0069	https://doi.org/10.5588/pha.20.0069	PROPN
ajlm-2065	201	2	.	.	PUNCT
ajlm-2065	202	1	vardhana	vardhana	PROPN
ajlm-2065	202	2	sa	sa	PROPN
ajlm-2065	202	3	,	,	PUNCT
ajlm-2065	202	4	wolchok	wolchok	PROPN
ajlm-2065	202	5	jd	jd	PROPN
ajlm-2065	202	6	.	.	PUNCT
ajlm-2065	203	1	the	the	DET
ajlm-2065	203	2	many	many	ADJ
ajlm-2065	203	3	faces	face	NOUN
ajlm-2065	203	4	of	of	ADP
ajlm-2065	203	5	the	the	DET
ajlm-2065	203	6	anti	anti	ADJ
ajlm-2065	203	7	-	-	ADJ
ajlm-2065	203	8	covid	covid	ADJ
ajlm-2065	203	9	immune	immune	ADJ
ajlm-2065	203	10	response	response	NOUN
ajlm-2065	203	11	.	.	PUNCT
ajlm-2065	204	1	j	j	PROPN
ajlm-2065	204	2	exp	exp	NOUN
ajlm-2065	204	3	med	med	PROPN
ajlm-2065	204	4	.	.	PUNCT
ajlm-2065	205	1	2020;217(6):e20200678	2020;217(6):e20200678	NUM
ajlm-2065	205	2	.	.	PUNCT
ajlm-2065	206	1	https://doi.org/10.1084/jem.20200678	https://doi.org/10.1084/jem.20200678	PROPN
ajlm-2065	206	2	choe	choe	PROPN
ajlm-2065	206	3	pg	pg	PROPN
ajlm-2065	206	4	,	,	PUNCT
ajlm-2065	206	5	kim	kim	PROPN
ajlm-2065	206	6	k	k	PROPN
ajlm-2065	206	7	-	-	PROPN
ajlm-2065	206	8	h	h	PROPN
ajlm-2065	206	9	,	,	PUNCT
ajlm-2065	206	10	kang	kang	PROPN
ajlm-2065	206	11	ck	ck	PROPN
ajlm-2065	206	12	,	,	PUNCT
ajlm-2065	206	13	et	et	PROPN
ajlm-2065	206	14	al.antibody	al.antibody	NOUN
ajlm-2065	206	15	responses	response	NOUN
ajlm-2065	206	16	8	8	NUM
ajlm-2065	206	17	months	month	NOUN
ajlm-2065	206	18	after	after	ADP
ajlm-2065	206	19	asymptomatic	asymptomatic	ADJ
ajlm-2065	206	20	or	or	CCONJ
ajlm-2065	206	21	mild	mild	ADJ
ajlm-2065	206	22	sars	sar	NOUN
ajlm-2065	206	23	-	-	PUNCT
ajlm-2065	206	24	cov-2	cov-2	NOUN
ajlm-2065	206	25	infection	infection	NOUN
ajlm-2065	206	26	.	.	PUNCT
ajlm-2065	207	1	emerg	emerg	PROPN
ajlm-2065	207	2	infect	infect	PROPN
ajlm-2065	207	3	dis	dis	PROPN
ajlm-2065	207	4	.	.	PUNCT
ajlm-2065	208	1	2021;27(3):928	2021;27(3):928	PROPN
ajlm-2065	208	2	.	.	PUNCT
ajlm-2065	209	1	https://doi.org/10.3201/eid2703.204543	https://doi.org/10.3201/eid2703.204543	PROPN
ajlm-2065	209	2	brown	brown	PROPN
ajlm-2065	209	3	lb	lb	PROPN
ajlm-2065	209	4	,	,	PUNCT
ajlm-2065	209	5	spinelli	spinelli	PROPN
ajlm-2065	209	6	ma	ma	PROPN
ajlm-2065	209	7	,	,	PUNCT
ajlm-2065	209	8	gandhi	gandhi	PROPN
ajlm-2065	209	9	m.	m.	VERB
ajlm-2065	209	10	the	the	DET
ajlm-2065	209	11	interplay	interplay	NOUN
ajlm-2065	209	12	between	between	ADP
ajlm-2065	209	13	hiv	hiv	PROPN
ajlm-2065	209	14	and	and	CCONJ
ajlm-2065	209	15	covid-19	covid-19	PROPN
ajlm-2065	209	16	:	:	PUNCT
ajlm-2065	209	17	summary	summary	NOUN
ajlm-2065	209	18	of	of	ADP
ajlm-2065	209	19	the	the	DET
ajlm-2065	209	20	data	datum	NOUN
ajlm-2065	209	21	and	and	CCONJ
ajlm-2065	209	22	responses	response	NOUN
ajlm-2065	209	23	to	to	ADP
ajlm-2065	209	24	date	date	NOUN
ajlm-2065	209	25	.	.	PUNCT
ajlm-2065	210	1	curr	curr	PROPN
ajlm-2065	210	2	opin	opin	PROPN
ajlm-2065	210	3	hiv	hiv	PROPN
ajlm-2065	210	4	aids	aids	PROPN
ajlm-2065	210	5	.	.	PUNCT
ajlm-2065	211	1	2021;16(1):63–73	2021;16(1):63–73	X
ajlm-2065	211	2	.	.	PUNCT
ajlm-2065	212	1	https://doi.org/10.1097/coh.0000000000000659	https://doi.org/10.1097/coh.0000000000000659	PROPN
ajlm-2065	212	2	south	south	ADJ
ajlm-2065	212	3	african	african	ADJ
ajlm-2065	212	4	health	health	NOUN
ajlm-2065	212	5	products	product	NOUN
ajlm-2065	212	6	regulatory	regulatory	ADJ
ajlm-2065	212	7	authority	authority	NOUN
ajlm-2065	212	8	.	.	PUNCT
ajlm-2065	213	1	sahpra	sahpra	PROPN
ajlm-2065	213	2	approves	approve	VERB
ajlm-2065	213	3	sars	sars	PROPN
ajlm-2065	213	4	-	-	PUNCT
ajlm-2065	213	5	cov-2	cov-2	NOUN
ajlm-2065	213	6	serology	serology	NOUN
ajlm-2065	213	7	test	test	NOUN
ajlm-2065	213	8	kits	kit	NOUN
ajlm-2065	214	1	[	[	X
ajlm-2065	214	2	press	press	NOUN
ajlm-2065	214	3	release	release	NOUN
ajlm-2065	214	4	]	]	PUNCT
ajlm-2065	214	5	.	.	PUNCT
ajlm-2065	215	1	25	25	NUM
ajlm-2065	215	2	august	august	PROPN
ajlm-2065	215	3	2020	2020	NUM
ajlm-2065	215	4	.	.	PUNCT
ajlm-2065	216	1	ng	ng	PROPN
ajlm-2065	216	2	kw	kw	PROPN
ajlm-2065	216	3	,	,	PUNCT
ajlm-2065	216	4	faulkner	faulkner	NOUN
ajlm-2065	216	5	n	n	CCONJ
ajlm-2065	216	6	,	,	PUNCT
ajlm-2065	216	7	cornish	cornish	PROPN
ajlm-2065	216	8	gh	gh	PROPN
ajlm-2065	216	9	,	,	PUNCT
ajlm-2065	216	10	et	et	PROPN
ajlm-2065	216	11	al	al	PROPN
ajlm-2065	216	12	.	.	PUNCT
ajlm-2065	217	1	preexisting	preexist	VERB
ajlm-2065	217	2	and	and	CCONJ
ajlm-2065	217	3	de	de	ADP
ajlm-2065	217	4	novo	novo	NOUN
ajlm-2065	217	5	humoral	humoral	ADJ
ajlm-2065	217	6	immunity	immunity	NOUN
ajlm-2065	217	7	to	to	ADP
ajlm-2065	217	8	sars	sar	NOUN
ajlm-2065	217	9	-	-	PUNCT
ajlm-2065	217	10	cov-2	cov-2	NOUN
ajlm-2065	217	11	in	in	ADP
ajlm-2065	217	12	humans	human	NOUN
ajlm-2065	217	13	.	.	PUNCT
ajlm-2065	218	1	science	science	NOUN
ajlm-2065	218	2	.	.	PUNCT
ajlm-2065	219	1	2020;370(6522):1339–1343	2020;370(6522):1339–1343	PROPN
ajlm-2065	219	2	.	.	PUNCT
ajlm-2065	220	1	https://doi.org/10.1126/science.abe1107	https://doi.org/10.1126/science.abe1107	PROPN
ajlm-2065	220	2	hassold	hassold	ADJ
ajlm-2065	220	3	n	n	SYM
ajlm-2065	220	4	,	,	PUNCT
ajlm-2065	220	5	brichler	brichler	NOUN
ajlm-2065	220	6	s	s	PROPN
ajlm-2065	220	7	,	,	PUNCT
ajlm-2065	220	8	ouedraogo	ouedraogo	NOUN
ajlm-2065	220	9	e	e	NOUN
ajlm-2065	220	10	,	,	PUNCT
ajlm-2065	220	11	et	et	PROPN
ajlm-2065	220	12	al	al	PROPN
ajlm-2065	220	13	.	.	PUNCT
ajlm-2065	220	14	impaired	impair	VERB
ajlm-2065	220	15	antibody	antibody	NOUN
ajlm-2065	220	16	response	response	NOUN
ajlm-2065	220	17	to	to	ADP
ajlm-2065	220	18	covid-19	covid-19	PROPN
ajlm-2065	220	19	vaccination	vaccination	NOUN
ajlm-2065	220	20	in	in	ADP
ajlm-2065	220	21	advanced	advanced	ADJ
ajlm-2065	220	22	hiv	hiv	PROPN
ajlm-2065	220	23	infection	infection	NOUN
ajlm-2065	220	24	.	.	PUNCT
ajlm-2065	221	1	aids	aids	PROPN
ajlm-2065	221	2	.	.	PUNCT
ajlm-2065	222	1	2022;36(4):f1	2022;36(4):f1	NUM
ajlm-2065	222	2	–	–	PUNCT
ajlm-2065	222	3	f5	f5	NOUN
ajlm-2065	222	4	.	.	PUNCT
ajlm-2065	223	1	https://doi.org/10.1097/qad.0000000000003166	https://doi.org/10.1097/qad.0000000000003166	PROPN
ajlm-2065	223	2	xu	xu	PROPN
ajlm-2065	224	1	x	x	PROPN
ajlm-2065	224	2	,	,	PUNCT
ajlm-2065	224	3	vesterbacka	vesterbacka	PROPN
ajlm-2065	224	4	j	j	PROPN
ajlm-2065	224	5	,	,	PUNCT
ajlm-2065	224	6	aleman	aleman	PROPN
ajlm-2065	224	7	s	s	PROPN
ajlm-2065	224	8	,	,	PUNCT
ajlm-2065	224	9	nowak	nowak	PROPN
ajlm-2065	224	10	p.	p.	PROPN
ajlm-2065	224	11	high	high	ADJ
ajlm-2065	224	12	seroconversion	seroconversion	PROPN
ajlm-2065	224	13	rate	rate	NOUN
ajlm-2065	224	14	after	after	ADP
ajlm-2065	224	15	vaccination	vaccination	NOUN
ajlm-2065	224	16	with	with	ADP
ajlm-2065	224	17	mrna	mrna	PROPN
ajlm-2065	224	18	bnt162b2	bnt162b2	PROPN
ajlm-2065	224	19	vaccine	vaccine	NOUN
ajlm-2065	224	20	against	against	ADP
ajlm-2065	224	21	sars	sar	NOUN
ajlm-2065	224	22	-	-	PUNCT
ajlm-2065	224	23	cov-2	cov-2	NOUN
ajlm-2065	224	24	among	among	ADP
ajlm-2065	224	25	people	people	NOUN
ajlm-2065	224	26	with	with	ADP
ajlm-2065	224	27	hiv	hiv	PROPN
ajlm-2065	224	28	–	–	PUNCT
ajlm-2065	224	29	but	but	CCONJ
ajlm-2065	224	30	hiv	hiv	PROPN
ajlm-2065	224	31	viremia	viremia	NOUN
ajlm-2065	224	32	matters	matter	VERB
ajlm-2065	224	33	?	?	PUNCT
ajlm-2065	225	1	aids	aid	NOUN
ajlm-2065	225	2	.	.	PUNCT
ajlm-2065	226	1	2022;36(3):479–481	2022;36(3):479–481	X
ajlm-2065	226	2	.	.	PUNCT
ajlm-2065	227	1	https://doi.org/10.1097/qad.0000000000003135	https://doi.org/10.1097/qad.0000000000003135	NOUN